University of Nebraska Medical Center

DigitalCommons@UNMC
Theses & Dissertations

Graduate Studies

Summer 8-14-2015

Transcriptional and Post-transcriptional Regulation of Hepcidin
and Iron Metabolism by Lipid Signaling in the Liver
Sizhao Lu
University of Nebraska Medical Center

Follow this and additional works at: https://digitalcommons.unmc.edu/etd
Part of the Molecular Biology Commons

Recommended Citation
Lu, Sizhao, "Transcriptional and Post-transcriptional Regulation of Hepcidin and Iron Metabolism by Lipid
Signaling in the Liver" (2015). Theses & Dissertations. 18.
https://digitalcommons.unmc.edu/etd/18

This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It
has been accepted for inclusion in Theses & Dissertations by an authorized administrator of
DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu.

Transcriptional and Post-transcriptional Regulation of Hepcidin and Iron
Metabolism by Lipid Signaling in the Liver
By
Sizhao Lu

A DISSERTATION

Presented to the Faculty of
the University of Nebraska Graduate College
in partial Fulfillment of the Requirements
for the Degree of Doctor of Philosophy

Biochemistry and Molecular Biology Graduate Program

Under the Supervision of Professor Duygu Dee Harrison-Findik

University of Nebraska Medical Center
Omaha, Nebraska
August, 2015
Supervisory Committee:
Justin L. Mott, M.D., Ph.D.
Kusum Kharbanda, Ph.D.
Robert G. Bennett, Ph.D.

Transcriptional and Post-transcriptional Regulation of Hepcidin and Iron
Metabolism by Lipid Signaling in the Liver
Sizhao Lu, Ph.D.
University of Nebraska Medical Center, 2015
Advisor: Duygu Dee Harrison-Findik, Ph.D.
Although iron is required for essential biological processes, excess iron is detrimental due
to oxidative damage induced by iron-mediated Fenton reactions, which promote tissue
injury. Cellular iron uptake, transport and storage must therefore be tightly regulated. This
task is accomplished mainly through hepcidin, the key iron-regulatory hormone. Hepcidin
is synthesized primarily in hepatocytes as a circulatory antimicrobial peptide. It controls
iron metabolism by inhibiting iron absorption from the duodenum and iron release from
reticuloendothelial macrophages. Besides synthesizing hepcidin, the liver plays an
important role in maintaining iron homeostasis by serving as the main storage organ for
excess iron. Patients with liver diseases frequently display disturbances of iron metabolism
but the underlying mechanisms are unclear. Due to obesity epidemic worldwide, the
incidence of nonalcoholic fatty liver disease (NAFLD) is on the rise. This study therefore
focuses on the regulation of hepcidin in NAFLD. NAFLD is the hepatic manifestation of
metabolic syndrome, which is characterized by visceral adiposity, dyslipidemia and insulin
resistance. Both the level and distribution of iron in the livers of NAFLD patients have
been shown to correlate with disease severity. NAFLD patients have also been reported to
display changes in hepcidin expression. The significance and relevance of these alterations
regarding NAFLD pathogenesis are unclear. Although impaired fatty acid metabolism and

lipid accumulation in the liver are major contributors to the pathogenesis of NAFLD, the
role of lipids or lipid derivatives in hepcidin regulation have not been investigated. The
studies presented in this dissertation identified new and unique mechanisms of hepcidin
gene regulation by saturated fatty acids and the biologically active lipid derivative,
ceramide in human hepatoma cells. The post-transcriptional regulation of hepcidin
expression by palmitic acid was mediated through AU-rich element binding protein,
Human Antigen R (HuR) and novel class of protein kinase C isoforms. Ceramide, on the
other hand, induced hepcidin transcription via inflammatory JAK/STAT3 signaling.
Furthermore, by using high fat-fed hepcidin knockout mice as an in vivo model, I have
implicated a role for hepcidin in the regulation of hepatic lipid metabolism, and
characterized these mice as a potential experimental model to study liver injury in NAFLD.
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GENERAL HYPOTHESIS AND OBJECTIVES
Obesity and metabolic syndrome are increasing worldwide in epidemic proportions
affecting both adult and adolescent populations. Nonalcoholic fatty liver disease (NAFLD)
is the hepatic manifestation of metabolic syndrome. The more severe form, nonalcoholic
steatohepatitis (NASH) is characterized by inflammation, apoptosis, hepatocyte ballooning,
fibrosis and cirrhosis. NAFLD/NASH patients also exhibit elevated serum and hepatic iron
content. Iron acts as a secondary risk factor in liver diseases but the molecular mechanisms
by which iron contributes to NAFLD/NASH pathogenesis are unclear.
Hepcidin is the key iron regulatory hormone, which is primarily synthesized in the liver.
Hepcidin inhibits iron transport in the duodenum and iron release from macrophages by
blocking the transport function of the iron exporter, ferroportin. Various factors such as,
iron, inflammation and endoplasmic reticulum (ER) stress have been reported to activate
the transcription of hepcidin gene, HAMP. Some studies, but not all, have also shown
elevated levels of hepcidin in the liver and sera of obese and/or NAFLD patients. The
potential mechanisms underlying this increase are unclear but a role for elevated
inflammatory cytokines or liver iron content in NAFLD patients have been proposed.
Lipid accumulation in the liver (steatosis) is one of the initial pathological changes
observed in NAFLD. Fat accumulates in the liver when the lipid uptake and lipogenesis
outweigh the rate of lipid oxidation and secretion. Besides serving as energy storage
molecules and structural components, lipids and lipid intermediates (e.g. ceramide) also
act as intracellular signaling molecules. Lipid-induced signaling participates in the
pathogenesis of NAFLD but its role in the regulation of hepcidin and iron metabolism has
not been investigated.
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We hypothesized that fatty acids and ceramide regulate hepatic HAMP mRNA levels
through distinct cell signaling mechanisms. Both fatty acids and ceramide are potent
inducers of apoptosis in hepatocytes. However, the direct effect of apoptosis on human and
mouse hepcidin gene expression is unknown. We therefore addressed this question by
using both in vitro and in vivo models of apoptosis induced by Fas signaling (see Chapter
III). The role of fatty acid- (Chapter IV) or ceramide- (Chapter V) induced cellular
signaling pathways in HAMP regulation was investigated in HepG2 human hepatoma cells.
We further hypothesized that hepcidin (i.e. iron)-mediated changes in liver lipid
metabolism contributes to NAFLD/NASH pathogenesis. To test this hypothesis, we
employed hepcidin knockout mice with iron overload phenotype that were fed either a
high-fat and high-sucrose or regular (control) diets. We also characterized these mice as
potential experimental models to study the mechanisms of liver injury in NASH.
The following specific aims have been proposed.
AIM 1. To identify the post-transcriptional mechanisms by which saturated fatty acids
stabilize hepcidin mRNA in human hepatoma cells.
AIM 2. To investigate the regulation of hepatic hepcidin transcription by ceramidemediated cell signaling in hepatoma cells.
AIM 3. To characterize hepcidin knockout mice with high-fat and high-sucrose intake as a
novel experimental model to study liver injury and to confirm the role of hepcidin-induced
iron overload in NAFLD/NASH pathology.
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Chapter I
Introduction
Review of Nonalcoholic Fatty Liver Disease, Iron Metabolism and Hepcidin

2
1

GENERAL SUMMARY

Due to changes both in dietary and life style habits, the global rate of obesity has been increasing
dramatically in the past two decades (1). According to the studies conducted in 2010, over one
billion of the world’s population, including developing countries, has been estimated to be
overweight, with 475 million out of these classified as obese (1). In U.S.A., the prevalence of
obesity in both men and women has been estimated to be above 35% (approximately 73.3million
in total number) in the year of 2010 (2). These numbers are expected to increase further in the near
future (3). Most dramatically, the rate of obesity in the adolescent population is increasing at an
alarming rate (1).
Once considered as an advantage in ancient times when food resources were limited (4), obesity in
our modern era is unfortunately recognized as a morbid state. Besides imposing a direct negative
impact on the quality of life, obesity is also closely associated with metabolic syndrome (5).
Metabolic syndrome is defined as a series of health conditions including excess body fat (in
particular visceral adiposity), dyslipidemia and abnormal cholesterol levels, high blood sugar,
insulin resistance, and hypertension, which acting in concert increase the risk for type 2 diabetes
mellitus and cardiovascular disease.
Insulin resistance, a key feature of metabolic syndrome, is associated with changes in the secretion
and signaling of the hormone, insulin (6). The β cells of pancreas are the major site of insulin
production. Under normal physiological conditions, the increases in the level of blood sugar (often
post-prandial) stimulate the secretion of insulin. Insulin released into the circulation modulates
glucose and lipid metabolism in a wide range of metabolic tissues to maintain blood glucose at a
normal level. The action of insulin is accomplished through its binding to insulin receptors, which
are members of the receptor tyrosine kinase family and expressed on the plasma membrane of target
cells. The formation of the insulin and insulin receptor dimer complex induces the autophosphorylation of tyrosine residues on the cytoplasmic receptor domains. This subsequently

3
results in phosphorylation of the insulin receptor substrates (IRS), IRS1 and IRS2, on tyrosine
residues (7). IRS, in association with the activated lipid kinase, phosphoinositide 3-kinase (PI3K),
further induces the phosphorylation and activation of the downstream protein kinase, PKB (a.k.a
Akt). Insulin regulates glucose metabolism by inducing the translocation of insulin signalingsensitive glucose transporters, such as GLUT4 in muscle and adipose tissue from the storage sites
to the plasma membrane, and thereby stimulating the uptake and utilization of glucose by these
metabolic tissues (8). In order to control and limit glucose output by the liver, insulin
simultaneously stimulates the synthesis of glycogen and suppresses gluconeogenesis (9). In
addition to glucose metabolism, insulin regulates lipid metabolism in the liver by inducing the
expression of enzymes involved in de novo lipogenesis through the transcription factor, sterol
regulatory element-binding protein-1c (SREBP-1c). On the other hand, insulin regulates lipid
metabolism in the adipose tissue by both decreasing lipolysis via the inhibition of the hormone
sensitive lipase (HSL) and stimulating lipogenesis (10). Taken together, these actions of insulin
exert a total effect of maintaining a normal postprandial level of blood glucose in healthy
individuals. However, in the condition of insulin resistance, as observed with obesity and metabolic
syndrome, the effect of insulin is blunted. As a result, glucose uptake by the muscle and glycogen
storage, but not gluconeogenesis, in the liver are inhibited. This in turn leads to a significant
elevation of blood glucose levels and thereby contributes to hyperglycemia. Similarly, in an insulinresistant state, the inhibition of HSL and lipolysis, and the increase in lipogenesis by insulin are
compromised. These changes then trigger the increased breakdown of triglycerides and release of
fatty acids into the circulation.
Liver is one of the first organs assaulted by the metabolic changes induced by insulin resistance
and metabolic syndrome. The excess fat in the circulation due to insulin resistance, are taken up
the by the liver resulting in fat accumulation (i.e. steatosis). The changes in liver insulin signaling
also contribute to the elevated levels of de novo lipid synthesis in the liver.
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The diagnosis of nonalcoholic fatty liver disease (NAFLD) is established when the level of steatosis
exceeds 5% of the liver tissue (11) in patients with little or no alcohol consumption (12). NAFLD
is therefore the hepatic manifestation of metabolic syndrome (13, 14). Analytical studies with
NAFLD patients have shown that the major source of fat in the liver is the uptake of surplus fat
from the circulation, due to adipose tissue lysis or excess dietary fat, accompanied by the increase
in de novo lipogenesis (15). Liver disposes of its excess lipid content in the form of VLDL secretion
(16) and fatty acid oxidation (17). Fatty acid oxidation also fulfills the energy requirements of this
metabolically active organ. The imbalance between lipid input and output in the liver plays an
important role in steatosis. The detailed molecular mechanisms of hepatic lipid accumulation in
NAFLD are discussed in later sections (see sections 2.6 of this chapter).
NAFLD encompasses a spectrum of pathological conditions including steatosis, steatohepatitis,
fibrosis, cirrhosis and hepatocellular carcinoma (12, 14, 18). Majority of NAFLD patients exhibit
simple steatosis, which is currently considered to be a benign condition. However, if untreated,
some of these patients can develop severe forms of nonalcoholic steatohepatitis (NASH), which is
characterized by inflammation (steatohepatitis) and fibrotic changes due to the activation of stellate
cells (12). A small percentage of NASH patients also present advanced stages of fibrosis and
cirrhosis, which may ultimately lead to hepatocellular carcinoma and death (19).
The mechanisms of NAFLD/NASH disease progression has been under intense investigation in
recent decades. The so-called “two-hit hypothesis” was quickly adopted from the pathogenesis of
alcoholic liver disease (ALD) as a popular theory to explain NAFLD/NASH pathogenesis (20). As
the name suggests, it describes the process in two consecutive steps. Namely, the “first-hit”, which
is widely accepted to be insulin resistance (21), promotes the development of simple steatosis. In
the absence of a second-hit, steatosis remains to be benign and does not progress to severe forms
of disease. However, the presence of a further hit (i.e. second-hit), such as abnormalities in

5
mitochondrial function, oxidative stress, lipid peroxidation, or inflammatory cytokines and
adipokines, then exacerbates hepatocellular injury and triggers NASH pathology (20–22).
In recent years, the “two-hit hypothesis” model of NAFLD/NASH pathogenesis has been
challenged. First, it has been recognized that steatosis is the consequence of the interplay between
multiple factors (i.e. insulin resistance, adipose tissue inflammation, and altered adipokine
secretion) rather than a simple phenomenon which was previously defined as the “first hit” (23).
As a result, a “multiple parallel-hits hypothesis” has been coined proposing that many progressive
hits collectively contribute to the pathogenesis of NAFLD/NASH (24). Secondly, clinical
observations have indicated that NASH is not always preceded by steatosis (23, 25). They
questioned the initial notion that steatosis and NASH represent the early and advanced stages of
NAFLD, respectively (23). It is feasible that the absence of typical NAFLD/NASH pathological
features, especially in patients with advanced cirrhosis, might be due to the portosystemic shunting
(26). Nevertheless, there is not enough direct evidence to support the sequential progression of
NASH from simple steatosis (27).
Although the mechanisms of NASH has not been clearly understood, iron has been proposed to
contribute to NASH pathogenesis. Being a transition metal, iron participates in the Fenton reaction
resulting in the production of highly toxic hydroxyl radicals (see section 3 of this chapter below for
detailed overview) (28). NAFLD patients frequently display elevated iron levels (29, 30), which
have been shown to correlate with the severity of disease and fibrosis (31–33). Despite these
observations, the regulation of iron homeostasis and how it contributes to the NAFLD/NASH
pathogenesis are not well understood.

2

REGULATION OF LIPID METABOLISM IN HEALTH AND NAFLD

Lipids are a class of hydrophobic molecules with both structural and bioenergetics functions. Free
fatty acids (FFA) are molecules consisting of a carbon chain with hydrogen atoms along the length,
and a carboxyl group and a hydrogen atom at either ends of the chain (Figure 1.1A). Based on the
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presence of single or double bonds in the carbon backbone, they can be classified as saturated (e.g.
palmitic, stearic acid) or unsaturated (e.g. oleic acid) (Figure 1.1A). Triacylglycerols (TAG), which
are present both in plant oils and animal fats in our diet, are comprised of three fatty acids joined
by a glycerol molecule (Figure 1.1A).
Fatty acids serve as major energy storage molecules. Namely, the oxidation of fatty acid yields
more ATP than any other biological substrate. Furthermore, fatty acids are important substrates for
the production of other lipid intermediates such as sphingolipids, which are essential for membrane
biogenesis and for the mediation of important intracellular signaling pathways.
As an endocrine organ, liver is important for the regulation of fatty acid metabolism. Under normal
conditions, healthy humans store fatty acids mainly in the adipose tissue in the form of non-toxic
triglycerides. In pathological conditions, liver takes over the burden of eliminating excess fatty
acids from the circulation. Unesterified free fatty acids in turn induces apoptosis and lipotoxicity
further activating certain cell signaling pathways, which lead to liver injury, as observed with
NAFLD patients. Here we provide a brief review of hepatic lipid metabolism and signaling
focusing on both physiological and NAFLD conditions.
2.1

Extrahepatic sources of fatty acids in the liver

Dietary fatty acids are one of the sources of fatty acids contributing to steatosis in the livers of
NAFLD patients (15). In the postprandial state, TAG obtained as dietary fats are hydrolyzed by
various lipases, which are present in the lumen of the intestine, to release free fatty acids (FFA).
FFAs are taken up by the absorptive enterocytes (34) to be re-synthesized into TAG in the
endoplasmic reticulum (ER) and packaged into chylomicrons (Figure 1.1B). Chylomicrons are
subsequently secreted into the blood stream through the lymphatic circulation. Lipoprotein lipases
(LPL) present in the peripheral vascular beds can lyse TAG within the chylomicrons to release fatty
acids to both the local tissues and blood (35). After losing part of their TAG content, chylomicrons

7
are converted to remnant particles, which are smaller in size. These remnants are then readily taken
up by the liver (36) (Figure 1.1B).
The specific mechanisms of fatty acid uptake into hepatocytes are not well understood. Passive
diffusion (37), and fatty acid transporters such as fatty acid transport proteins (FATPs) and fatty
acid translocase (FAT/CD36) (38, 39), are believed to play a role in this process. Under
physiological conditions, hepatocytes also store limited amount of triglycerides in the form of small
lipid droplets for immediate energy requirements (40). Lipid droplets are decorated with families
of lipid-droplet surface proteins on the phospholipid monolayer, including perilipin and cell-deathinducing DFFA-like effector (Cide). It is believed, that the presence of perilipins restrict lipolysis
under basal conditions whereas their phosphorylation by protein kinase A stimulates lipolysis (41,
42). Among the three isoforms of Cide proteins (Cidea, Cideb and Cidec), Cidec, also known as
FSP27, is highly expressed in the white adipose tissue (43). The important role of DICEC/FSP27
in lipid storage was underlined by the observations that overexpression of FSP27 resulted in
triglyceride accumulation whereas FSP27 knockdown decreased the size of lipid droplets (44).
In cases of energy deprivation, such as fasting, the lipolysis activity of the adipose tissue is elevated
to supply fatty acids as an energy source for relevant tissues (41). The enzyme, adipose triglyceride
lipase (ATGL) specifically catalyzes the hydrolysis of TAG to produce diacylglycerol (DAG) and
fatty acids. The enzyme, hormone-sensitive lipase (HSL) can then release additional fatty acids
from DAG (Figure 1.1B). Releasing of the first fatty acid is the rate-limiting step in this reaction,
and free fatty acids released into the circulation are bound by albumin for the uptake into
hepatocytes.
2.2

Hepatic lipogenesis

In NAFLD patients, de novo lipogenesis (i.e. freshly synthesized lipids within the liver) also
contributes to steatosis (15, 45). Under non-pathological conditions, such as dietary carbohydrate
supply exceeding the capacity of the liver for glycogen storage, substrates are diverted to pathways
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of free fatty acid synthesis within the liver (Figure 1.1B) (46). The de novo lipogenesis (DNL)
pathway has been extensively studied (36, 47) and will be described here briefly . The catabolism
of glucose through the tricarboxylic acid cycle yields citrate, which is subsequently transported to
the cytosol and converted to acetyl-CoA. The enzymes, acetyl-CoA carboxylase (ACC) catalyze
the conversion of acetyl-CoA to malonyl-CoA. Malonyl-CoA, which serves as a two-carbon donor,
is added to the acetyl-CoA primer by the enzyme, fatty acid synthase (FAS). Palmitic acid (PA) is
the primary product of FAS. Palmitic acid precursor can be elongated by two carbon atoms to
produce the saturated FA, stearic acid. The desaturation of saturated FA, which is catalyzed by
stearoyl-CoA desaturase-1(SCD-1), yields unsaturated FA, such as oleic acid. (48).
Insulin regulates mRNA expression of lipogenic genes through the activation of the transcription
factor, sterol regulatory element binding protein-1c (SREBP-1c). SREBPs are considered to be the
master transcriptional regulators of genes involved in lipid metabolism (49). This family consists
of three members, SREBP-1a, SREBP-1c and SREBP-2. SREBP-1c is the predominant isoform
responsible for the regulation of lipogenic genes in the liver (49). Insulin signaling regulates
SREBP-1c both at the transcriptional and post-translational levels. The newly synthesized SREBP
precursor is anchored at ER membrane (50) in association with both the SREBP cleavage activating
protein, SCAP and the ER-retention protein, Insig (51). The activation of SREBP requires its
dissociation from Insig and subsequent translocation to the Golgi apparatus. In Golgi, SREBP-1c
protein is cleaved and its active N-terminal fraction released to be imported into the nucleus (52).
The suppression of Insig-2a (53) and SREBP-1c phosphorylation by Akt are important steps in
insulin-signaling-mediated processing of SREBP-1c. Furthermore, insulin up-regulates the nuclear
translocation of SREBP-1c through the activation of mammalian target of rapamycin complex 1
(mTORC1), a nutrient- and growth factor-responsive kinase (54). Activation of transcription
factors, such as liver X receptors (LXRs) (55) and SREBP-1c itself (56) are also believed to be
mechanisms by which insulin can up-regulate SREBP-1c at the transcriptional level. Most of
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SREBP-1c targets genes, such as acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS),
participate in de novo fatty acid synthesis pathway and harbor sterol regulatory element (SRE)
DNA-binding sequences in their promoters (49).
Glucose modulates the expression of genes involved in lipogenesis through the activation of the
transcription factor, carbohydrate response element binding protein (ChREBP). The
phosphorylation of ChREBP and its physical interaction with other molecules allows it to sense the
level of intracellular glucose (49). Under basal conditions, when intracellular glucose levels are
normal, ChREBP is phosphorylated by both by the cAMP-dependent protein kinase (a.k.a. protein
kinase A, PKA) and the AMP-activated protein kinase (AMPK) (57, 58). When glucose levels are
elevated, this leads to the stimulation of the pentose phosphate pathway and thereby the production
of xylulose 5-phosphate (X5P). X5P subsequently activates protein phosphatase 2A (PP2A).
Following dephosphorylation by PP2A, ChREBP is activated and translocates to the nucleus (59).
Besides the post-translational modifications, the activity of ChREBP as a glucose sensor is
mediated by intramolecular interaction between the low glucose inhibitory domain (LID) and a
glucose response activation conserved element (GRACE) of ChREBP. When the glucose level is
low, the interaction between LID and GRACE inhibits the DNA-binding activity of ChREBP.
However, with high levels of glucose , this inhibition is eliminated resulting in ChREBP activation
(58, 60). Activated ChREBP then binds to the promoters of genes, which are involved in glycolysis
and lipogenesis, and activates their transcription (49).
2.3

Hepatic fatty acid secretion

Very low density lipoproteins (VLDL) are a class of lipoproteins important for lipid transport in
the liver. Triglycerides accumulated in the liver are primarily exported via VLDL secretion to
prevent steatosis (Figure 1.1B). Similar to chylomicrons in the intestine (see section 2.1 above),
the assembly of VLDL requires apolipoprotein B (apoB) as the scaffold protein. Following its
synthesis, the liver-specific form of apolipoprotein B, apoB-100, is translocated across the ER
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membrane into the lumen and subsequently lipidated by microsomal triglyceride transfer protein
(MTP) to form the primordial VLDL particles (61). Through the physical interaction, MTP
stabilizes the newly synthesized apoB-100 (62, 63). Accordingly, in the absence of MTP, apoB100 is not optimally lipidated and becomes prone to proteasomal degradation (64). Furthermore,
liver-specific deletion of MTP in mice has been reported to cause a significant decrease in VLDL
synthesis accompanied by an increase in cytosolic fat droplets (65). The primordial VLDL particles
subsequently fuse with the triglyceride-rich particles to form the mature VLDL particles (61).
The expression of MTP is directly associated with VLDL secretion and is therefore frequently
employed as marker for the study of hepatic lipid secretion (66). The promoter of MTP gene harbors
multiple DNA-binding sites including hepatic nuclear factor-1 and 4 (HNF-1 and 4) response
element, direct repeat (DR) 1, forkhead box (FOX), and sterol and insulin response elements
(SRE/IRE). The binding of transcription factors, HNF-1α and 4α are important for the basal
transcriptional expression of MTP (67–69). The agonists of PPARα are believed to stimulate MTP
expression through the DR1 sequence in its promoter (70). Both the FOX and SRE/IRE response
element sites have been suggested to mediate the inhibitory effect of insulin on MTP transcription
(71, 72), It should however be noted that it is unclear whether insulin plays a significant role in the
regulation of MTP expression and VLDL secretion because various experimental models of
hyperinsulinemia display strong MTP promoter activity (73–75). Furthermore, excess dietary
sucrose, fructose or fat supply induce MTP expression through yet unidentified mechanisms (75,
76).
2.4

Hepatic fatty acid oxidation

Besides the synthesis or transport, oxidation of fatty acids is also an important component of hepatic
lipid metabolism (Figure 1.1B). Liver is the central organ for fatty acids oxidation, which is the
major pathway for fatty acid disposal and energy production. Of the three organelles, namely
mitochondria, peroxisomes and ER, which participate in the oxidation of fatty acids, mitochondrial
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β-oxidation pathway plays the most prominent role (36). When lipolysis is stimulated under nonpathological (e.g. fasting) or pathological (e.g. insulin resistance) conditions, fatty acids are
activated to acyl-CoA esters and shuttled into the mitochondrial matrix. The carnitine-palmitoyltransferase (CPT) system facilitates the transport of acyl-CoA into mitochondria in a two-step
reaction (36). The enzyme, CPT1, which is located at the outer membrane of mitochondria,
converts acyl-CoA to acylcarnitines. CPT1 catalyzes the rate-limiting step of β-oxidation (77) and
its activity is inhibited by malonyl-CoA, a metabolic intermediate in the lipogenesis pathway (see
section 2.2 above). Acylcarnitines are then transported across the mitochondrial inner membrane
via the enzyme, carnitine acylcarnitine translocase. The enzyme, CPT2, which is localized in the
mitochondrial inner membrane, then catalyzes the reverse reaction to restore CoA group to
acylcarnitines. The released carnitines are subsequently used for the next round of shuttling
reactions. Once inside the mitochondrial matrix, acyl-CoA carbon chain is shortened by 2 carbons
at a time through a four-step β-oxidation reaction to produce acetyl-CoA.
Peroxisome proliferator-activated receptor α (PPARα) is the major transcription factor participating
in the regulation of genes related to fatty acid uptake and oxidation. Peroxisome proliferatoractivated receptors (PPARs) are a group of nuclear receptors and transcription factors belonging to
the steroid receptor superfamily (78). PPAR family contains three isoforms, PPARα, PPARβ/δ, and
PPARγ. The liver and other organs with high FA oxidation capacity mainly express the isoforms,
PPARα and PPARβ/δ (79). PPARα is activated by lipid intermediates, which arise from the
lipogenesis and lipolysis pathways, and fatty acid catabolism pathways (80). Upon activation,
PPARα forms heterodimers with another nuclear receptor, retinoid X receptor (RXR) (80).
Together with other co-activators (80), the PPARα/RXR heterodimer complex activates the
transcription of the target genes involved in the regulation of FA transport and β-oxidation by
binding to PPAR response element (PPRE) in their promoters (81). PPARα promotes fatty acid
uptake by up-regulating the expression of FA transporters, such as FATP1 and FAT/CD36 (82, 83).
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Moreover, PPARα activates mitochondrial β-oxidation by controlling the transcription of ratelimiting enzymes, CPT1 and CPT2 (84, 85). In addition, PPARα regulates the transcription of
SREBP-1c , thereby controlling lipogenesis (86). Although PPARβ/δ are not highly expressed in
the liver, their levels have been suggested to be elevated in steatotic livers (87). They might act in
concert with PPARα in the transcriptional regulation of genes responsible for hepatic lipid
metabolism (87). In addition, PPARγ is highly expressed in fat tissues and plays a major role in the
maintenance of lipid homeostasis by controlling lipogenesis in the white adipose tissue (88). The
participation of PPARβ/δ and PPARγ in the pathogenesis of steatosis is currently being investigated.
2.5

Lipid derivatives in the liver

Besides fatty acids, fat accumulation in the liver gives rise to other lipid derivatives such as
lysophosphatidic acid and ceramide (Figure 1.1B). However, the involvement of these
intermediates in NAFLD pathogenesis is not well understood. We were particularly interested in
ceramide because of its connection to saturated fatty acids. Ceramide belongs to the sphingolipid
family of lipids. This family is unique in that besides their traditional role as structural molecules
for membrane biogenesis, they have recently been recognized as intracellular second messengers.
One of the pathways for ceramide (and other sphingolipid) synthesis, is so-called “de novo
synthesis pathway”, which utilizes saturated fatty acid, especially palmitic acid, as the starting
substrate (Figure 1.2). Ceramide is synthesized through a four-step reaction catalyzed by enzymes
localized in the ER (89). Serine palmitoyltransferase (SPT), which transfers a serine residue to
palmitoyl-CoA to produce 3-keto-sphinganine is the rate-limiting enzyme of de novo ceramide
synthesis pathway. Ceramide can further be modified to produce other species of the sphingolipid
family (Figure 1.2). In addition to the de novo pathway, two other alternative pathways exist for
ceramide biosynthesis. One of them is the “sphingomyelinase (SMase) pathway”, which hydrolyses
sphingomyelin located in the cell membrane for the rapid production of ceramide. The other
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pathway known as the “salvage pathway” recycles ceramide from the catabolism of sphingolipids
(Figure 1.2) (90).
The rate of de novo ceramide synthesis is correlated with the availability of its substrate. The
activity of SPT, which catalyzes the rate-limiting first step of the de novo ceramide synthesis
pathway, is stimulated by serine and palmitoyl-CoA (91). Both endotoxin (i.e. lipopolysaccharide,
LPS) and inflammation have been shown to be involved in the pathogenesis of NAFLD. The family
of toll-like receptors (TLR) are important for the regulation of innate immune responses and each
member is activated by different ligands (92). TLR4 is activated by the binding of LPS but besides
LPS, saturated fatty acids also serve as natural ligands for TLR4 (93). Moreover, the activation of
TLR4 by saturated fatty acids and LPS up-regulates the expression SPT, the enzyme required for
de novo ceramide synthesis (94). This up-regulation is dependent on the activation of proinflammatory kinase, IKKβ, which is part of the TLR-specific signaling cascade (94).
Inflammatory cytokines, in particular TNF-α, have been shown to stimulate the activity of
sphingomyelinase (SMase) for the rapid production of ceramide (95, 96). Ceramide production in
NAFLD and diabetes patients is elevated, and the increase in ceramide production has been shown
to contribute to the pathogenesis of metabolic diseases. Patients with type 2 diabetes exhibit
elevated ceramide content in the serum (97, 98) and skeletal muscle (99) . Hepatic steatosis
correlates with over-production of ceramide in the adipose tissue (100). High-fat diet-intake has
been shown to increase hepatic ceramide content in animal models (101, 102). Weight loss in
NASH patients has also been reported to lead to the suppression of genes, which are related to
ceramide production (103).
2.6

Mechanisms of hepatic lipid accumulation in NAFLD

Steatosis, as observed in the livers of NAFLD patients, develops as a result of both hepatic and
systemic dysregulation of lipid metabolism, which cannot be compensated by the lipid oxidation
and export capacity of the liver (12). Although obesity and insulin resistance cause changes in lipid
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metabolism, there are other factors, which make the liver conducive to excessive accumulation of
hepatic triglycerides. Here, we briefly review the changes which contribute to hepatic steatosis by
focusing on major players relevant to this process.
In obese individuals, the adipose tissue is significantly expanded by increases in both adipocyte
mass and synthesis. Visceral adiposity induces an inflammatory state and macrophages are
infiltrated into the adipose tissue. This results in an increase in both the local and systemic
expression of inflammatory cytokines and adipokines (104). Inflammatory cytokines inhibit insulin
signaling and are therefore considered to be one of the major contributors of insulin resistance in
obesity (105). Insulin resistance in adipose tissue impairs the inhibitory effect of insulin on the
enzyme activity of hormone-sensitive lipase (HSL) (10). As a result of this, the rate of lipolysis is
elevated despite the presence of high levels of insulin in the circulation (Figure 1.3). In agreement,
NAFLD patients have been shown to exhibit an increase in the lipolysis activity of their
subcutaneous adipose tissues (106). By using stable-isotope labeling method, Donnelly et al. have
analytically demonstrated that in NAFLD patients, about 60% of hepatic triglyceride content
originates from the uptake of fatty acids originating from the adipose tissue. This study further
emphasizes the importance of adipocyte lipolysis in the development of hepatic steatosis (107).
Dietary fat is another prominent source of hepatic triglycerides (Figure 1.3). Based on the species
and structure, the dietary fats are usually categorized as polyunsaturated, monounsaturated, and
saturated fatty acids, and trans-fats (12). In animal models fed with different compositions of highfat diets, it has been demonstrated that saturated and monounsaturated, but not polyunsaturated
fatty acids, are capable of inducing hepatic steatosis (108). The effect of saturated fats was further
confirmed by a number of other studies using both animal models and tissue culture cells (109,
110). In a retrospective study comparing the dietary composition of NASH patients with age and
BMI-matched controls, NASH patients consumed significantly higher amounts of saturated fats
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from their diet (111). Trans-fats, which commonly exist in modern diets, have also been shown to
cause NASH in rodent models (112).
Both adipose tissue lipolysis and dietary fat absorption elevate the level of circulating fatty acids,
which are taken up by the liver. The differential expression of the fatty acid transporter, FAT/CD36,
in the livers (i.e. elevated) and adipose tissues (i.e. decreased) of NAFLD patients, compared to
controls (113, 114), strongly points out a role for hepatocyte transporters in elevated fatty acid
uptake.
The increased rate of freshly synthesized lipids within the liver (i.e. de novo lipogenesis) also adds
to the burden of hepatic triglyceride accumulation (Figure 1.3). Isotope studies with NAFLD
patients pointed out that 26% of the liver triglycerides derive from de novo lipogenesis, compared
to 5% in normal control individuals (15, 115). De novo lipogenesis is regulated by both blood
glucose and insulin levels through the transcription factors, ChREBP and SREBP-1c, respectively
(see section 2.2 above). Peripheral insulin resistance hampers the uptake and utilization of glucose
in metabolic tissues (e.g. muscle), and consequently causes hyperglycemia. In addition, the hepatic
insulin-resistance further increases the levels of blood glucose by both activating gluconeogenesis
and suppressing glycogenesis (9). Increased glucose levels activate ChREBP, which subsequently
actives the expression of the enzymes participating in lipogenesis. Accordingly, the deletion of
ChREBP in mice significantly decreased the expression of a variety of genes involved in
lipogenesis (116). Overexpression of ChREBP, on the other hand, stimulated the expression of
lipogenic genes resulting in steatosis (117). Furthermore, steatosis level in NASH patients has been
shown to correlate with elevated hepatic ChREBP expression (117). Taken together, these studies
highlight the significance of ChREBP in lipogenesis and thereby steatosis, as observed in NAFLD
patient livers. In addition to glucose, insulin stimulates lipogenesis by activating the transcription
factor, SREBP-1c. However, the studies with both the experimental rodent models and NAFLD
patients have shown, that despite the presence of insulin resistance, hepatic up-regulation of
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SREBP-1c was not affected (118, 119). In a mouse model of steatosis, the absence of SREBP-1c
ameliorated fatty liver phenotype (120) further supporting the importance of SREBP1-c in steatosis.
Oxidation of fatty acids is essential to satisfy the energy requirements for metabolic functions and
to maintain lipid homeostasis in the liver (121). In agreement, mice with disrupted expression of βoxidation genes developed hepatic steatosis (122, 123). As mentioned earlier, PPARα is a central
player in the regulation of β-oxidation. In a genetic rat model of NAFLD, agonists of PPARα
significantly alleviated steatosis (124). This improvement was associated with the up-regulation of
a spectrum of genes involved in β-oxidation. In NAFLD patients, CPT1, the rate-limiting enzyme
of mitochondrial β-oxidation, was down-regulated (113). In addition, the livers of NAFLD patients
displayed abnormalities in mitochondrial structure and function, suggesting disturbances in the
mitochondrial β-oxidation pathway in these livers (125–128).
VLDL secretion is responsible for the export of extra triglycerides from the liver. Inhibition of
MTP, the key enzyme of VLDL assembly and secretion, results in hepatic lipid accumulation (129).
As supported by multiple studies, the level of VLDL secretion is elevated in NAFLD patients
compared to control individuals (121, 130, 131). It should however be noted, that the initial linear
increase in VLDL secretion in correlation with hepatic lipid content has been shown to reach a
plateau without further increase in VLDL secretion despite elevated hepatic triglyceride loading
(121). This saturation phenomenon might be due to the limited capability of the liver to secrete
large VLDL particles (121).
In summary, the development of hepatic steatosis occurs as a net result of the overwhelmed capacity
of the liver for lipid oxidation and secretion in concert with an increase in the overall rate of hepatic
lipid uptake and de novo synthesis (Figure 1.3).
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2.7

Lipid-mediated signaling pathways in NAFLD

Hepatic steatosis compromises the metabolic processes in the liver and sensitizes hepatocytes to
secondary insults, such as mitochondrial dysfunction, oxidative stress, ER stress, apoptosis and
inflammation (12). The accumulation of triglycerides in the form of lipid droplets is not detrimental
per se but rather considered to be both a protective response and a measure of the lipid burden in
hepatocytes (132). Indeed, the inhibition of triglyceride production alleviates steatosis but
exacerbates the level of fibrosis and injury in the liver (133). Free fatty acids and other lipid
intermediates are considered to be the most harmful lipid species in hepatocytes (132, 134). In this
section, a brief summary of the signaling events induced by fatty acids and the lipid derivative,
ceramide will be discussed.
2.7.1

Fatty acid-induced signaling

i- Fatty acid-induced apoptosis
The word apoptosis, derived from a Greek word meaning “leaves falling from a tree” (135),
describes a specific type of programmed cell death process characterized by membrane blebbing,
shrinkage of the cell, chromatin condensation, nuclear fragmentation and the formation apoptotic
bodies (136). Apoptosis can be induced either through the binding of a death ligand to a specific
cell surface receptor (i.e. extrinsic pathway) or the leakage of cytochrome c through the
mitochondrial outer membrane (i.e. intrinsic pathway) (137). Death receptors, including tumor
necrosis factor (TNF)-α receptor, TNF-related apoptosis-inducing ligand (TRAIL), and Fas are
highly expressed at a basal level in healthy hepatocytes (137). Binding of the corresponding ligand
to the receptor stimulates the cleavage and activation of cysteine-aspartic proteases called initiator
caspases, which include caspase 8 and 10. These caspases then activate the downstream caspases,
caspases 3, 7 and 6 for the execution of the apoptotic process (136). The intrinsic apoptotic pathway,
which is initiated when the pro-apoptotic Bcl-2 family proteins, such as Bax and Bak, permeabilize
the mitochondrial outer membrane and release cytochrome c. Cytochrome c subsequently activates

18
caspase-9, which then activates the executioner caspases (i.e. caspase 3, 7 and 6). The activation of
apoptosis in hepatocytes requires the cross-talks between the extrinsic and the intrinsic pathways
through the cleavage of BH-3 only protein, Bid, which facilitates the leakage of cytochrome c (136).
Fatty acids, in particular saturated fatty acids, induce apoptosis (i.e. lipoapoptosis) in various cell
types including hepatocytes (138, 139). The differences between the efficacy of saturated and
unsaturated fatty acids to induce apoptosis might be due to their innate properties. Namely,
unsaturated fatty acids are more readily esterified to form triglycerides, which decreases their
toxicity (140). In fact, unsaturated fatty acids rescue apoptosis induced by the saturated fatty acid,
palmitate by enhancing the conversion of palmitate to triglyceride (134). In hepatoma cells, fatty
acid-induced apoptosis is dependent on the phosphorylation of c-Jun N-terminal kinase (JNK),
which directly activates the proapoptotic Bcl-2 family of proteins (139). Moreover, JNK mediates
saturated fatty acid-induced up-regulation of death receptor expression in hepatoma cells, and thus
sensitizes the cells to further insult via the death (141). In addition, saturated fatty acids also induce
ER stress, which plays an essential role in the induction of lipoapoptosis, as shown in hepatoma
cells (142, 143). In NAFLD patients with severe form of disease, lipoapoptosis in hepatocytes of
the liver is accompanied by an increase in the expression of cell surface death receptors (144, 145).
Furthermore, the presence of plasma markers specific for hepatic apoptosis in NAFLD patients
have been proposed to be strong and independent predictors of NASH (146).
ii- Fatty acid-induced protein kinase C activation
A role for lipid-mediated activation of protein kinase C (PKC) signaling has been proposed in
metabolic syndrome and NAFLD (147). Based on the requirement for diacylglycerol (DAG) and/or
calcium (Ca2+) for enzymatic activity, PKC isoforms are categorized into three groups; classical
(PKCα, β, and γ), novel (PKC ε, η and θ) and atypical (PKC ζ and λ) kinases (148). The activation
of classical PKC isoforms requires both Ca2+ and DAG, while the novel PKC isoforms require only
DAG. Atypical PKC isoforms do not require DAG or Ca2+ for enzymatic activity (149). G protein-
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coupled receptors and receptor tyrosine kinases, which are the classical PKC activators, induce the
hydrolysis of phosphatidylinositol 4, 5-bisphosphate via phospholipase C for the production of
DAG. DAG then activates specific PKC isoforms, as mentioned above (150). However, in cases of
insulin resistance and metabolic syndrome, DAG levels are increased due to elevated de novo
lipogenesis and fatty acid production (151, 152). Feeding of rodents with high-fat diets has been
shown to result in increased hepatic DAG levels and the activation of PKC was associated with the
development of insulin resistance (153). In a mouse model where NASH was induced by the
administration of a methionine-and choline-deficient (MCD) diet, the levels of PKC activation were
elevated in the liver (154). Similarly, in hepatoma cells, saturated, but not unsaturated, fatty acids
induced production of DAG, which was accompanied by the activation of PKC (155, 156). The
molecular mechanisms of PKC activation and its contribution to NAFLD pathogenesis are not
completely understood. Nevertheless, a role for PKC, in particular novel class PKC isoforms (e.g.
PKC ε), in insulin resistance has been proposed (147). A study conducted with liver biopsies from
patients undergoing bariatric surgery has shown that hepatic DAG and PKCε content are the
strongest predictors of insulin resistance (157). Furthermore, a rat model of PKCε knockdown was
protected against high-fat-feeding-induced hepatic insulin resistance (158). PKCε has also been
reported to inhibit insulin signaling through its integration with the insulin receptor and impairing
its kinase activity (158).
2.7.2

Ceramide-induced signaling

In connection with lipid accumulation and inflammatory signaling, the production of lipid
derivative, ceramide is stimulated in NAFLD livers (see section 2.5 of this chapter). Patients with
type II diabetes have also been reported to exhibit elevated levels of ceramide in the blood stream
(97, 98). There are only limited number of studies showing ceramide production in the livers of
NAFLD patients (159). The liver however has been suggested to be a key organ for ceramide
synthesis (90). Similarly, studies with high-fat diet-fed mice have also reported elevated hepatic
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ceramide content (101, 102). The precise role of ceramide in the pathogenesis of NAFLD and
metabolic syndrome are not well understood. Some studies have shown that ceramide, by
antagonizing Akt (i.e. insulin) signaling, can participate in the development of insulin resistance in
skeletal muscle and fat tissues (160, 161). Other studies have reported the involvement of ceramide
in different signaling pathways related to inflammation. In an in vitro model of human fibroblasts,
JAK/STAT3 signaling pathway has been shown to be activated by elevated ceramide levels, which
was dependent on JAK2 kinase isoform (162). Similarly, the DNA-binding activity of NF-κB has
been shown to be stimulated by ceramide treatment of various cancer cell lines (163, 164).
Furthermore, ceramide and its derivatives have been shown to activate NF-κB in HepG2 human
hepatoma cells (165). Studies using tissue culture cells have reported a role for stress-activated
kinase, JNK in mediating the effects of ceramide analogs (166–168). The signaling pathways
activated by ceramide in hepatocytes will be further discussed in later chapters (see chapter V).

3

REGULATION OF IRON METABOLISM AND ITS RELATIONSHIP TO NAFLD

This section will provide a brief review of iron physiology and the proteins involved in the
regulation of iron homeostasis with an emphasis on the role of central iron regulator, hepcidin. The
relationship of iron to NAFLD pathogenesis will also be discussed.
3.1

Physiology of Iron

Iron is an essential element for all living organisms from bacteria to humans (169). An adult human
body contains an average of 3 to 4 g of iron per kg of body weight distributed in different parts of
the body (170). Most of it is integrated into hemoglobin for red blood cell synthesis in bone marrow.
As red blood cells are essential for the tissue delivery of oxygen, iron is connected with cellular
respiration. Similarly, iron is also utilized for the synthesis of muscle oxygen-binding protein,
myoglobin. Oxygen is required for aerobic respiration in mitochondria to generate ATP. Enzymes
in the electron transport chain of aerobic respiration harbor conserved iron sulfur (Fe-S) clusters,
which are important for their biological function. Iron is also associated with DNA replication,
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DNA repair, cell cycle and growth. Ribonucleotide reductase is a pivotal enzyme for DNA
synthesis and needs iron as a cofactor for optimal activity. In mammalian cells, iron deprivation
has been shown to attenuate ribonucleotide reductase activity and arrest cell growth (171).
Iron however can act like a double-edged sword. Despite being indispensable for fundamental
biological functions, as mentioned above, excess free iron can also be deleterious. As a transition
metal, iron shuttles between ferric (Fe3+) and ferrous (Fe2+) forms by accepting and donating
electrons, and takes part in Fenton reaction. The interaction of iron with H2O2 results in the
production of a highly reactive oxygen species called hydroxyl radical (•OH) (28). •OH can attack
DNA backbone and other macromolecules including proteins and lipids thereby causing lipid
peroxidation, DNA damage and injury to cellular membranes (172). The levels of iron in the human
body must therefore be tightly regulated.
The regulation of iron homeostasis is achieved at multiple sites in the body (173). Dietary iron is
absorbed by the enterocytes in the duodenum. On the other hand, macrophages of the
reticuloendothelial system are responsible for recycling iron from hemoglobin by phagocytosing
senescent erythrocytes. The transport of iron in the circulation is carried out by the transferrin
protein (174). One molecule of transferrin has the capacity to bind two atoms of Fe3+. This
facilitates safe transport of iron to distant organs via transferrin binding to transferrin receptors 1
and 2. Transferrin receptor 1 is ubiquitously expressed whereas transferrin receptor 2 is primarily
expressed in the liver. Transferrin receptor 2 displays less affinity for transferrin compared to
transferrin receptor 1 (175).
The liver is an important organ for iron metabolism for various reasons some of which will be
discussed later. Most importantly, the liver carries the major burden of iron overload by serving as
the prominent storage organ for excess iron, and thereby protecting the body from its harmful
effects (176). Tissue iron is stored in the iron-storage protein, ferritin. Each ferritin molecule has
the capacity to store up to 4,500 atoms of Fe3+ in its spherical structure, which is available for
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recycling (177). Both transferrin and ferritin proteins are also frequently used in the clinic as
diagnostic markers to assess the iron status of patients. In the last two decades, novel proteins such
as multi-transmembrane iron transporter proteins and soluble regulators have been discovered,
which revolutionized our understanding of iron metabolism. These proteins will be discussed below.
3.2

Iron import and export pathways

Iron from the diet is absorbed mostly in the form of inorganic ferric iron or heme on the apical site
of enterocytes in the duodenum (173). The intestinal uptake of dietary heme is not well understood.
A role of heme carrier protein 1 (HCP1) has been suggested (178) but the specificity of HCP1 for
heme uptake is controversial. The iron is subsequently released from the heme molecule via heme
oxygenase-1 (HO-1) (179). On the other hand, the mechanisms of inorganic iron uptake are well
defined. Prior to uptake, ferric iron is reduced to soluble ferrous iron by a ferric reductase on the
apical surface of enterocytes (180). The apical divalent metal transporter 1 (DMT1) is then
responsible for the transport of ferrous iron into the enterocyte (181). DMT1 is a Fe2+/H+ cotransporter (182), and its transport of Fe2+ is dependent on a proton gradient. Once within the
enterocyte, iron is either incorporated into ferritin (see above) for intracellular storage or exported
via the basolateral site into to the circulation. Basolateral iron export is accomplished by the only
known mammalian iron exporter protein, ferroportin. DMT1 and ferroportin have similar structures,
both being multi-transmembrane proteins (173).
Unlike enterocytes, macrophages of the reticuloendothelial system take up iron via phagocytosis,
and digestion of senescent erythrocytes (see above). Iron released from heme molecules via HO-1
is subsequently exported by ferroportin. Due to its overlapping role in different organs, ferroportin
is a major determinant of circulating iron levels. The regulation of this iron exporter was better
understood after the discovery of the central iron-regulatory hormone, hepcidin. The interaction
between ferroportin and hepcidin resembles the interaction of a circulatory hormone (i.e. hepcidin)
with its receptor (ferroportin), which will be discussed further below.
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3.3

Hepcidin, the key iron regulatory hormone

Since iron homeostasis is regulated at multiple distant sites, the presence of soluble factors, which
play a key role in controlling the cross-talk between these sites, was long suspected. This hypothesis
was confirmed by the discovery of hepcidin. The fact that hepcidin is mainly synthesized in
hepatocytes also gave the liver center stage in the regulation of iron metabolism (Figure 1.4).
Hepcidin was discovered independently by different laboratories (183–185). Krause et al. and
Hunter et al. have identified hepcidin as a small peptide with weak antimicrobial activity in the
human blood ultrafiltrate (183) and urine (184), respectively. The involvement of hepcidin in iron
metabolism was indicated by Pigeon et al., who have shown the induction of hepcidin mRNA in a
mouse model with iron loading (185). Interestingly, the coincidental disruption of surrounding
chromosomal regions in a USF2 knockout mouse model (186) has been reported to result in iron
overload. This observation then led to the discovery that, hepcidin gene (HAMP), which was codeleted due to its proximity to USF2 gene (185), is responsible for the regulation of iron
homeostasis. A direct role of USF2 in iron regulation was however excluded because a USF2
knockout mouse model from another laboratory, which does not have disruption of HAMP gene,
does not display an iron overload phenotype (187). The important role of HAMP in iron metabolism
was also supported by human studies with primary genetic iron overload disorders. Mutations in
HAMP gene was identified in patients with juvenile hemochromatosis, a severe early-onset form
of genetic iron overload disorder associated with hemojuvelin (HJV) gene (188). Similarly
attenuated HAMP expression, which was unresponsive to oral iron administration, was observed
in genetic hemochromatosis (GH) patients harboring mutations in GH gene, Hfe (189). The
regulation of hepcidin by iron and its effect on iron homeostasis has been depicted in Figure 1.5.
Although humans express a single hepcidin gene, HAMP, mice expresses two hepcidin genes,
Hamp and Hamp2. Various studies, including the one from our laboratory (190), indicate, that
Hamp mouse gene is the equivalent of human HAMP gene regarding the regulation of iron
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metabolism (187, 191). Overexpression of Hamp, but not Hamp2, resulted in severe iron deficiency
and anemia (187, 191). Studies with different Hamp and Hamp2 knockout mouse lines generated
in our laboratory have also shown, that further ablation of Hamp2 gene in Hamp knockout mice
did not exacerbate the iron-overload phenotype observed with Hamp deletion (190).
Hepcidin is synthesized as an 84 amino acid pre-prohepcidin protein with an N-terminal 24-amino
acid signal sequence, which is cleaved to yield prohepcidin protein (173). The prohepcidin
precursor protein is subsequently cleaved by proteases, such as furin-like prohormone convertases
(171), at the C-terminus to form the 25-amino acid mature, hepcidin peptide. This soluble form is
released into the circulation to function as a biologically active protein (Figure 1.6). Furthermore,
shorter (truncated at the N-terminal) forms of 20- and 22-amino acid hepcidin peptides have been
detected in human serum and urine (184, 192).
Hepatocytes are the major site of hepcidin synthesis (193). Other cell types such as adipocytes in
obesity (194) and macrophages (195) have been reported to exhibit very low levels of hepcidin
mRNA expression. In accordance with the importance of hepatocytes as the major site of synthesis,
liver-specific hepcidin knockout mice have been shown to display similar levels of systemic ironoverload as the global hepcidin knockout mice, which lacked hepcidin expression in all of the
organs (190, 196).
Biologically active hepcidin peptide harbors intramolecular disulfide bridges. It adopts a simple
hairpin structure with 4 disulfide bonds forming between the 8 cysteine residues (197). The five Nterminal amino acids are critical for the biological function of hepcidin (198). By contrast, the
disruption of the C-terminal amino acids and the mutation of any of the cysteine residues have been
reported to exert negligible effects on the function of hepcidin (198).
The mechanistic insight into the function of hepcidin in iron metabolism was first described by
Nemeth et al. (199). Using a stable cell line expressing GFP-tagged ferroportin, they have shown

25
that hepcidin induced the internalization and lysosomal degradation of ferroportin on the plasma
membrane through a direct and specific interaction, which resembled the binding of a ligand to its
receptor. Further reports have shown that hepcidin-induced internalization of ferroportin is
dependent on tyrosine phosphorylation, while the degradation process involved ubiquitination
(200). By inducing the degradation of ferroportin, hepcidin interferes with cellular iron transport,
and ultimately decreases serum iron levels. Vice versa, a decrease in hepcidin expression will cause
an increase in cellular iron transport resulting in elevated levels of serum iron (Figure 1.5).
After a pivotal role has been established for hepcidin as the master switch of iron metabolism,
intensive investigations were performed to understand the regulation of its expression. The
evidence for the circulatory hepcidin protein to be regulated at the level of secretion is not strong
(201). The growing consensus however was that hepcidin is regulated at the mRNA level (202–
204). Accordingly, several studies have shown that hepcidin is transcriptionally regulated by iron
loading, inflammatory signals, erythroid activity, endoplasmic reticulum (ER) stress and growth
factor signaling (205–208). A brief overview of the pathways relevant to this dissertation has been
presented below.
Besides being an iron-regulatory protein itself, the expression of hepcidin is strictly regulated by
iron (Figures 1.5). Bone morphogenic protein (BMP) receptor and SMAD signaling pathways play
a central role in the feedback regulation of hepcidin in response to iron loading. Hepcidin has been
shown to be stimulated by various BMP ligands (209, 210). BMP6 knockout mice exhibited severe
iron overload with very low hepcidin expression levels, which highlighted the specificity of BMP6
ligand in iron homeostasis (211). Liver-specific SMAD4 knockout mice also exhibited a dramatic
decrease in hepcidin expression levels accompanied by iron overload (207). Furthermore, the
ablation of SMAD4 in these mice abrogated the response of hepcidin transcription to iron loading
(207). Overexpression of SMAD4 stimulated the transcription of hepcidin gene through the BMPresponse elements in the promoter (207, 212). As mentioned above, hemochromatosis patients with
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mutations in hemochromatosis gene, HFE, transferrin receptor 2 (TRF2) or hemojuvelin (HJV)
genes display decreased hepcidin expression (202). These studies suggest that the hepatocyte cell
surface proteins encoded by these genes are upstream regulators of hepcidin in response to iron
loading. The exact mechanisms underlying cellular iron sensing are still unclear but the modulation
of BMP/SMAD signaling pathway by TRF2, HFE or HJV might be one of the potential
mechanisms (202, 204).
Besides being an iron-regulatory protein, hepcidin also serves as an acute phase protein, and is
associated with innate immunity and infection. As an antimicrobial peptide, the regulation of
hepcidin by inflammatory cytokines has already been established (213, 214). Mediators of
inflammation, such as LPS, turpentine, and interleukins, IL-1 and IL-6 have been shown as potent
stimulators of hepcidin mRNA expression (213–215). IL-6 is one of the best studied mediators of
hepcidin up-regulation in response to inflammatory stimuli. IL-6 knockout mice have been reported
to exhibit decreased responsiveness to turpentine (213). IL-6 activates HAMP promoter through
JAK/STAT3 signaling pathway and the subsequent binding of STAT3 to the cis-element in the
promoter (205, 216). Inflammation-induced hepcidin up-regulation has been accepted as the major
contributor in the development of anemia of chronic disease (217).
Oxidative and endoplasmic reticulum stress play a role in the pathogenesis of liver diseases (218).
Endoplasmic reticulum (ER) stress, also called unfolded protein response (UPR), is the response
of the cell to the accumulation of unfolded or misfolded proteins in the ER (218). A chemical
inducer of ER stress, tunicamycin, has been shown to up-regulate hepcidin expression at the
transcriptional level in human hepatoma cells and mice livers (219). One of the underlying
mechanisms has been shown to be the activation of cyclic AMP response element–binding protein
H (CREBH) and its trans-activation of the hepcidin gene promoter (219). Oxidative stress, on the
order hand, has previously been shown by us to induce the suppression of hepcidin transcription in
the liver by alcohol exposure (220).
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Although studies up-to-now concentrated on the transcriptional regulation of hepcidin, posttranscriptional mechanisms can also be involved. MicroRNAs have recently been shown to regulate
hepcidin mRNA expression. The microRNA, miR-122 indirectly regulates the transcription of
mouse hepcidin genes by targeting 3’UTR regions of HFE and Hjv mRNA, which are upstream
regulators of hepcidin expression (see above) (221). By using an iron deficiency mouse model and
human hepatoma cells, Zumbrennen-Bullough et al. have reported, that an increase in miR-130a
levels exerts a negative effect on BMP-6-induced HAMP transcription by reducing the mRNA
stability of ALK2 gene, which encodes for BMP type I receptor (222). Although these studies
investigated post-transcriptional mechanisms, the primary focus was still the transcriptional
regulation of hepcidin gene. Hence, the confirmation for molecular mechanisms, which directly
target the 3’UTR of hepcidin mRNA is still lacking. We present evidence and discuss such
mechanisms in this study (see Chapter IV)
3.4

The relationship between iron and NAFLD pathogenesis

Elevated iron levels are frequently observed in patients with NAFLD and metabolic syndrome
(223). About one third of the NAFLD patient population exhibit elevated levels of serum iron
markers, such as serum ferritin (29, 224). Multiple large-scale population studies in different
regions of the world confirmed an association between hyperferritinemia and type 2 diabetes (225–
227). An association between serum ferritin levels and the increase in the number of features, which
are indicative of metabolic syndrome, has been reported, suggesting a link between serum iron
marker elevation and the progression of metabolic disease (30).
As explained above, the liver plays an important role in iron metabolism and protects the body from
harmful effects by serving as the central iron storage organ. Valenti et al. reported that in a
European population of NAFLD patients, iron accumulation in hepatocytes was associated with
more severe liver damage and fibrosis (31). Concurrently, Nelson et al. have shown that different
patterns of iron overload in the liver (i.e. hepatocellular, reticuloendothelial or mixed phenotype)
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were observed in 34.5% of patients in the “Nonalcoholic Steatohepatitis Clinical Research Network”
(32). In contrast to previously published studies, Nelson et al. further reported that patients with
reticuloendothelial iron deposition phenotype in the liver are more likely to display more advanced
NASH pathology with elevated hepatic inflammation and injury, and higher levels of fibrosis (32).
Despite the inconsistencies in iron deposition patterns, which might be due to the differences in
patient groups, these studies established a strong association between hepatic iron content and
NAFLD disease progression.
The mechanisms by which iron overload and hepatic iron deposition contribute to the development
of metabolic syndrome and NAFLD are unclear. Iron overload-induced production of reactive
oxygen species might serve as an important secondary risk factor, which exacerbates NAFLD
pathogenesis. In support of this theory, oxidative stress levels are elevated in NAFLD patients with
hepatic iron overload compared to those without (228). High-fat diet-feeding induced higher levels
of oxidative stress, as well as severe fibrosis and NASH pathology in HFE knockout mice, as
compared to wild-type counterparts (229). Furthermore, a role for iron in insulin signaling has been
proposed (230). Accordingly, phlebotomy has been reported to improve insulin sensitivity in
patients with NAFLD (231) and chelating iron restored insulin receptor signaling in tissue culture
cells (232). In addition, iron has been suggested to modulate lipid metabolism and steatosis (233,
234), which is further discussed in Chapter VI of the dissertation.
3.5

Modulation of hepcidin expression in NAFLD

Although a clear connection has been established between iron and NAFLD progression, the
regulation of hepcidin has not been widely investigated. By using severely obese patients
undergoing bariatric surgery, Bekri et al. reported that the increase in hepcidin mRNA levels in
adipose tissue is associated with elevated inflammation markers but not with obesity or NASH
conditions (194). However, the conclusions drawn from this study are inconclusive due to the study
design and the emphasis put on adipocytes, which express negligible levels of hepcidin compared
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to hepatocytes (194). Weiss et al. examined hepcidin mRNA expression in liver biopsies of NAFLD
patients and reported significantly increased levels of hepatic hepcidin expression (33). Similarly,
in a large scale patient study, Martinelli et al. have reported a linear relationship between serum
hepcidin levels, measured by mass spectrometry analysis and the increase in characteristic features
of metabolic syndrome (30). Another independent study with NAFLD patients from Turkey
established an association between an increase in serum hepcidin levels and lipid parameters (235).
Hamza et al. reported similar findings, namely that hepcidin-25 levels in the serum of obese
children are significantly up-regulated compared to age- and sex-matched controls (236). However,
it should be noted that elevated hepcidin expression levels were not detected in all the studies
performed with obese diabetic individuals. Serum concentrations of hepcidin was decreased in
patients with type 2 diabetes in association with insulin resistance (237). Moreover, hepatic
hepcidin expression was significantly suppressed in a high-fat diet mouse model (238). Despite all
these studies, the mechanisms which regulate hepcidin expression in NAFLD are not well
understood. Certain factors, such as inflammatory cytokines or iron loading, have been proposed
as potential contributors (33, 194, 239). The direct roles of lipids and/or lipid intermediates in the
regulation of hepcidin expression, have however not been investigated.
Nevertheless, it is important to point out that, since hepcidin is the master switch of iron metabolism,
any changes in hepcidin expression (i.e. inhibition or induction), will result in altered iron
accumulation and sequestration in the livers of NAFLD patients contributing to disease progression.
Namely, induction of hepcidin will ultimately inhibit ferroportin and iron export thereby
sequestering iron in Kupffer cells of the liver, triggering oxidative stress, inflammation and
fibrogenic signaling. On the other hand, hepcidin inhibition will lead to elevated iron absorption,
due to elevated ferroportin and iron export, and excess iron will ultimately cause hepatocyte injury
and exacerbate NAFLD pathology.
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Figure 1.1. Illustration of fatty acid structure and metabolic pathways: (A) The structure of
fatty acids. Saturated fatty acids, palmitic and stearic acid, and unsaturated fatty acid, oleic acid
are shown as representative structures. Triacylglycerol is synthesized from glycerol and three
molecules of fatty acids through esterification reactions. (B) Schematic diagram of metabolic
pathways induced by fatty acids. Dietary fats, absorbed by the enterocytes, enter circulation in the
form of chylomicrons, which are digested by lipoprotein lipases (LPL) present in the peripheral
vascular beds to release fatty acids (FA). The remnants are readily taken up by the liver. In the
adipose tissue, triacylglycerol (TAG) is hydrolyzed through a two-step reaction by adipose
triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL) to release FA. Hepatocytes take
up circulating FA through passive diffusion or transporter-dependent mechanisms. Dietary
glucose furthermore stimulates de novo lipogenesis in the liver for the production of FAs. The
liver disposes of FAs by oxidation or secretion in the form of very low density lipoproteins
(VLDL). Microsomal triglyceride transfer protein (MTP) plays a key role in the assembly and
secretion of VLDL. Additionally, FAs serve as substrates for the synthesis of lipid intermediates,
as represented by ceramide.
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Figure 1.2. Ceramide synthesis pathways: The de novo synthesis pathway produces ceramide
through a four-step sequential reaction cascade. Serine palmitoyltransferase (SPT) catalyzes the
initial rate-limiting step. Alternatively, ceramide can be synthesized from the hydrolysis of
sphingomyelin located in the cell membrane by sphingomyelinase (SMase) (SMase pathway) and
from the recycling of spingosine into ceramide (Salvage pathway). Ceramide also serves as a
substrate for the production of sphingomyelin, spingosine and ceramide-1-phosphate.
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Figure 1.3. Mechanisms of hepatic lipid accumulation: Peripheral insulin resistance (e.g.
insulin resistance in myocytes) hinders the uptake and utilization of glucose by the tissues and
elevates serum glucose, which in turn stimulates de novo fatty acid (FA) synthesis in the liver.
Insulin resistance in adipocytes accelerates lipolysis by desensitizing lipases to insulin and results
in elevated serum FA, which are then taken up by the hepatocytes. Additionally, dietary fats are a
major source of hepatic FA. FA is esterified to form non-toxic triglycerides. FA oxidation in
mitochondria and triglyceride secretion in the form of VLDL are the major FA disposal
pathways. Steatosis develops when the capacity of FA disposal in the liver is overwhelmed by the
increased levels of FA input and de novo lipogenesis.
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Figure 1.4. The function and synthesis of hepcidin: (A) Hepatocytes are the major site of
hepcidin synthesis. After initial processing of pre-prohepcidin, the 25-amino acid biologicaly
active mature hepcidin peptide is secreted into the circulation. As the central iron-regulatory
protein, hepcidin inhibits iron absorption from the enterocytes in the duodenum and iron release
from the reticuloendothelial macrophages, and thereby decreases circulating iron levels. Hepcidin
accomplishes this regulatory function by binding to and inducing the internalization and
lysosomal degradation of the only known iron exporter, ferroportin. (Image adopted from World J
Gastroenterol. 2009 Mar 14; 15(10): 1186–1193 with permission). (B) Schematic diagram of
pre-prohepcidin. Hepcidin is synthesized as an 84 amino acid pre-proprotein. The N-terminal 24amino acid signal sequence is cleaved to produce prohepcidin, which is further cleaved by furinlike prohormone convertases to yield the 25-amino acid mature hepcidin peptide.
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Figure 1.5. Regulation of iron homeostasis by hepcidin: (A) Under normal physiological
conditions, hepcidin is expressed at the basal level. Enterocytes absorb dietary iron at the apical
site and export it into the circulation through ferroportin at the basolateral membrane. Iron in
senescent red blood cells are phogocytosed by macrophages and recycled into circulation via
ferroportin. The liver stores excess iron in hepatocytes and Kupffer cells. (B) In iron deficiency,
hepcidin expression is reduced, which leads to elevated levels of ferroportin, duodenal iron
transport and iron egress by macrophages. (C) In iron overload, hepcidin expression is induced,
which reduces ferroportin levels and limits duodenal iron transport and iron release by
macrophages to restore iron homeostasis. (Figure adopted from Annu Rev Pathol. 2009;4:489515. with permission)
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Chapter II
Experimental Procedures
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1

CELL CULTURE

The cells were grown in a MCO-17AIC CO2 incubator (Sanyo, Moriguchi, Osaka, Japan) with 5%
CO2 and humidified atmosphere at 37oC. HepG2 cells, a human hepatoma cell line, were obtained
from the Biochemistry Department of University of Adelaide in Australia. HepG2 cells were
cultured in a high glucose (4.5 g/L glucose) Dulbecco’s modified Eagle’s medium supplemented
with glutamine (2 mM) and 10% fetal calf serum (Atlantic Biologicals, GA., USA). Cell culture
medium was replenished every 2-3 days. For sub-culturing, cells were detached by incubating with
a 0.25% trypsin-1 mM EDTA (Life Technologies., CA., USA) solution for 2 min. at 37oC. For the
studies described in later sections, 1.3×106 or 3.9 ×106 cells were seeded in 25 cm2 or 75 cm2 flasks,
respectively, 12-24 h. prior to the start of the experiment.

2

ANIMAL MODELS

Animal experiments were approved by the Institutional Animal Care and Use Committee at the
University of Nebraska Medical Center. The wild-type mice strains used in this dissertation
include C57BL/6J (the Jackson Laboratory, ME., USA), C57BL/6NCR (National Institute of
Health, USA). Hamp Floxed and Hamp Knockout mice on C57BL/6J genetic background were
generated in our laboratory in cooperation with a commercial company (Ozgene Pty. Ltd., Perth,
Australia), as published previously (1). The mouse colonies were maintained in a controlled
environment behind a sterile barrier at the Animal Care facility at the University of Nebraska with
constant temperature, humidity and 12:12-h light-dark cycle. Free access to food and water was
provided. Transgenic mice were genotyped, as described below (see section 16 of this chapter). At
the end of experiments, mice were anesthetized with a Ketamine (100 mg/kg b.w.) and Xylazine
(10 mg/kg b.w.) solution and sacrificed to harvest organs and cardiac blood.
Serum was isolated from clotted blood by centrifuging at 1300 RPM for 15 min. at room
temperature. The harvested livers were kept frozen at -80°C ultra-freezer for RNA extraction or
protein lysate preparations. For histological analysis, fresh liver tissues were fixed in 10% Buffered
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Formalin (Thermo Fisher Scientific, Waltham, MA, USA) and delivered to the Tissue Science Core
Facility at the University of Nebraska Medical Center for paraffin-embedding, and subsequent
sectioning and staining with Hematoxylin and Eosin (H & E).

3

RNA EXTRACTION

Procedures involving RNA studies were performed using RNase-free tubes (Ambion®, Life
Technologies) and pipette tips with barriers (ARTTM, Thermo Fisher Scientific) to avoid RNA
degradation. For RNA extractions, 50mg of liver tissue or 4–5x 106 HepG2 cells were re-suspended
in 1 mL. TRIzol reagent (Invitrogen, CA., USA). Prior to re-suspension in Trizol, the liver tissues
were cut into fine pieces in a sterile petri dish on ice using clean disposable razor blades. To resuspend HepG2 cells, 1 mL of TRIzol reagent was directly pipetted onto the cells attached to the
tissue culture flasks, which were rinsed twice with sterile 1X phosphate-buffered saline (PBS)
solution (Invitrogen).The TRIzol suspensions of tissues or cells were then incubated at room
temperature for 5 min. prior to the addition of 200 μL of chloroform. The tubes were vortexed
vigorously for 15 seconds and incubated at room temperature for 3 min. The organic and aqueous
phases were separated by centrifugation at 12000 x g for 15 min. at 4 oC. The aqueous phase, which
contained RNA, was carefully removed into a clean RNAase-free tube, and mixed with 500 μL of
isopropanol, and incubated at room temperature for 10min. To pellet RNA, the tubes were
centrifuged at 12000 x g for 10 min. at 4 oC. To remove salt contamination, RNA pellets were resuspended in 1 mL of 75% ethanol and centrifuged at 7500 x g for 5 min. To dry out residual
ethanol, the tubes containing RNA pellets were kept at room temperature. Subsequently, RNA were
dissolved in 30–50 μL of diethylpyrocarbonate (DEPC)-treated RNAase-free distilled water
(Thermo Fisher Scientific) by incubating at 45 oC for 10 minutes. The quality and purity of
extracted RNA were validated by agarose gel electrophoresis. RNA concentrations were
determined by measuring the absorption at 260 nm with Biomate3 spectrometer (Thermo Fisher
Scientific). RNA suspensions were aliquoted and kept at -80 oC ultrafreezer for further use.
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4

cDNA SYNTHESIS AND QUANTITATIVE REAL-TIME PCR

cDNA was synthesized from 3 μg of isolated RNA (see above) using 6.25 μM random hexamers
(Applied Biosystems, Life Technologies) and Superscript II reverse transcriptase enzyme
(Invitrogen) according to the manufacturer’s instructions. cDNA was diluted with 60 μL of
autoclaved distilled water and separated into 3 aliquots for real time PCR experiments. Real-time
PCR (qPCR) reactions were performed in triplicates using either Taqman universal PCR master
mix (Life Technologies) or iTaq Universal SYBR Green Supermix (Bio-Rad, CA, USA) with
StepOnePlus instrument (Life Technologies). Taqman fluorescent probe (5’ 6-[FAM]; 3’
[TAMRA-Q]) and primers, spanning through exon boundaries, were designed with Primer Express
1.0 Program (Applied Biosystems) and synthesized commercially (Sigma-Aldrich, PA., USA and
Thermo Fisher Scientific). Pre-designed primers used for SYBR green qPCR were obtained from
PrimerBank (2). Glyceraldehyde dehydogenase (GAPDH) gene was used as the endogenous
control for qPCR experiments. The qPCR assays were performed with ABI PRISM 7700 Sequence
Detection System (applied Biosystems) with the following cycling conditions: Taqman [50oC
2min., 95 oC 10min., 40 cycles of (95 oC 15sec., 60 oC 1min)]; SYBR green [50 oC 2min., 95 oC
30sec., 40 cycles of (95 oC 15sec., 60 oC 1min)]. Melting curve analysis was performed for SYBR
green qPCR assays to validate the specificity of the primers. Gene amplification was calculated
using comparative CT method, as described (3). The sequences of Taqman probe and primers, and
SYBR green primers, which were used for the experiments in this dissertation, are shown below
(see Table 2.1 and Table 2.2).

5

RNA HALF-LIFE MEASUREMENT

HepG2 cells were treated with palmitic acid (PA) or solvent (isopropanol) in the presence of the
transcription inhibitor, actinomycin D for indicated time points. The level of HAMP mRNA
expression, as measured by qPCR (see above), was expressed as fold-change of that in control cells,
which were treated with solvent in the presence of DMSO, at corresponding time points. Rate
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constant for RNA decay (kdecay) was determined with linear regression (least-square) analysis. RNA
half-life was calculated with the equation: t1/2 = ln2 / kdecay.
6

XBP1-SPLICING ASSAY

XBP1-splicing assay is based on the fact that spliced form of XBP1 mRNA lacks the recognition
sequence for Pst1, which is present in the unspliced form. In brief, PCR was performed with cDNA
using a specific primer set for XBP1: (forward: 5’-AAACAGAGTAGCAGCTCAGACTGC-3’
reverse: 5’-TCCTTCTGGGTAGACCTCTGGGAG-3’). The amplicons 448 bp and 474 bp, which
indicate spliced and unspliced forms of XBP-1, respectively were subsequently digested with Pst I
at 37oC for 2 hours. Following digestion, unspliced XBP1 amplicon (474 bp) yielded 290 bp and
183 bp fragments. The digested products were subjected to DNA agarose gel electrophoresis.
GAPDH was amplified with the following primers as loading control: forward: 5’TGGTATCGTGGAAGGACTC-3’ reverse: 5’- AGTAGAGGCAGGGATGATG-3’.

7

WHOLE CELL LYSATE ISOLATION AND SUBCELLULAR FRACTIONATION
OF CELLS

To prepare whole cell lysates, HepG2 cells or liver tissues were incubated for 15 min. in lysis buffer
[10 mM Tris-HCl (pH 7.4), 100 mM NaCl, 5 mM EDTA and 10% glycerol] supplemented with 1
mM PMSF, 0.5% Triton X-100, protease inhibitor cocktail, pepstatin A (Sigma-Aldrich), and
activated sodium orthovanadate (ACROS Organics, Thermo Fisher Scientific). The lysates were
sonicated (50% amplitude, 3 x 5 sec. cycles) with ultrasonic dismembrator 150T (Thermo Fisher
Scientific) to facilitate cell lysis. Following centrifugation at 3000 x g for 5 min. (4°C), supernatants
were collected and used for western blotting.
To isolate cytosolic and nuclear fractions, HepG2 cells were trypsinized and washed twice with 1
X PBS. The cell pellets were subsequently re-suspended in a hypotonic buffer (10 mM Tris-HCl,
10 mM NaCl, 2.5 mM MgCl2) and incubated on ice for 5 min. Following centrifugation at 1700 x
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g for 10 min. (4°C), supernatants were collected and used as cytosolic fractions. The nuclei pellets
were then washed twice with hypotonic buffer to eliminate residual cytosol contamination. Washed
pellets were re-suspended in an extraction buffer (50 mM Tris-HCl, 420 mM NaCl, 2.5 mM MgCl2,
1% Igepal, 0.5% deoxycholate) and sonicated (30% amplitude, 3 x 5 sec. cycles). Sonicated lysates
were centrifuged at 2800 x g for 10 min. (4°C) to remove cell debris. The supernatants were utilized
as nuclear fractions. The protein concentrations in whole cell lysates or cellular fractions were
determined by a commercial protein assay dye reagent (BioRad) based on Bradford-dye-binding
method.

8

WESTERN BLOTTING

The cell lysate proteins (10-50 μg) were resolved with SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) using Mini-PROTEAN gel electrophoresis system (Bio-Rad). The resolved proteins
were subsequently transferred onto polyvinylidene fluoride (PVDF) membranes (Bio-Rad) via
electrophoresis in a transfer buffer (Thermo Fisher Scientific) containing 10 % methanol overnight
at 4°C with constant 20 volts, followed by 1 h. of 40 volts transfer the next day. PVDF membranes,
which were washed briefly with 1 x Tris-buffered saline (TBS) solution (Sigma-Aldrich), were
blocked with 2% nonfat milk (BioRad) dissolved in 1 x TBS buffer for 1 h. at room temperature.
Blocked and TBST (1 x TBS supplemented with 0.1% TWEEN-20)-washed membranes were then
incubated with respective primary antibodies (as listed in Table 2.5) overnight rotating at 4°C in
heat-sealed plastic pouches (Thermo Fisher Scientific). The next day, membranes were washed
twice with TBST and incubated with corresponding secondary (anti-mouse or anti-rabbit)
antibodies (Cell Signaling, MA., USA) for 1 h. at room temperature. Immune-reactive bands were
detected by the ImmunStar-AP Substrate (Bio-Rad Laboratories) using Genemate films (Thermo
Fisher Scientific).
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9

CASPASE-3/7 ACTIVITY ASSAY

The livers harvested from mice or cultured HepG2 cells were homogenized in a lysis buffer [20
mM KCl, 20 mmol/L MOPS, 2 mM MgCl2, 1 mM EDTA, 0.5% Triton X-100, (pH 7.2)] and
incubated for 30 min. on ice. The lysates were centrifuged at 14500 x g for 30 min. at 4 °C, to
collect supernatants, which were used for the assay. Caspase-3/7 enzyme activity was measured by
using 5 μg Ac-DEVD-AMC caspase-3 fluorogenic substrate (BD Biosciences, NJ., USA). The
amount of AMC released in the assay was quantified with a Perkin-Elmer Luminescence
Spectrophotometer LS 55 (Perkin Elmer, MA., USA). A standard curve was generated by using
commercially-obtained free AMC reagent (Sigma-Aldrich). Caspase-3 enzyme activity is
expressed as nmoles of AMC released per mg of protein. The protein concentrations in liver lysates
were determined, as described above (see section 7 of this chapter).

10 LIPID DROPLET STAINING
Following treatment with fatty acids, HepG2 cells were washed twice with 1 X PBS solution and
fixed with 4% paraformaldehyde (Sigma-Aldrich) at room temperature for 15 min. The fixed cells
were stained with 0.2 mg/mL Nile Red (ACROS Organics) for 5 min. at room temperature. The
nuclei were counter-stained with Hoechst 33342 dye (Invitrogen). Fluorescent images were
obtained with a Nikon Eclipse E400 fluorescence microscope with red and UV filter sets for Nile
Red and Hoechst 33342 dye, respectively (Nikon, NY, USA) using a CC-12 digital camera
(Olympus, NY, USA) and analySIS software (Olympus Soft Imaging System).

11 IMMUNOFLUORESCENT STAINING
HepG2 cells were seeded onto poly-L-lysine-coated coverslips in 24-well plates. After treatments,
cells were washed twice with 1 X PBS solution and fixed with 4% paraformaldehyde (SigmaAldrich) for 15 min. at room temperature. Fixed cells were permeabilized with 0.5% Triton X-100
for 15 min. prior to blocking with 5% BSA (Sigma-Aldrich) for 1 h. After washes with 1x PBS,
cells were incubated with an anti-HuR primary antibody (1:50 dilution, sc-5261, Santa Cruz, CA,
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USA) by rotating overnight at 4°C. Control cells were incubated in parallel with normal mouse IgG
(Santa Cruz). The next day, cells were washed three times with 1X TBS buffer supplemented with
0.1% TWEEN-20 (TBST) and incubated with a secondary Texas Red-conjugated horse anti-mouse
IgG (1:300 dilution, Vector Laboratories) for 1 h. at room temperature. Subsequently, coverslips
were washed with 1X TBST 3 times and mounted with VECTASHIELD® Hard-Set Mounting
Medium with DAPI (Vector Laboratories, CA, USA).
Fluorescent images were obtained, as described above (see section 10 of this chapter). ImageJ
software (National Institutes of Health, USA) was used to process microscopic images. The
merging of HuR and DAPI images into a two-channel image was performed for co-localization
analysis using ImageJ plug-in Squassh (4). The percentage of nuclei-localized HuR (Csignal) was
calculated by computing the percentage of HuR pixels, which are co-localizing with DAPI pixels.
The percentage of cytosolic HuR was subsequently calculated by using the formula, 100% -Csignal.
12 CHROMATIN IMMUNOPRECIPITATION (ChIP)
50 x 106 HepG2 cells were fixed with 1% formaldehyde (Sigma-Aldrich) for 10 min. at room
temperature. The cross-linking was stopped with 0.1375M glycine (Thermo Fisher Scientific)
solution. The cells were subsequently washed twice with ice-cold 1 x PBS and lysed with ChIP
lysis buffer [5 mM PIPES (pH 8.0), 85 mM KCl, 0.5% Nonidet P-40 (NP-40)] supplemented with
protease inhibitors (see section 7 of this chapter above). Nuclear fractions, which were collected
by centrifugation at 1000rpm for 10 min. at 4°C, were lysed on ice for 10 min. with lysis buffer [50
mM Tris-Cl (pH 8.0), 10 mM EDTA, 1% SDS] supplemented with protease inhibitors. The lysates
were sonicated using ultrasonic Dismembrator 150T (Thermo Fisher Scientific) to shear chromatin
using the following settings: 50% amplitude, 6 x 30 sec. cycles with 1 min. incubation on ice in
between cycles. The shearing efficiency of chromatin was analyzed using standard techniques and
DNA-Agarose Gel electrophoresis. For immunoprecipitation, 100 μg of sheared chromatin was
first pre-cleared for 2 hours at 4°C with 50 μL protein A-Agarose beads (Santa Cruz), which were
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blocked with Herring Sperm DNA (Promega, WI, USA). 5 μL of pre-cleared chromatin solution
was saved as Input DNA control for further analysis (see below). The rest of pre-cleared chromatin
was then incubated with anti-STAT3 (Cell Signaling, #9132), anti-NF-κB p65 (Cell Signaling,
#4764) or anti-c-Jun (Santa Cruz, #sc-45) primary antibodies by rotating overnight at 4°C. Normal
rabbit or mouse IgG (Santa Cruz) was used as negative controls. The next day, chromatin and IgG
complexes were captured by incubating with 50 μL of blocked protein A-Agarose beads for 2 hours
at 4oC. Immunoprecipitates were subjected to several round of washes as follows: 1x with low salt
buffer [20 mM Tris/HCl (pH 8.0), 2 mM EDTA, 150 mM NaCl, 0.1% SDS and 1% Tritonx-100],
1 X with high salt buffer [20 mM Tris/HCl (pH 8.0), 2 mM EDTA, 500 mM NaCl, 0.1% SDS and
1% Tritonx-100], 1X with lithium chloride wash buffer [10 mM Tris/HCl (pH 8.0), 1 mM EDTA,
250 mM LiCl, 1% Triton x-100, 1% Igepal and 1% deoxycholic acid] and 3x with 1x TE buffer.
Chromatin was subsequently eluted using a freshly-prepared elution buffer (100 mM NaHCO3 and
1% SDS). Cross-linking of eluted chromatin and Input DNA controls (see above) was reversed by
incubating overnight in 200 mM NaCl at 65°C. The reverse-cross-linked samples were treated with
DNase-free RNase (0.1 mg/mL Thermo Fisher Scientific) and proteinase K (0.1 mg/mL, Thermo
Fisher Scientific) solutions and subsequently purified by a commercial Qiaquick PCR purification
kit (Qiagen, MD, USA). Purified chromatin solutions were used as a template in PCR reactions to
amplify HAMP promoter using specific primers designed with Primer-BLAST (NCBI), as listed in
Table 2.4 and Taq polymerase (Thermo Fisher Scientific). The ChIP method was validated by using
IL-6-treated HepG2 cells as positive control.

13 RIBONUCLEOPROTEIN IMMUNOPRECIPITATION ASSAYS
Ribonucleoprotein immunoprecipitation (RNP-IP) assays were performed, as described (5). Briefly,
30 µg of HuR antibody (RN004P, MBL International, MA, USA) or normal rabbit IgG (Santa Cruz)
was pre-conjugated to 100 µL of protein A-Agarose beads (Santa Cruz) overnight at 4°C. HepG2
cells were trypsinized and lysed to isolate cytosolic fractions with lysis buffer containing 0.5 mM
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Tris-HCl (pH 7.4), 100 mM NaCl, 2.5 mM MgCl2. Cytosolic proteins were first pre-cleared with
50 µL of plain protein A-Agarose for 30 min. at 4°C. For immunoprecipitation (IP), pre-cleared
lysates were mixed with 100 µL of antibody-conjugated protein A-Agarose and incubated at 4°C
for 3 h. Following centrifugation at 5,000 x g for 5 min. at 4oC, the supernatants were discarded
and the beads were subsequently washed twice with wash buffer [50 mM Tris-HCl (pH 7.5), 150
mM NaCl, 1 mM MgCl2 and 0.05% NP-40]. 10 µl of IP aliquots were saved for further
immunoblotting analysis. Immunoprecipitated RNA were then eluted using 0.1% SDS and
proteinase K (0.1 mg/ mL, Thermo Fisher Scientific), and purified with TRIzol (Life Technologies).
HAMP mRNA was quantified by qPCR, as described above (see section 4 of this chapter). 18s
rRNA, which has been shown not to interact with HuR (6, 7), was used as a negative control for
RNP-IP assays.

14 GENERATION OF PLASMID DNA CONSTRUCTS AND DUAL LUCIFERASE
REPORTER ASSAYS
1.5 kbp or 0.6 kbp HAMP promoter regions were amplified by PCR using Phusion High-Fidelity
DNA Polymerase (Thermo Scientific) and specific primers, as listed in Table 2.3. Following
restriction enzyme digestions, PCR products were inserted into pGL3-Basic Luciferase Reporter
Vector (Promega Corp.). The ligated plasmids were electroporated into competent DH5α bacterial
cells with a MicroPulse electroporator system (BioRad) and plated on antibiotic-containing LBagar plates using standard techniques. DNA, isolated from bacterial colonies, were subsequently
sequenced to verify correct plasmid clones harboring HAMP promoter sequences in the forward
direction. The 101 bp full length HAMP 3’UTR region was also amplified by PCR using specific
primers harboring a 5’phosphate group (see Table 2.3). PCR amplicons were inserted into PmeI
site of the pMIR-REPORT reporter vector (Life Technologies) by a standard blunt end cloning
technique. The plasmid clone harboring 3’UTR in the “forward” direction was confirmed by DNA
sequencing.
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Mutagenesis of a specific cis-element in the HAMP promoter or 3’UTR regions was performed
with a commercial mutagenesis kit (Quickchange II Site-Directed Mutagenesis. Agilent
Technologies, CA., USA) using specific primers, as listed in Table 2.3 below.
Plasmid DNA were purified using a commercial kit (Plasmid Maxi Prep, Qiagen). HepG2 cells
were transfected with either empty (as control) or recombinant reporter vectors using lipofectamine
3000 reagent (Life Technologies). pRL-SV40 plasmid encoding renila luciferase was cotransfected to standardize the transfection efficiency. Dual luciferase reporter assays were
performed according to manufacturer’s instructions (Promega). IL-6 treatment was employed as a
positive control to validate the assay system.

15 TRANSFECTION OF miRNA MIMIC AND siRNA
30 pmol of negative control miRNA or miR-214 mimic (Life Technologies) were introduced into
HepG2 cells with Nucleofector transfection apparatus (Lonza, IL, USA). Plasmids and siRNA were
transfected by using Lipofectamine 3000 or Lipofectamine RNAiMax (Life Technologies),
respectively, according to the instructions of the manufacturer. For siRNA experiments, two
consecutive transfections were performed to increase transfection efficiency.

16 GENOTYPING of Hamp KNOCKOUT (KO) MICE
Genotyping was performed using genomic DNA, isolated from mice tails by a commercial kit
(Promega Corp.), as a template in PCR reactions. PCR was performed using allele-specific primer
sets. The diagnosis of wild-type (860 bp) Hamp allele was performed by using primers, 5’ACTCTAATGAGGAAGGACCAGAGG-3’ and 5’-CTGTCTCATCTGTGAAAGCAGAAG-3’,
which also amplified wild-type Hamp2 allele (968 bp). Null Hamp allele (439 bp) was amplified
by

using

primers,

5’-ACTCTAATGAGGAAGGACCAGAGG-3’

and

5’-

AGTACTGATATCATCGATGGCG-3’. PCR conditions were: 1 cycle of 95°C for 5 min., 35
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cycles of [95°C for 30 sec., 58°C for 1.5 min., 72°C for 30 sec.], and 1 cycle of final extension at
72°C for 5 min.

17 INDUCTIVELY COUPLED MASS SPECTROMETRY (ICP-MS)
To quantify tissue iron, mice livers were analyzed by ICP-MS at the Redox Biology Center of the
University of Nebraska in Lincoln. Tissues were weighed and digested with metal-grade nitric acid
for 2–3 h at room temperature followed by overnight digestion at 80°C. The digestions were
subsequently cooled and diluted 20-fold prior to ICP-MS analysis. Gallium (50 ppb) was added as
internal standard. Iron was quantitated by measuring at m/z = 56 and 57Fe was used for
confirmation. Helium (5 mL/min) was employed as collision gas for the elimination of polyatomic
interferences. Each sample was analyzed in triplicate.

18 QUANTIFICATION OF HEPATIC TRIGLYCERIDES
Triglycerides were quantified in Dr. K. Kharbanda’s laboratory at Omaha VA Medical Center, as
published previously (8, 9). Briefly, 50 mg of mice liver tissues were homogenized using a
tissuemizer (Tekmar Ultra-Turrax) in 2 mL CHCl3:MeOH (2:1) solution. Residual tissue particles
were filtered through Whatman #1 filter paper (Thermo Fisher Scientific). The total volume of
filtered lysates were brought to 2.5 mL with CHCl3:MeOH (2:1). After the addition of 0.5 mL of
water containing 0.04% CaCl2 (i.e. total volume of 3 mL), the samples were thoroughly mixed by
vortexing and then centrifuged at 3,000 rpm for 5 min. at room temperature. The upper aqueous
phase was removed and lower organic phase was washed thrice with 1mL of an organic
solution/water mix (3.06 % chloroform, 48.98 % methanol, 47.94% water and 0.02% CaCl2). After
sequential separation of phases to eliminate non-lipid substances, the organic solution mix
containing the lipids was evaporated using a centrivac apparatus overnight. The next day, dried
samples were hydrolyzed in 0.25 mL of 95% ethanol and 25 μL of 8.0 M KOH solution by
incubating for 20 min. at 65oC. The triglyceride content was determined by using a commercial kit
(Thermo DMA kit 2750) according to manufacturer’s instructions (Thermo Scientific), and
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measuring absorbance at 510nm wavelength with a DU-640 Spectrophotometer (Beckman Coulter).
The final hepatic triglyceride amount was calculated by standardizing the amount in the whole liver
to the body weight, and expressed as μmol per liver per 100 gram body weight (µmol/L/100 g b.w.).

19 SIRIUS RED STAINING AND QUANTIFICATION
Paraffin-embedded liver tissues were prepared as described above (see section 2 of this chapter).
Tissue sections were de-waxed with sequential incubations in organic solutions (3x in xylene for
3min., 2 X in 100% ethanol for 2 min., and 1X each in 95%, 80%, and 50% ethanol for 2 min).
They were then stained with a Picrosirius Red solution (0.1% Sirius Red in saturated picric acid)
for 60 min. The sections were subsequently washed twice with acetic acid for 2 min. and thrice
with 100% ethanol followed with three cycles of xylene washes, each for 3 min. The washed
sections were mounted using a ShandonMount mounting medium (Thermal Fisher Scientific).
Images of Sirius Red-stained mice livers were obtained using a Nikon Eclipse E400 light
microscope with a CC-12 digital camera and analySIS software. The quantification of the images
was performed with ImageJ software using 10 independent images (10 x magnification) obtained
from each stained section. Briefly, the microscopic images were split into red, green, and blue
channels with the RGB stack command. The green channel was selected and threshold was
manually set for each image to correctly reflect the staining in the original image. 10 nonoverlapping fields in each image were selected and the staining was quantified with the ROI
manager of ImageJ.

20 STATISTICAL ANALYSIS
The significance of differences between groups was determined by Student’s t-test or one-way
ANOVA with Tukey's HSD post-hoc test by using SPSS software (IBM, Armonk, NY). A value
of P < 0.05 was accepted as statistically significant.
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Table 2.1. Taqman qPCR Fluorescent Probe and Primer Sequences of human (Hu) and
mouse (Mu) genes
Gene
Hu-HAMP
Hu-GAPDH
Mu-Hamp
Mu-Hamp2
Mu-GAPDH

Forward Primer
(5'-3')
TGCCCATGTTCCAGAG
GC
TGAAGGTCGGAGTCA
ACGG
TGCAGAAGAGAAGGA
AGAGAGACA
GCGATCCCAATGCAGA
AGAG
TCACTGGCATGGCCTT
CC

Reverse Primer
(5'-3')
CCGCAGCAGAAAATG
CAGAT
AGAGTTAAAAGCAGC
CCTGGTG
CACACTGGGAATTGTT
ACAGCATT
TGTTACAGCACTGACA
GCAGAATC
GGCGGCACGTCAGATC
C

Taqman Probe (5’-3’)
AAGGAGGCGAGACAC
CCACTTCCC
TTTGGTCGTATTGGGC
GCCTGG
CAACTTCCCCATCTGC
ATCTTCTGCTGT
AGGAAGAGAGACATC
AACTTCCCCATCTGC
TTCCTACCCCCAATGT
GTCCGTCG
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Table 2.2. SYBR qPCR primer sequences of mouse (Mu) genes
Forward Primer (5’-3’)

Reverse Primer (5’-3’)

Mu-MTP

CTCTTGGCAGTGCTTTTTCTCT

GAGCTTGTATAGCCGCTCATT

Mu-CPT1

CTCCGCCTGAGCCATGAAG

CACCAGTGATGATGCCATTCT

Mu-FSP27

ATGAAGTCTCTCAGCCTCCTG

AAGCTGTGAGCCATGATGC

Mu- G6PC

CGACTCGCTATCTCCAAGTGA

GTTGAACCAGTCTCCGACCA

Mu-PCK1

CTGCATAACGGTCTGGACTTC

CAGCAACTGCCCGTACTCC

Mu-PPARα

AGAGCCCCATCTGTCCTCTC

ACTGGTAGTCTGCAAAACCAAA

Mu-SREBP-1C

GCAGCCACCATCTAGCCTG

CAGCAGTGAGTCTGCCTTGAT

Mu-Col1a1

GCTCCTCTTAGGGGCCACT

CCACGTCTCACCATTGGGG

Mu-SAA3

GCCTGGGCTGCTAAAGTCAT

TGCTCCATGTCCCGTGAAC

CTGCAAGAGACTTCCATCCAG

AGTGGTATAGACAGGTCTGTTGG

GTGGAGATTGTTGCCATCAACGA

CCCATTCTCGGCCTTGACTGT

Gene

Mu-IL-6
Mu-GAPDH
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Table 2.3. Sequences of primers used for cloning and site-directed mutagenesis experiments
Forward Primer (5’-3’)

Reverse Primer (5’-3’)

1.5 kbp HAMP
promoter

GGACGCGTCTGGGCCTGGTA
GTGGAAAG

GACTCGAGTGAGCTTGCTCTG
GTGTCTG

0.6 kbp HAMP
promoter

GGACGCGTTGTCATTTATGGC
CAAAAGTTTGCT

GACTCGAGTGAGCTTGCTCTG
GTGTCTG

0.6 kbp HAMP
promoter ΔSTAT3

CTGTCTCATTTCCAGGTGGTG
GCGCCGAAAA

TTTTCGGCGCCACCACCTGGA
AATGAGACAG
TTTGGAAAACAAAAGAACCA
GCC
CCCTCCCTTCCTTAATTCCTGC
TGCCCCAG

Gene

HAMP 3’UTR
HAMP 3’UTR ΔARE

AACCTACCTGCCCTGCCC
CTGGGGCAGCAGGAATTAAG
GAAGGGAGGG
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Table 2.4. The sequence of primers employed in ChIP assays specific for human (Hu) and
mouse (Mu) gene promoters
Gene
Hu-STAT3
Hu-NF-κB
Hu-c-Jun/AP-1
Mu-Hamp

Forward Primer (5’-3’)

Reverse Primer (5’-3’)

GAGGGTGACACAACCCTGTT
TCATTTATGGCCAAAAGTTTGC
T
TGAGGGTGACACAACCCTGT

ACCGAGTGACAGTCGCTTTT

GCCATACTGAAGGCACTGA

GTGTGGTGGCTGTCTAGG

CAAGCATCAGCGTGTGCC
CTGCTGGGTCTTGAGCTTGC
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Table 2.5. Primary antibodies used for western blotting

Antigen

Company

Catalog number

Dilution

P-SMAD 1/5

Cell Signaling

#9516

1:1000

HuR

Santa Cruz

sc-5261

1:2000

P-JNK

Cell Signaling

#9251

1:1000

P-STAT3 (Ser 727)

Cell Signaling

#9134

1:1000

P-STAT3 (Tyr 705)

Cell Signaling

#9131

1:1000

STAT3

Cell Signaling

#9132

1:1000

P-NF-κB p65

Cell Signaling

#3033

1:1000

NF-κB p65

Cell Signaling

#4764

1:1000

αSMA

Sigma

A2547

1:2000

Histone H3

Active Motif

#39163

1:4000

gapdh

Millipore

MAB374

1:4000
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Chapter III

Apoptosis Induced by Fas Signaling Does Not Alter Hepatic Hepcidin Expression

This chapter has been adopted from
Lu, S., Zmijewski, E., Gollan, J., and Harrison-Findik, D. D. (2014) Apoptosis induced
by Fas signaling does not alter hepatic hepcidin expression. World J Biol Chem. 5, 387–
397

75
1

ABSTRACT

A connection between hepcidin expression and lipid metabolism in non-alcoholic fatty liver disease
(NAFLD) has been implicated. Our studies with hepatoma cells also indicated induction of
hepcidin expression by saturated fatty acids. Fatty acids are well-recognized for promoting
apoptosis, which contributes to the pathogenesis of NAFLD. However, the direct effect of apoptosis
on hepcidin is unknown. We therefore investigated whether apoptosis induced via Fas ligand
directly affects hepcidin expression in HepG2 cells and the livers of wild-type male C57BL/6J and
C57BL/6NCR mice. HepG2 cells were treated with CH11, an activating antibody for human Fas
receptor, for 12 hours to induce extrinsic apoptotic pathway. Mice were injected with sublethal
doses (0.2 µg/g b.w.) of Jo2, an activating antibody for mouse Fas receptor. Although CH11
promoted apoptosis in HepG2 cells, as shown by significant activation of caspase-3/7, it did not
alter the expression of human hepcidin gene, HAMP. Jo2 treatment of mice for 6 hours, but not 1
hour, induced significant apoptosis, acute phase reaction and IL-6 expression in the liver. Similar
to HepG2 cells, Jo2 did not affect hepatic mRNA expression of mouse hepcidin gene, Hamp. IL-6
is a strong activator of JAK/STAT signaling pathway and STAT3 is known to induce hepcidin
transcription. Accordingly, Jo2-induced phosphorylation (i.e. activation) of STAT3 in the liver.
However, no interaction of STAT3 with Hamp promoter was observed, as confirmed by chromatin
immunoprecipitation assays. The effect of Jo2 was stronger in the livers of C57BL/6J than
C57BL/6NCR mice. C57BL/6J mice exhibited more prominent activation of apoptosis, liver injury
and acute phase reaction. However, C57BL/6J mice did not display any changes in hepatic Hamp
expression. Taken together, the results obtained with our in vitro and in vivo experimental models
strongly suggest that neither human nor mouse hepcidin genes are regulated by apoptosis induced
through Fas receptor activation in the liver.

2

INTRODUCTION
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Apoptosis is involved in the pathogenesis of various liver diseases (1). Hepatocyte apoptosis can
be activated via the extrinsic apoptotic pathway through the binding of ligands to death receptors
such as Fas, TNF Receptor 1 (TNFR1), TRAIL receptor 2 (TRAIL-R2) and TRAIL receptor 1
(TRAIL-R1). Upon ligand binding, the receptor will trimerize and the C-terminal death domain
will recruit Fas-associated protein with death domain (FADD) to form death-inducing signaling
complex (DISC), which subsequently recruits procaspase-8 and induces its self-cleavage and
activation. Activated caspase-8 can directly cleave and activate caspase-3/7, the executioner
caspase, which is responsible for the cleavage of target proteins to execute apoptosis. Caspase-3/7
activation is frequently used as a marker for apoptosis. Flice-Inhibitory Protein Long form (FLIPL)
blocks apoptosis by inhibiting the recruitment and auto-proteolytic cleavage of procaspase-8. In
addition, in hepatocytes, the signal from death receptor can be amplified through the mitochondrial
apoptotic pathway. Activated caspase-8 can cleave Bcl-2 family protein, Bid. The truncated form
of Bid (tBid) then activates pro-apoptotic Bcl-2 family proteins, and induces permeabilization of
the mitochondrial outer membrane and the leakage of mitochondrial content, including cytochrome
c. Cytochrome c in turn forms a complex with apoptotic peptidase activating factor 1 (APAF-1),
and recruits and activates caspase-9, which subsequently cleaves caspase-3/7 and executes
apoptosis.
A role for apoptosis has been suggested in hepcidin regulation (2, 3). Hepcidin is the central ironregulatory hormone. It is synthesized primarily by the liver, as an 84 amino acid precursor
antimicrobial peptide. Pre-propeptide is subsequently cleaved to 25 amino acid biologically active
circulatory form of hepcidin. Unlike humans with one copy of hepcidin gene, HAMP, mice express
two hepcidin genes, Hamp and Hamp2. Hamp has been shown to be the equivalent of human gene.
Our studies with different Hamp transgenic mouse lines have also confirmed the function of Hamp
as the key iron regulator (4). The exact role of Hamp2 is as yet unknown. Hepcidin exerts its
regulatory function by blocking the transport of dietary iron in the intestine and the release of iron
from macrophages. The suppression of hepcidin expression in the liver therefore leads to systemic
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iron overload whereas its induction causes iron deficiency and anemia. Besides its role as an ironregulatory hormone, hepcidin also serves as an acute phase protein and is connected to innate
immunity (5–7). Inflammatory cytokines such as IL-6, endotoxin and infections trigger hepcidin
transcription in the liver. The effect of IL-6 is mediated through the activation of JAK/STAT3
pathway and the binding of STAT3 to the hepcidin gene promoter (8, 9). Fas receptor signaling
and apoptosis are involved in controlling inflammatory innate immune responses (10). Apoptosis
also plays a major role in the pathogenesis of liver diseases including NAFLD (11, 12). It is
therefore important to investigate the regulation of hepcidin by Fas signaling and apoptosis in the
liver.
Weizer-Stern et al. have demonstrated that p53, a tumor suppressor and inducer of apoptosis,
participates in the regulation of hepcidin (13). In their study, a putative p53 response element on
the hepcidin gene promoter has been identified and validated by chromatin immunoprecipitation
assays. Over-expression of p53 in hepatoma cells has been shown to induce hepcidin gene
transcription and conversely, the silencing of p53 resulted in down-regulation of hepcidin
expression (13). It is however unclear whether p53-mediated apoptosis is involved in the regulation
of hepatic hepcidin expression (13). On the other hand, Li et al. have suggested a role for Fas
signaling in the regulation of hepcidin expression in tissue culture cells and female mouse livers
(14). A lethal dose of anti-Fas activating antibody, Jo2 has been reported to exert an immediate
stimulatory and a late suppression effect on Hamp mRNA expression in the liver (14). Although a
relationship between FLIPL, IL-6, STAT3 and hepcidin expression has been shown, they did not
however establish a direct correlation between apoptosis and hepcidin. Besides causing cell death,
Fas induced DISC formation also participates in the activation of cell signaling pathways, including
IL-6 and NF- κB (15). As mentioned above, hepcidin transcription is induced by inflammatory
cytokine signaling (5–7), which is mediated through the activation of JAK/STAT3 pathway (8, 9).
As an iron regulatory protein, hepcidin is also regulated by the signals from iron sensors, such as
bone morphogenetic protein 6 (BMP6) (16–18). The BMP receptor-specific Smad pathway (via
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the phosphorylation of transcription factors, Smad1/5/8) has been shown to be involved in the upregulation of hepcidin transcription. BMP6 knockout mice exhibit iron overload and reduced
hepcidin expression (19–21). Similarly, mice lacking the expression of the common Smad protein,
Smad4 exhibit iron overload and a dramatic decrease in the expression of hepcidin in the liver (22).
In addition, growth factors such as epidermal growth factor and hepatocyte growth factor suppress
the expression of hepcidin by inhibiting the signaling of the BMP-Smad pathway (23).
The main aim of the studies described in this chapter is to investigate the causal relationship
between Fas-signaling-induced effector caspase activation and apoptosis, and the regulation of
human and mouse hepcidin gene transcription. These studies will help us to further understand the
regulation and the role of hepcidin in liver diseases including NAFLD.

3
3.1

RESULTS
Effect of fatty acids and apoptosis on HAMP expression in HepG2 cells.

We first validated whether saturated fatty acid, palmitic acid (PA) induced apoptosis in HepG2
cells under our experimental conditions. For these experiments, HepG2 cells were treated with 0.10.3 mM palmitic acid and 0.3 mM unsaturated fatty acid, oleic acid (OA, as control), for 8 hours.
The effect of isopropanol (i.e. the solvent for fatty acids) was also examined. The levels of apoptosis
in these cells were determined by caspase-3/7 activity assays (Figure 3.1A). In agreement with
previous reports (24, 25), PA, but not OA, induced apoptosis in HepG2 cells, as shown by
significantly elevated caspase-3/7 activity levels (Figure 3.1A). The effect of PA on apoptosis was
concentration-dependent (Figure 3.1A). Due to the fact, that PA is capable of inducing other
signaling pathways besides apoptosis (26), we selected a better defined system of apoptosis to study
its direct effect on hepcidin regulation. For these studies, CH11 antibody, an activating antibody
for human Fas receptor, was selected to induce apoptosis in HepG2 cells. CH11 antibody treatment
for 12 hours induced apoptosis in HepG2 cells in a concentration-dependent manner, as confirmed
by caspase-3/7 activity assays (Figure 3.1B). A significant induction of caspase-3/7 activity was
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observed with all concentrations of CH11 (50-500 ng/mL) (Figure 3.1B). The level of apoptosis
detected with 500 ng/mL CH11 treatment was similar to that observed with cells incubated with
0.3 mM palmitic acid (Figure 3.1A and 3.1B). To test the effect of PA or CH11-induced apoptosis
on HAMP mRNA expression, we performed qPCR experiments (Figure 3.1C). HAMP expression
in 0.3 mM PA-treated cells was significantly up-regulated compared to solvent-treated control cells.
Unlike PA, CH11-induced apoptosis did not significantly alter the level of HAMP mRNA
expression compared to control cells treated with PBS (Figure 3.1C). These findings exclude a
role for Fas-mediated apoptotic pathway in the regulation of HAMP transcription in hepatoma cells.
This also strongly suggests that the induction of HAMP expression observed in PA-treated cells is
facilitated by mechanisms other than PA-mediated apoptosis signaling pathways.
3.2

The effect of short-term and long-term Jo2 treatment on apoptosis, acute phase response
and mouse Hamp expression in the livers of C57BL/6NCR mice

Since activation of human Fas did not alter human hepcidin gene expression, we performed
experiments with Jo2, which is an activating antibody specific to mouse Fas. In our animal studies,
we used a sublethal (0.2 µg/g b.w.) dose of Jo2 antibody to eliminate complications such as massive
liver injury and mortality. In agreement, this dose of Jo2 did not cause mortality in any of our timepoints studied. Since previous studies (14) suggested a time-dependent effect of Jo2 on hepcidin
expression, we injected male C57BL/6NCR strain wild-type mice with Jo2 or NaCl (control), and
sacrificed after either 1 (short-term) or 6 (long-term) hrs. The macroscopic appearances of mouse
livers after 6 h Jo2 treatment did not present any significant changes compared to NaCl-injected
control mice livers (Figure 3.2).
Following 1 hr. of Jo2 treatment, no significant increase in caspase-3/7 activity in the liver was
observed compared to control mice (Figure 3.3A). The activation of acute phase reaction in the
livers of these mice was evaluated by determining the levels of IL-6 and SAA3 mRNA expression
by qPCR. Similar to caspase-3/7 activity, no significant changes were observed with the expression
of these acute phase reaction genes (Figures 3.3B and C). The mRNA expression of Hamp in mice
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livers was unaltered by Jo2 exposure either, as confirmed by qPCR (Figure 3.3D). In contrast, 1
hour Jo2 treatment induced a small but significant increase in Hamp2 mRNA expression (Figure
3.3E). By comparison, C57BL/6NCR mice sacrificed 6 hours after Jo2 injections displayed a
significant increase in caspase-3/7 activity in the livers compared to NaCl-injected control mice
(Figure 3.3A). Similarly, the expression of acute phase reaction markers, IL-6 and SAA3 were also
elevated in mice exposed to Jo2 for 6 hours compared to control mice (Figures 3.3B and C). The
levels of Hamp and Hamp2 mRNA expression in mice treated with Jo2 for 6 hours were not
significantly different from that in control mice (Figures 3.3D and E).
3.3

Jo2-mediated STAT3, SMAD1/5 activation and Hamp promoter occupancy

The cytokine, IL-6 is known to activate hepcidin transcription via the JAK/STAT3 signaling
pathway (8, 9). We therefore investigated the activation of STAT3 in mice treated with Jo2 or NaCl
(control) for 1 or 6 hours. Six hours, but not 1 hour of Jo2 exposure, was sufficient to induce the
phosphorylation of STAT3 in the livers of mice, compared to respective control mice (Figure 3.4).
Despite the activation of STAT3, we did not observe any significant changes in STAT3 binding to
Hamp promoter in Jo2-treated mice compared to control mice, as determined by chromatin
immunoprecipitation (ChIP) assays (Figure 3.5).
NF-κB is one of the prominent transcription factors activated by Fas ligand binding. NF-κB
activates the transcription of inflammatory cytokines including IL-6 (1). We therefore investigated
the phosphorylation of the p65 subunit of NF-κB in mice treated with Jo2 for 1 or 6 hrs. time
periods. In contrast to STAT3, Jo2 induced a fast and transient activation of NF-κB. The
phosphorylation of p65 in the liver was observed within 1 hour after Jo2 injection and was absent
at 6 hours after Jo2 exposure (Figure 3.4).
Besides JAK/STAT3 pathway, hepcidin is also regulated by bone morphogenetic protein 6 (BMP6)
and SMAD pathway. This pathway has also been suggested to play a negative role in growth factorinduced regulation of hepcidin expression in the liver (23). We therefore determined the activation
of transcription factors, SMAD1 and SMAD5, which are activated downstream of BMP signaling
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pathway. Similar to NF-κB, Jo2 treatment induced an early and transient activation of SMAD1/5
in the liver. The induction in SMAD1/5 phosphorylation observed by 1 hr. Jo2 exposure was
significantly weakened by 6 hr. after Jo2 injection (Figure 3.4). The binding of SMAD4, the
common mediator of SMAD signaling, to mouse Hamp promoter was also examined by ChIP
assays. No significant increase in SMAD4 occupancy of Hamp promoter region harboring a
SMAD4 binding site was observed at 6 hrs. after Jo2 injection, as compared to controls (Figure
3.5).
3.4

The effect of long-term Jo2 treatment on apoptosis, acute phase response and mouse
hepcidin gene expression in the livers of C57BL/6J mice

In order to investigate the effect of Jo2 further, we employed a sub-strain of C57BL/6 mice. Of
note, C57BL/6NCR and C57BL/6J strains exhibit substantial genetic differences (27). In contrast
to C57BL/6NCR mice, the macroscopic appearances of C57BL/6J livers after 6 h Jo2 treatment
were significantly different than control livers (Figure 3.2). Compared to that observed with
C57BL/6NCR, C57BL/6J mice treated with a sublethal dose of Jo2 (0.2 µg/g b.w.) for 6 hours
exhibited a significantly higher elevation of caspase-3/7 activity (Figure 3.6A). Similar robust
activation was also observed with the expression of acute phase marker genes, IL-6 and SAA3
(Figures 3.6B and 3.6C). However, despite stronger apoptosis and acute phase reactions, Jo2
treatment did not induce any significant changes in the expression of both Hamp and Hamp2 in the
livers of C57BL/6J mice, as was the case with C57BL/6NCR mice (compare Figures 3.6D, E and
3.3D, E). Furthermore, we tested the effect of an even higher concentration of Jo2 (0.32 µg/g b.w.).
Although this concentration of Jo2 caused mortality (40 %), it did not induce any changes in the
mRNA level of Hamp. (Figure 3.6D). In contrast to the effect of sublethal Jo2 dose in
C57BL/6NCR mice (Figure 3.2E), the treatment with 0.32 µg/g of Jo2 induced a significant
suppression of Hamp2 mRNA expression in C57BL/6J mice livers (Figure 3.6E).
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3.5

The effect of Jo2 on liver enzymes in C57BL/6J and C57BL/6NCR mice

Since Jo2-induced apoptosis and acute phase reactions were stronger in the livers of C57BL/6J
mice, compared to C57BL/6NCR mice, we measured the serum levels of ALT and AST. These
liver enzymes are commonly used as diagnostic markers in the clinic to determine liver injury. The
sublethal dose of Jo2 (0.2 µg/g) did not cause a significant elevation of serum ALT or AST levels
in C57BL6/NCR mice (Figures 3.7A and B). However, the sera of C57BL/6J mice injected with
this concentration of Jo2 exhibited a dramatic increase in both ALT and AST levels, compared to
controls (Figures 3.7A and B). The injection of C57BL/6J mice with a higher dose of Jo2 (0.32
µg/g) induced further increase in serum ALT and AST levels (data not shown). These findings with
ALT and AST further support our previous findings that Fas ligand activation and apoptosis do not
alter hepatic hepcidin gene expression.

4

DISCUSSION

Apoptosis is one of the key factors which contribute to the pathogenesis of liver diseases including
NAFLD (1, 11, 28). Apoptosis not only causes hepatocyte death directly but also induces
inflammation and hepatic fibrosis (29, 30). The inhibition of caspase enzymes via known caspase
inhibitors has been shown to effectively alleviate hepatocyte apoptosis and tissue damage in animal
models of liver injury (31). Due to its highly reactive nature, and the liver serving as the major
storage organ for it, iron is considered an important secondary risk factor in the progression of
various liver diseases (32, 33). Therefore, it is of great importance to understand the interaction
between apoptosis and iron metabolism. Since hepcidin is the central regulator of iron homeostasis
and is primarily synthesized in the liver, this study investigated the effect of apoptosis on the
regulation of hepcidin expression in the liver. Previously, Weizer-Stern et al. have elegantly
demonstrated that p53, a tumor suppressor gene and an inducer of apoptosis, elevates human
hepcidin gene transcription in HepG2 cells by binding to the corresponding response elements in
hepcidin gene promoter (13). They have also reported that the overexpression of p53 blunts the
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stimulatory effect of IL-6 on hepcidin gene expression. Although indirect, these findings, for the
first time, suggested a relationship between apoptosis and hepcidin and thereby the regulation of
iron metabolism. However, due to various reasons, the in vivo relevance of this potential interaction
is unclear. First, apoptosis signaling in cancer cell lines is frequently distorted and secondly, forced
overexpression of p53 might have caused artificial effects. However, in a recent study, Li et al.
have investigated the relationship between Fas-activated apoptosis signaling and expression of
hepcidin gene expression (14). Fas activation decreased both mouse and human hepcidin mRNA
expression in vitro. They have also shown that Balb/C3 female mice injected with a lethal dose of
Jo2 antibody (which killed mice within 4 hours) exhibit a biphasic regulation of mouse hepcidin
mRNA expression in the liver. Namely, an immediate elevation (observed within 0.5-1 hour) was
followed by a suppression (observed within 4 hours). They suggested that these changes in hepcidin
expression correlate with the changes in FLIPL and IL-6 expression, as well as the activation of
the transcription factors, NF-κB, and STAT3. The knock-down or over-expression of FLIPL
exerted a negative and a positive effect, respectively, on hepcidin expression. Based on their data,
Li et al. have proposed a model suggesting that the stimulatory effect of Fas on hepcidin expression
is achieved via IL-6 and STAT3, which themselves are activated by FLIPL and NF-κB. However,
Li et al. did not establish a direct association between Fas-induced apoptosis and hepcidin upregulation. Thus, it is unclear whether Fas-mediated apoptosis is directly involved in the regulation
of hepcidin gene expression in the liver.
We examined the effect of Fas signaling on hepatic hepcidin gene expression both in vivo and in
vitro. In our in vitro studies, the effect of CH11 was evaluated on human hepcidin gene, HAMP
expression in HepG2 hepatoma cells. Despite the induction of apoptosis by CH11 in a concentration
dependent manner, as confirmed by the increased caspase-3/7 activity, HAMP expression was not
significantly altered in HepG2 cells. Although we cannot exclude the possibility that Fas-mediated
signaling in HepG2 cells might be different than primary human hepatocytes, our findings strongly
suggest that hepatic HAMP expression does not correlate with the significant induction of caspase
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activation. Of note, the liver is composed of various cell types and it is therefore feasible that not
only hepatocytes, but other cells such as Kupffer cells, might be involved in the regulation of
hepcidin gene by apoptosis. Hence, an in vivo experimental model whereby male C57BL/6NCR
mice are injected with Jo2 antibody to specifically activate Fas-mediated apoptosis was employed
to study hepcidin gene expression in the whole liver. Male mice were chosen for these studies
because unlike humans, female mice express higher levels of hepcidin compared to male mice (34).
As described in Results section above, a sublethal concentration of Jo2 antibody was chosen based
on reports showing, that this dose is optimal to specifically study the activation of Fas-mediated
apoptosis in liver diseases (35). This was also confirmed by the lack of lethality in our experiments.
The absence of significant changes both in caspase activation and acute phase gene expression
indicates that short-term (1h) Jo2 treatment is not sufficient to promote apoptosis or acute phase
responses in mice livers. Accordingly, no macroscopic changes in the livers were observed, as
compared to control mice. Further, mouse hepcidin gene, Hamp expression in the liver was also
not altered. In contrast, longer (6 h) treatment significantly induced apoptosis and acute phase
reactions. Concurrently, the livers of these mice displayed macroscopic differences, such as a
darker color, suggesting the presence of hepatic hemorrhage and liver injury. Interestingly, these
changes did not correlate with the level of Hamp mRNA expression in the liver. Similar to shortterm, the longer treatment of mice with Jo2 did not alter the level of hepcidin gene expression.
It is well known that hepcidin gene transcription is strongly stimulated by IL-6 and JAK/STAT3
signaling pathway. Since, we have shown that long-term, but not short-term, Jo2 treatment can
induce acute phase reactions in the liver, the phosphorylation status of STAT3 was investigated to
confirm its activation. In accordance with our acute phase gene expression findings, we observed
STAT3 phosphorylation following 6 hours, but not 1 hour, of Jo2 treatment. Taken together, our
findings show that the activation of IL-6/ STAT3 axis by Fas is not sufficient to induce Hamp
transcription and strongly suggest the presence of inhibitory mechanisms. This is also supported
by our ChIP findings, which show that the occupancy of Hamp promoter by STAT3 is similar in
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the livers of both Jo2-treated and control mice, despite the differences in the activation status of
STAT3. In contrast to STAT3, the phosphorylation of NF-κB was observed with short-term, but
not long-term, Jo2 treatment. NF-κB is involved in inflammatory cytokine production in the liver
including IL-6 (28). It is therefore possible that Jo2-mediated early phase activation of NF-κB
subsequently facilitates the induction of IL-6 transcription and consequent activation of STAT3,
which was observed in the livers of mice with longer Jo2 treatment.
Hepcidin is also activated by BMP/Smad pathway and SMAD4 knockout mice display reduced
hepcidin expression (22). However, 6 hour Jo2 administration did not significantly alter the
phosphorylation of SMAD1/5 proteins, which are transcription factors known to be activated by
BMP pathway. Growth factors have been shown to suppress the signaling of BMP/SMAD pathway
and its stimulatory effect on hepcidin gene expression in the liver (23). Of note, liver injury is
known to stimulate the expression of growth factors as part of the liver regeneration process. It is
therefore feasible that Fas-induced liver injury might suppress Smad activation and thereby
counteract the stimulation of Hamp transcription by STAT3. However, it should also be noted that
despite significant differences in the level of liver injury, acute phase response and apoptosis, both
C57BL/6J and C57BL/6NCR mice (under similar experimental conditions) did not display any
significant changes in liver Hamp expression. This suggests that mechanisms other than growth
factors and inhibitory SMADs might play a role in this process. Jo2-induced liver damage
accompanied by DNA damage and the activation of p53 might be involved since p53 has been
shown to suppress the stimulatory effect of IL-6 on hepcidin gene expression (13). Furthermore,
we observed differential regulation of Hamp2 expression by Jo2 in the liver. Since the function of
Hamp2 is yet unknown, the significance of this finding and its potential role in liver injury and
disease require further future studies.
In our current study presented in this chapter, we validated that hepatic expression of hepcidin is
not altered by apoptosis induced through Fas signaling. We therefore believe that, palmitic acidmediated activation of hepcidin expression in hepatoma cells was mediated by mechanisms other

86
than apoptosis. Apoptosis is widely recognized as a secondary risk factor in NAFLD/NASH
pathogenesis. However, the findings presented in this chapter exclude a role for apoptosis in the
regulation of hepcidin and iron metabolism in NAFLD.
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Figure 3.1. Caspase-3/7 activity and human hepcidin gene (HAMP) expression. (A) HepG2
cells were treated with 0.1- 0.3mM palmitic acid (PA) or 0.3mM oleic acid (OA) for 8 hours.
Untreated (unt.) and solvent (isopropanol)-treated (solv.) cells were employed as control.
Caspase-3/7 activity was determined, as described in the experimental procedures (see Chapter
II) and was expressed as nanomole of flurogenic substrate cleaved per milligram of cell lysate
(nmol/mg). (B) HepG2 cells were treated with 50,100,150 and 500 ng/mL of CH11 antibody for
12 hours. Induction of apoptosis was confirmed by measuring caspase-3/7 activity. (C) cDNA,
synthesized from RNA isolated from CH11-treated, PA-treated and respective control cells, was
employed as a template in Taqman qPCR assays to determine HAMP mRNA expression, as
described in experimental procedures. HAMP expression in CH11-treated or 0.3mM PA-treated
cells was expressed as fold expression of that in respective control cells.

90
A

5

*

6

Caspase-3/7 Activity
(nmol/mg)

Caspase-3/7 Activty
(nmol/mg)

7

5
4

*

3
2
1
0

C
*

Fold HAMP
Expression

2.5
2
1.5
1
0.5
0

PBS 50

Figure 3.1

*
4
3

*

2

*

*

1
0

Cont. Solv. 0.1 0.2 0.3 0.3
PA (mM) OA (mM)
3

B

100 150 500
CH1 (ng/mL)

Solv. 0.3
PA (mM)

PBS

50

100 150
500
CH11 (ng/mL)

91
Figure 3.2. Macroscopic analysis of livers from Jo2-treated mice. C57BL/6J and
C57BL/6NCR strain wild-type male mice, which were injected with Jo2 antibody (0.2 µg/g b.w.)
or NaCl (as control), were sacrificed 6 hours later. Representative images are shown.
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Figure 3.3. Caspase-3/7 activity, and the expression of acute phase response genes and
mouse hepcidin genes, Hamp and Hamp2 in the liver. C57BL/6NCR strain wild-type male
mice, which were injected with Jo2 antibody (0.2 µg/g b.w.) or NaCl (as control), were sacrificed
1 hr. or 6 hrs. later. (A) Caspase-3/7 activity was measured, as described in experimental
procedures. IL-6 (B), SAA3(C), Hamp (D) and Hamp2 (E) gene expression was determined by
qPCR and mRNA expression in Jo2-treated mice expressed as fold change of that in
corresponding control mice.
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Figure 3.4. Phosphorylation of STAT3, NF-κB (P65) and SMAD 1/5 in the liver. Whole cell
lysates prepared from the livers of C57BL/6NCR mice injected with Jo2 (0.2 µg/g b.w.) and
sacrificed after 1 or 6 hours were employed for western blotting using anti-phospho-STAT3 (PSTAT3), anti-total STAT3, anti-phospho-P65 (P65) and anti-phospho-SMAD1/5 antibodies, as
described in experimental procedures with specific antibodies (see Chapter II TABLE 2.5). Antigapdh antibody was used as protein loading control.
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Figure 3.5. Chromatin Immunoprecipitation (ChIP) assays. The binding of STAT3 or
SMAD4 to the HAMP promoter in the livers of C57BL/6NCR mice, which were injected with
Jo2 (0.2 µg/g b.w.) or NaCl (control) and sacrificed 6 hours later, was determined by ChIP
assays, as described in experimental procedures. Total input DNA was used as control to evaluate
the amount of chromatin.
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Figure 3.6. The effect of Jo2 on apoptosis, acute phase response, and Hamp and Hamp2 gene
expression in C57BL/6J mice. C57BL/6J male mice (n = 21) were injected with 0.2 µg/g b.w.
and 0.32 µg/g b.w. Jo2 or saline and sacrificed 6 hours later. Cell lysates and RNA isolated from
the livers were employed in caspase-3/7 assays (A) or to synthesize cDNA as a template for SYB
green qPCR assays to determine IL-6 (B) or SAA3 (C) gene expression. Hamp (D) and Hamp2
(E) mRNA expression was determined by Taqman qPCR. Gene expression in Jo2 injected mice
was expressed as fold change of that in control mice.
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Figure 3.7. Comparison of liver enzyme levels in sera of Jo2 injected C57BL/6J and
C57BL/6NCR mice. Mice injected with Jo2 (0.2µg/g b.w.) were sacrificed 6 hours later. Serum
ALT (A) and AST (B) enzymes were measured at Clinical Chemistry Laboratory of University of
Nebraska Medical Center.
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Chapter IV
Saturated Fatty Acids Induce Post-transcriptional Regulation of HAMP mRNA via
AU-rich Element Binding Protein, HuR in Human Hepatoma Cells

This chapter has been adopted from a publication re-submitted to Journal of Biological Chemistry
(S.L. et. al, Manuscript ID.JBC/2015/648212).
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ABSTRACT

Iron is implicated in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). Hepcidin,
synthesized primarily in the liver, is the master switch of iron metabolism. The aim of this study
is to investigate the regulation of human hepcidin gene, HAMP expression by fatty acids in
HepG2 human hepatoma cells. For these studies, both saturated fatty acids, palmitic or stearic
acid, and unsaturated fatty acid, oleic acid were used. Palmitic acid and to a lesser extent stearic
acid, but not oleic acid, up-regulated HAMP mRNA levels, as determined by qPCR. Published
studies up-to-now have mainly described the transcriptional regulation of HAMP. To understand
whether fatty acids regulate HAMP mRNA at the transcriptional or post-transcriptional level, we
employed the transcription inhibitor, actinomycin D in our experiments. Palmitic acid-mediated
induction of HAMP mRNA expression was not blocked by actinomycin D. Furthermore, palmitic
acid activated HAMP 3’UTR, but not promoter, activity, as shown by reporter assays. HAMP
3’UTR harbors a single AU-rich element (ARE). Mutation of this ARE abolished the effect of
palmitic acid suggesting the involvement of ARE-binding proteins (ARE-BP). The ARE-BP,
HuR stabilizes mRNA through direct interaction with AREs on 3’UTR. HuR is regulated by
phosphorylation-mediated nucleo-cytoplasmic shuttling. Palmitic acid activated this process. The
binding of HuR to HAMP mRNA was also induced by palmitic acid in HepG2 cells. Silencing of
HuR by siRNA abolished palmitic acid-mediated up-regulation of HAMP mRNA levels. Protein
kinase C is known to phosphorylate HuR. Staurosporine, a broad-spectrum protein kinase C
inhibitor inhibited both saturated fatty acid-mediated translocation of HuR and induction of
HAMP expression. Similarly, rottlerin, a novel class protein kinase C inhibitor, abrogated
palmitic acid-mediated up-regulation of HAMP expression. In conclusion, our findings clearly
show that saturated, but not unsaturated, fatty acids control post-transcriptional regulation of
HAMP through novel protein kinase C- and HuR-dependent mechanisms. The studies in this
chapter are also demonstrating for the first time that HAMP is directly regulated at 3’UTR by a
functional AU-rich element sequence and RNA-binding proteins.
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INTRODUCTION

Due to the increasing prevalence of obesity worldwide, metabolic syndrome, characterized by
visceral adiposity, dyslipidemia and insulin resistance is becoming a major public health problem.
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome.
The accumulation of fat in the liver, which occurs in the absence of significant alcohol
consumption, is a key feature of NAFLD (1). Increased lipolysis as a result of insulin resistance
and lipid uptake from the diet contributes to the elevated levels of free fatty acids (FFA) in the
circulation. The increase in both the uptake of FFA by hepatocytes and de novo FA synthesis
leads to fat accumulation in the livers of NAFLD patients (see Chapter I for detailed overview)
(2).
Although lipid accumulation alone may be benign, more aggressive forms of NAFLD can
develop. Iron has been shown to be one of the risk factors in the pathogenesis of NAFLD (3).
Clinical studies with NAFLD patients have shown a clear correlation between hepatic iron
deposition and more advanced disease stages with liver fibrosis (4–6). Iron acts as a risk factor by
inducing oxidative stress and mitochondrial dysfunction (3). Hepcidin is the key iron-regulatory
protein, which is primarily synthesized in the liver (7). Humans express a single hepcidin gene,
HAMP. It controls iron absorption from the duodenum and iron release from macrophages by
inhibiting the iron exporter, ferroportin (8). Besides being an iron-regulatory protein, hepcidin
also acts as an acute phase protein. In NAFLD patients, HAMP expression has been suggested to
be regulated by both systemic iron levels (6, 9) and inflammation (10). A role for lipids in the
regulation of HAMP expression has not been established. A microarray study however reported
that the saturated fatty acid, palmitic acid (PA) modulates HAMP expression in HepG2 cells but
the underlying mechanisms are unknown (11).
Previous studies on hepcidin expression have mainly focused on the transcriptional regulation of
HAMP. Inflammatory cytokines, serum transferrin, erythropoiesis signaling and elevated hepatic
iron stores have all been shown to stimulate the promoter activities of both human and mouse
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hepcidin genes via the activation of specific transcription factors (12–15). It should however be
noted that other iron-regulatory proteins, transferrin receptor 1 and ferritin are regulated at the
post-transcriptional and translational level, respectively by iron-regulatory RNA-binding proteins
(IRP), IRP1 and IRP2 (16). Although no IRP recognition sequences have been identified in
HAMP mRNA, the involvement of post-transcriptional mechanisms warrant further investigation.
In addition to transcriptional regulation, post-transcriptional regulation serves the purpose of
modulating gene expression by regulating the half-life of specific transcripts or changing the rate
of translation (17). Both proteins and non-coding RNAs (ncRNAs) participate in posttranscriptional regulation by direct interaction with specific sequences in the target mRNA.
MicroRNAs (miRNAs) are small (~22nt) RNAs that are processed from endogenous hairpin
structured precursor transcripts by Dicer (18). Upon being fully processed, mature miRNAs are
mounted onto RNA-induced silencing complex (RISC) and thereby guide the latter to target
sequences by pairing of nucleotides 2 to 8 of the miRNA (seed sequence) with corresponding
sequences in the 3’UTR of target mRNA, and degrade or sequester the latter (19). miRNA is a
very versatile post-transcriptional regulator targeting transcripts of genes involved in different
biological processes such as cancer development and metabolism (20, 21). In addition, AU-rich
element (ARE) (i.e. AUUUA pentamer embedded in a U-rich context) in the 3’UTR of mRNA is
also a well-recognized cis-element in the regulation of mRNA stability targeted by AU-rich
element binding proteins (ARE-BPs) (17). ARE-BPs include human antigen R (HuR),
tristetraprolin (TTP), butyrate response factor 1 (BRF1), ARE/poly(U)-binding/degradation factor
1 (AUF1), and KH-type splicing regulatory protein (KSRP) among others (17). Unlike other
ARE-BPs, which mostly act as negative regulators and induce mRNA decay, HuR, has however
been shown to exert a stabilization effect on the target mRNA (17). Phosphorylation is important
for HuR function. HuR harbors several phosphorylation sites for various kinases including AMPactivated kinase (AMPK), p38-MAPK (mitogen-activated protein kinase), and protein kinase C
(PKC) (22). Following phosphorylation, HuR translocates from the nucleus to the cytoplasm (17,
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22). The phosphorylation-mediated nucleo-cytoplasmic shuttling of HuR is essential for its
mRNA stabilization function (22).
The limited studies conducted up-to-now examined mainly the role of microRNAs in the
regulation of hepcidin genes. An indirect role for miR-122 and miR-130a has been reported in the
regulation of mouse and human hepcidin gene expression. Namely, miR-122 and miR-130a
modulated HAMP expression by altering the mRNA stability of transcriptional activators, which
are known to activate HAMP transcription (23, 24). Other post-transcriptional regulation
mechanisms besides microRNAs directly targeting HAMP 3’UTR have not been identified.
HAMP 3’UTR harbors a single AU-rich element (ARE) but its functional role in the posttranscriptional regulation of HAMP expression is unknown.
Saturated fatty acids have been shown to activate various signaling pathways in hepatoma cells
including protein kinase C isoforms (25–29), which, as mentioned above, is a potent HuR
activator. However, the role of HuR or PKC in HAMP regulation has not been investigated. The
objective of the studies in this chapter is to understand the mechanisms by which hepatic HAMP
mRNA expression is regulated by saturated fatty acids. As described below, we have identified a
functional role for a single ARE in HAMP 3’UTR and the ARE-binding protein, HuR in posttranscriptional regulation of HAMP expression by lipids in human hepatoma cells. These findings
will help us to further understand the role of hepcidin and iron in obesity and fatty liver disease
pathogenesis.

3
3.1

RESULTS
Regulation of HAMP mRNA expression by fatty acids in HepG2 cells

For these studies, HepG2 cells were treated with saturated fatty acids, palmitic acid (PA) and
stearic acid (SA) or unsaturated fatty acid, oleic acid (OA). Most of the studies reported in the
literature use fatty acids which are conjugated to bovine serum albumin (BSA) to facilitate their
uptake by hepatocytes. Our preliminary studies however have shown that BSA by itself

108
dramatically suppresses the basal hepcidin expression in HepG2 cells. We observed this effect
with different commercial BSA preparations including high quality tissue culture-grade BSA
(data not shown). We therefore performed all the experiments described in this chapter using unconjugated fatty acids. We also chose 0.1 and 0.3 mM fatty acid concentrations for our studies
based on the studies reported in the literature, which describe optimal lipid signaling in tissue
culture cells (30, 31).
Hepatocytes take up free fatty acids through diffusion and specific transporters such as CD36 and
fatty acid transport polypeptide (FATP) (32). In order to validate that un-conjugated fatty acids
were taken up by HepG2 cells under our experimental conditions, the intracellular lipid content
was examined by Nile Red staining, as described in experimental procedures (Figure 4.1). A
significant increase in lipid content was observed in cells treated with 0.3 mM saturated fatty
acids, PA and SA or unsaturated fatty acid, OA, as compared to control cells treated with solvent
(isopropanol) (Figure 4.1). In contrast to PA or SA-treated cells, OA-treated cells exhibited
punctate lipid droplet-like structures (Figure 4.1). This is consistent with previous reports
showing that unsaturated fatty acids are more readily esterified to produce triglycerides (33, 34).
To investigate the role of fatty acids in the regulation of HAMP expression, HepG2 cells were
treated with different concentrations of PA, SA or OA for 8 h. Control cells were treated with
solvent, as described in experimental procedures. HAMP mRNA expression was determined by
real-time PCR (qPCR), as described in experimental procedures (see Chapter II). Cells treated
with PA displayed a concentration-dependent increase in HAMP mRNA expression compared to
solvent-treated control cells (Figure 4.2A). Similar concentrations of SA exerted a less prominent
induction than PA. In contrast to PA and SA, OA treatment did not significantly alter HAMP
expression compared to control cells (Figure 4.2A). In accordance with HAMP mRNA
expression, PA treatment also elevated the level of hepcidin protein expression compared to
control cells treated with solvent, as determined by western blotting (Figure 4.2B). These
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findings strongly suggest a role for saturated fatty acids, in particular PA, but not saturated fatty
acids in the regulation of hepatic hepcidin expression.
Earlier studies mainly concentrated on the regulation of HAMP expression at the transcriptional
level (12–15). We therefore examined the effect of fatty acids on HAMP transcription by
performing luciferase reporter assays. For these studies, HepG2 were cells transfected with pGL3 Basic vector harboring 1.5 kbp HAMP promoter (HAMP Prom-Luc), which contains consensus
DNA-binding sequences for various transcription factors implicated in the regulation of HAMP
transcription (12–15). As control, HepG2 cells were also transfected with empty vector, as
described in experimental procedures. HepG2 cells transfected with the recombinant vector
displayed higher luciferase activity compared to cells transfected with the empty vector (Figure
4.2C). However, the levels of HAMP promoter activity were similar in HepG2 cells treated with
PA or solvent control (Figure 4.2C). These reporter assay studies indicated that PA did not
stimulate 1.5 kbp HAMP promoter activity and therefore suggested that transcriptional
mechanisms might not be responsible for HAMP regulation by saturated fatty acids. In order to
investigate this further, we treated HepG2 cells with the transcription inhibitor, actinomycin D. as
expected, actinomycin D by itself significantly inhibited basal HAMP mRNA expression in
HepG2 cells (Figure 4.2D). On the other hand, HepG2 cells treated with PA in the presence of
actinomycin D exhibited a significant increase in HAMP mRNA expression compared to cells
treated with actinomycin D and solvent control (Figure 4.2E). Actinomycin experiments yielded
results, which were in agreement with reporter studies in that despite the inhibition transcriptional
mechanisms, saturated fatty acids can activate HAMP expression. This prompted us to investigate
post-transcriptional regulation mechanisms.
First we conducted experiments to investigate the effect of palmitic acid on HAMP mRNA
stability. For these investigations, time course experiments (0-10 h.) were performed with HepG2
cells treated with PA or solvent in the presence of actinomycin D. From 4 h. onwards, PA-treated
cells displayed significantly higher levels of HAMP mRNA compared to solvent treated control
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cells (Figure 4.2F). The half-lives of HAMP mRNA, calculated as described in experimental
procedures, were 2.70 ± 0.08 and 4.44 ± 0.01 h. in solvent and PA-treated cells, respectively
(Figure 4.2G). Our findings strongly suggest that palmitic acid stabilized HAMP mRNA in
HepG2 cells. We then conducted further studies to investigate the mechanisms by which saturated
fatty acid, PA regulates HAMP expression at the post-transcriptional level, which are described
below.
3.2

The role of palmitic acid in HAMP 3’UTR regulation

3’UTR regions of mRNA are important in the regulation of mRNA stability by various posttranscriptional pathways (17). The effect of PA on the 3’UTR region of HAMP was therefore
investigated by reporter assays. For these studies, the entire (101bp) 3’UTR region of HAMP
gene was inserted downstream of the luciferase gene in pMIR reporter vector, as described in
experimental procedures (see Chapter II). To perform dual luciferase reporter assays, HepG2
cells, transfected with either the empty pMIR vector (control) or recombinant pMIR vector
harboring HAMP 3’UTR (HAMP 3’UTR), were co-transfected with the reference plasmid, pRLSV40. Treatment with PA significantly stimulated luciferase activity in cells transfected with the
HAMP 3’UTR but not with empty vector (Figure 4.3A). Our reporter assay experiments strongly
suggested the involvement of 3’UTR in the regulation of HAMP mRNA expression by PA.
3.3

Functional role of AU-rich element (ARE) in HAMP 3’UTR

AU-rich element binding proteins (ARE-BP) regulate mRNA stability through the recognition of
AU-rich elements (ARE) in 3’UTR (17). The examination of HAMP 3’UTR revealed a single
ARE (Figure 4.3B). We performed mutagenesis with the ARE by deleting the “UUU” in the
AUUUA sequence. Recombinant pMIR vector harboring mutant HAMP 3’UTR (3’UTR ΔAU)
was employed in luciferase reporter assays. Unlike in cells transfected with wild-type 3’UTR, PA
failed to up-regulate luciferase activity in cells transfected with mutant HAMP 3’UTR (3’UTR
ΔAU) (Figure 4.3C). Mutagenesis experiments strongly suggest a functional role for HAMP

111
3’UTR ARE in PA-mediated up-regulation of HAMP RNA expression. Since we have established
a clear functional role for this single ARE-sequence within HAMP 2’UTR, we explored the role
of RNA-binding proteins that may bind to HAMP 3’UTR for post-transcriptional regulation of
hepcidin expression, as described below.
3.4

AU-rich element RNA-binding proteins (ARE-BP) and HAMP 3’UTR activation

The ARE-BP, HuR is well-known for its role in enhancing mRNA stability (17). The activation
of HuR is achieved via phosphorylation and subsequent nucleo-cytoplasmic shuttling (22). We
therefore examined the sub-cellular distribution of HuR in HepG2 cells treated with either PA or
solvent by immunofluorescent staining. Cells stained with normal mouse IgG as negative control
did not display any specific signal (Figure 4.4A). In solvent-treated control cells, HuR protein
was mainly located in the nucleus (Figure 4.4A). Upon PA treatment, HuR shuttled from nucleus
to the cytosol and exhibited a more diffuse distribution (Figure 4.4A). In contrast, unsaturated
fatty acid (OA) did not induce the translocation of HuR to the cytosol (Figure 4.4A). The
percentage of HuR localized in the cytosol was quantified, as described in experimental
procedures. In HepG2 cells treated with solvent, PA or OA, 8.01 ± 2.56%, 35.33 ± 3.89% and
10.07 ± 3.16% of HuR resided in the cytosol, respectively (Figure 4.4B).
The PA-induced nucleo-cytoplasmic shuttling of HuR was further supported by western blotting
performed with whole cell lysates, and nuclear and cytosolic fractions isolated from control or
PA-treated HepG2 cells. PA treatment did not affect the basal protein expression levels of HuR
(Figure 4.5). PA-treated cells displayed a significant increase in the level of cytosolic HuR
protein compared to that in control cells (Figure 4.5). Accordingly, the expression level of HuR
protein in the nucleus was decreased following PA treatment (Figure 4.5). Both
immunofluorescent staining and western blotting experiments indicate that nucleo-cytoplasmic
shuttling of HuR protein is induced by saturated fatty acids in hepatoma cells.
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Phosphorylation by protein kinases including protein kinase C (PKC) is important for the
shuttling and activation of HuR (22). Independently, PA has also been shown to induce the
activation of multiple isoforms of PKC (25–29). We therefore examined the role of PKC in posttranscriptional regulation of HAMP by PA. For these studies, HepG2 cells were first treated with
staurosporine, a potent broad-spectrum protein kinase C inhibitor (35, 36). The level of HuR
shuttling was determined in HepG2 cells treated with PA in the presence of 0.2 µM staurosporine
or DMSO as control. PA-induced nucleo-cytoplasmic shuttling of HuR was abolished in cells
treated with staurosporine, but not with DMSO, as confirmed by immunofluorescent staining and
further quantification (Figures 4.6A and 4.6B). Cells treated with PA in the presence of DMSO
as control displayed a significant increase (from 7.51 ± 2.67% to 38.55 ± 5.18%) in the level of
cytosolic HuR (Figure 4.6B). In contrast, HepG2 cells treated with PA and staurosporine did not
exhibit a significant change (from 9.30 ± 4.83% to 11.76 ± 6.48%) in HuR translocation
compared to cells treated with solvent and staurosporine (Figure 4.6B). Contrary to DMSO,
staurosporine treatment significantly blocked PA-mediated induction of HAMP mRNA
expression in HepG2 cells. (Figures 4.7A and 4.7B).
Both classical and novel classes of PKC isoforms have been suggested to phosphorylate HuR (22).
We therefore employed PKC inhibitors, Go6976 and rottlerin, which have been shown to block
classical or novel class of PKC isoforms, respectively (28, 37). Rottlerin (10 μM), but not
Go6976 (1 μM), treatment abolished PA-induced HAMP mRNA increase in HepG2 cells
(Figures 4.7C and 4.7D).
3.5

The effect of HuR silencing on HAMP mRNA expression

To determine the direct role of ARE and HuR in HAMP mRNA regulation by PA, we employed a
commercial human HuR siRNA pool, comprised of four different specific siRNAs, as described
in experimental procedures, to suppress HuR expression. In parallel, HepG2 cells were
transfected with control siRNA (Figures 4.8A and 4.8B). The expression levels of HuR mRNA
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and protein in cells transfected with control or HuR siRNA was determined by qPCR and western
blotting (Figure 4.8A). Significant inhibition of HuR was achieved in HuR siRNA-transfected
cells compared to control cells under our experimental conditions. Subsequently, transfected
HepG2 cells were treated with 0.3 mM PA or solvent and HAMP mRNA expression was
determined by qPCR. In solvent-treated HepG2 cells, the basal expression level of HAMP mRNA
was down-regulated by HuR siRNA compared to control siRNA (Figure 4.8B). PA-induced
increase in HAMP mRNA levels was significantly abrogated in HuR siRNA-transfected cells
compared to cells transfected with control siRNA (Figure 4.8B). Our siRNA experiments clearly
show that HuR is required for PA-mediated up-regulation of HAMP mRNA expression.
3.6

The Physical Interaction of HuR with HAMP 3’UTR

To confirm the direct interaction of HuR with HAMP mRNA, ribonucleoprotein
immunoprecipitation (RNP-IP) assays were performed, as described in experimental procedures
(see Chapter II). For these assays, we used cytosolic fractions, which were isolated from HepG2
cells, as described in experimental procedures. Specific immunoprecipitation of HuR proteins by
our anti-HuR antibody was confirmed by western blotting (Figure 4.9A inset). The amount of
HAMP mRNA in HuR or control IgG co-precipitated total RNA was quantified by qPCR. The
level of HAMP mRNA present in control IgG immunoprecipitates was not different between PA
and solvent-treated HepG2 cells (Figure 4.9A). In contrast, 8.58 ± 0.51-fold more HAMP mRNA
was detected in HuR-immunoprecipitates of PA-treated HepG2 cells compared to those from
solvent-treated cells (Figure 4.9A). To confirm specificity, the presence of 18s rRNA in HuR
immunoprecipitates was determined, as a negative control. PA treatment did not significantly
alter the level of 18s rRNA validating our RNP-IP assays (Figure 4.9B).
3.7

The regulation of microRNAs by palmitic acid and its effect on HAMP mRNA

Micro RNAs (miRNAs) are negative regulators of mRNA stability and translation (38, 39). We
therefore determined whether PA-mediated up-regulation of HAMP mRNA involves the
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suppression of miRNAs, which might potentially target HAMP 3’UTR. Online algorithms (e.g.
TargetScan, miRGen, RNA22) for in silico identification of miRNA targets were employed to
scan HAMP 3’UTR sequence. The results obtained from different databases commonly identified
miR-214. Previous studies have also shown that miR-122 indirectly regulates HAMP gene
expression by targeting 3’UTR of other upstream iron-regulatory genes, such as Hfe and Hjv (23).
We therefore included these two microRNAs in our investigations and determined the expression
levels in PA or solvent-treated HepG2 cells by qPCR, as described in experimental procedures.
PA elevated the expression of miR-214 but not miR-122 (Figures 4.10A and 4.10B). Contrary to
our hypothesis, PA treatment did not suppress, but induced, the expression of miR-214.
Nevertheless, we further investigated the potential role of miR-214 in HAMP regulation by
transfecting HepG2 cells with miR-214 mimic or negative control miRNA. HAMP mRNA
expression was determined 24 h. after transfections. In parallel, the mRNA expression level of
mitogen-activated protein kinase kinase 3 (MEK3), which is a validated miR-214 target (40), was
also determined by qPCR. Compared to negative control miRNA, miR-214 mimic significantly
elevated HAMP mRNA expression (Figure 4.10C). However, the expression of MEK3 mRNA
was significantly suppressed by miR-214 mimic confirming its specificity under our experimental
conditions (Figure 4.10D). These findings in concert with the defined role of miRNAs as mRNA
destabilizers strongly suggest that miR-214, despite being regulated by PA, is not directly
involved in the induction of HAMP mRNA expression in PA-treated HepG2 cells.

4

DISCUSSION

Hepatic iron overload in NAFLD patients has been shown to be associated with disease severity
(3–5). Clinical studies have also reported changes in the expression levels of hepcidin, the key
iron regulator, in the liver and sera of NAFLD patients (6, 9). However, the underlying
mechanisms are unclear. Hepcidin expression has been suggested to respond to changes in iron
levels or obesity-mediated inflammatory cytokines (6, 9, 10). Obesity and NAFLD are associated
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with dysregulated lipid metabolism. This study investigated the regulation of human hepcidin
gene, HAMP by fatty acids in hepatoma cells. Our findings have not only clearly shown that
saturated fatty acids, particularly palmitic acid, stimulate hepcidin expression in human liver cells
but also revealed that HAMP expression can be regulated at the post-transcriptional level. This
post-transcriptional pathway utilizes a single AU-rich element (ARE) in HAMP 3’UTR.
Furthermore, we have identified an additional role for the ARE-binding protein, HuR in the
regulation of iron homeostasis. Interestingly, our findings also suggested an association of novel
class protein kinase C isoforms with HAMP and iron metabolism. Collectively, we have shown
unique mechanisms, which connect iron homeostasis with lipid metabolism in hepatoma cells,
and have implications for the pathogenesis of fatty liver disease and obesity.
Previous studies have particularly focused on the transcriptional regulation of HAMP. Unlike
other iron-regulatory proteins such as ferritin and transferrin receptor 1, which are regulated by
RNA-binding proteins, IRP1 and IRP2, our knowledge on the post-transcriptional regulation of
HAMP is very limited. An indirect role for microRNAs has been suggested in the regulation of
mouse and human hepcidin genes via the targeting of transcriptional activators (23, 24). In
agreement, our findings in this study have also indicated that miR-214 participates in HAMP
regulation by saturated fatty acids, which likely occur through similar indirect mechanisms. In
fact, miR-214 mimic up-regulated HAMP expression, which is in contrast to the widely accepted
miRNA function. Namely, as explained in Introduction section above, microRNAs have been
shown to destabilize mRNA by binding to their 3’UTR (21, 39). It is possible that miR-214 may
have inhibited an as yet unidentified suppressor of HAMP. Nevertheless, our and other studies do
not support a direct role for miRNAs in the regulation of human or mouse hepcidin gene
expression. Further studies are required to accurately characterize the role of miR-214 in HAMP
regulation. In this study we have shown other post-transcriptional mechanisms, which directly
target and regulate the 3’UTR of HAMP.
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Our studies with actinomycin D confirmed the post-transcriptional regulation of HAMP by
saturated fatty acids. Namely, despite blocking transcription with actinomycin D, palmitic acid
treatment induced HAMP up-regulation, which was similar to that in cells incubated with palmitic
acid in the absence of actinomycin D. Accordingly, palmitic acid treatment significantly extended
the half-life of HAMP mRNA. Furthermore, palmitic acid did not stimulate HAMP promoter, as
shown by reporter assays using a construct harboring a 1.5 kbp HAMP promoter region. Similar
results were obtained with shorter (0.6 and 0.9kbp) versions of HAMP promoter (data not shown).
In contrast, palmitic acid directly stimulated HAMP 3’UTR, as shown by dual luciferase assays.
Taken together, these findings clearly indicated that post-transcriptional mechanisms are
responsible for the induction of hepatic HAMP mRNA by saturated fatty acids.
Numerous studies using different experimental models have clearly shown that palmitic acid
treatment activates both the classical and novel class isoforms of protein kinase C (PKC) (26–28,
41). Our experiments suggested a role for these kinases in the regulation of HAMP by saturated
fatty acids. The fact that palmitic acid treatment activated HAMP 3’UTR and that PKC inhibition
abrogated saturated fatty acid-mediated HAMP mRNA up-regulation, prompted us to investigate
the role of ARE-binding proteins, which are regulated by PKC signaling. The ARE-BP, HuR has
been shown to be involved in the post-transcriptional regulation of genes mediating inflammatory
reactions and tumorigenesis by targeting AU-rich elements (17, 22). Nucleo-cytoplasmic
shuttling of HuR, regulated by phosphorylation, is crucial for its function (22). Both classical
(PKCα) and novel (PKCδ) PKC isoforms have been shown to phosphorylate HuR at serine
residues within or adjacent to the HuR-nucleo-cytoplasmic shuttling sequence (HNS) and thereby
activate its translocation to the cytoplasm (42, 43). Saturated, but not unsaturated, fatty acids
clearly induced the nucleo-cytoplasmic shuttling of HuR, which was confirmed both by
immunofluorescence studies and subcellular fractionation of HepG2 cells. Accordingly, PKC
inhibitors blocked both HuR translocation and induction of HAMP expression by palmitic acid.
Inhibitor studies have also suggested that palmitic acid induces HAMP mRNA expression through
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the activation of novel class of PKC isoforms. Further studies are required to confirm that the
direct phosphorylation of HuR by PKC is essential for saturated fatty acid-mediated up-regulation
of HAMP mRNA levels.
To further understand whether HAMP is a potential target of HuR, we analyzed HAMP 3’UTR
and identified one classical AU-rich element (ARE). Mutation of this ARE completely abolished
palmitic acid-mediated activation of HAMP 3’UTR, as shown by reporter assays, and thereby
confirmed the importance of this cis-element. The direct role of HuR was subsequently confirmed
by various experiments. RNP-IP assays indicated the physical interaction of HuR with HAMP
mRNA. Further proof was obtained by HuR siRNA studies, which successfully knocked down
HuR in HepG2 cells. HuR inhibition by siRNA abolished PA-induced elevation of HAMP mRNA.
These findings confirm that HAMP is a target of HuR, which mediates the regulation of HAMP
by saturated fatty acids. Although HuR binding is sufficient for HAMP activation, the interaction
of other post-transcriptional regulators with HuR on HAMP 3’UTR cannot be excluded.
Interestingly, we detected the presence of miR-214 in immune complexes pulled down with our
anti-HuR antibody in HepG2 cells. Further investigations are required to understand the
importance of ARE-BP and microRNA interaction in the regulation of HAMP mRNA stability.
In summary, we have identified a novel regulatory mechanism for human hepcidin gene
expression, which occurs at the post-transcriptional level through AU-rich element RNA-binding
protein, HuR and protein kinase C signaling. These findings have implications for understanding
the role of iron metabolism in the pathogenesis of fatty liver disease and obesity. Since this ARE
sequence is also present in 3’UTR of mouse hepcidin genes, mouse models of NAFLD can be
used for further studies. Targeting of AU-rich element RNA-binding proteins might also provide
novel therapeutic approaches for the treatment of diseases associated with metabolic syndrome.
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Figure 4.1. Fatty acid-induced lipid accumulation in HepG2 cells. HepG2 cells cultured on coverslips
coated with poly-lysine were treated with 0.3 mM palmitic acid (PA), stearic acid (SA), oleic acid (OA)
or solvent control (Solv.) for 8 h. Intracellular lipid content was stained with Nile Red and nuclei
counterstained with Hoechst 33342, as described in experimental procedures (see Chapter II). The images
obtained with Nikon Eclipse E400 fluorescence microscope were processed and overlaid with ImageJ.
Representative fluorescent images are shown (X 40).

122

Nile Red

Solv.

PA

SA

OA

Figure 4.1

Hoechst

Merge

123
Figure 4.2. Post-transcriptional regulation of HAMP by saturated fatty acids. (A) HepG2 cells were
treated with 0.1 mM or 0.3 mM PA, 0.3 mM SA and OA for 8 hours (h). cDNA synthesized from RNA
was employed in Taqman qPCR to determine HAMP mRNA expression. Gene expression in fatty acidtreated cells was expressed as fold change of that in solvent-treated control cells. The inset shows
hepcidin protein expression in solvent or PA-treated cells, as determined by western blotting. (B)
Hepcidin protein expression levels in PA or solvent-treated cells were determined by western blotting. (C)
pGL-3 Basic vector harboring a 1.5kb HAMP promoter region (HAMP Prom-Luc) or empty pGL-3 Basic
vector was transfected into HepG2 cells together with pRL-SV40 plasmid as a reference for transfection
efficiency. 24 h. after transfections, the cells were treated with 0.3 mM PA or solvent for 8 h. Dual
luciferase reporter assays were performed, as described. The relative luciferase levels were expressed as
fold change of that in solvent-treated cells transfected with empty vector. (D) HepG2 cells were treated
with DMSO or 1µg/mL actinomycin D (ACTD) for 8 hours. HAMP mRNA expression, determined by
qPCR, in ACTD-treated cells was expressed as fold change of that in DMSO-treated controls. (E) HepG2
cells were treated with 0.3 mM PA or solvent in the presence of ACTD for 8 h. HAMP mRNA expression,
determined by qPCR, in PA and ACTD-treated cells was expressed as fold change of that in cells treated
with solvent and ACTD (F) HepG2 cells were treated with solvent (solid line) or 0.3 mM PA (dashed line)
in the presence of 1µg/mL actinomycin D (ACTD). Control cells were treated with solvent in the
presence of DMSO. Cells were harvested every 2 h until 10 h. HAMP mRNA expression at different time
points was expressed as fold change of that in respective control cells. (G) The half-life of HAMP mRNA
in HepG2 cells treated with solvent or 0.3 mM PA was calculated, as described in experimental
procedures and expressed in hours. Asterisks indicate statistical significance (p<0.05).
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Figure 4.3. The role of palmitic acid (PA) in the regulation of HAMP 3’UTR. (A) HepG2 cells,
transfected with pMIR vector harboring 3’UTR of HAMP gene (3’UTR) or empty pMIR vector, were
treated with PA or solvent. pRL-SV40 vector was co-transfected as a reference for transfection efficiency.
Dual luciferase assays were performed, as described in experimental procedures. The relative luciferase
levels were expressed as fold change of that in solvent-treated cells transfected with empty vector. (B)
HAMP 3’UTR region harboring a single AU-rich element (ARE) is shown as a schematic diagram. The
position of ARE sequence (AUUUA) is underlined. (C) Mutagenesis of AU-rich element in HAMP
3’UTR region was performed by deleting the UUU base pairs by site-directed mutagenesis, as described
in the experimental procedures. HepG2 cells were transfected with pMIR vector harboring wild-type
3’UTR or 3’UTR with mutated AU-rich element (3’UTR ΔAU) to perform dual luciferase assays, as
described above.
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Figure 4.4. PA-induced nucleo-cytoplasmic shuttling of HuR protein (immunofluorescent staining).
(A) HepG2 cells cultured on coverslips were treated with 0.3 mM PA, OA or solvent (Solv.). HuR protein
expression was detected with an anti-HuR primary antibody and secondary Texas Red-conjugated horse
anti-mouse IgG. Normal mouse IgG was employed as negative control for the immunofluorescent
staining. Nuclei were counterstained with DAPI. The images obtained with Nikon Eclipse E400
fluorescence microscope were processed and overlaid with ImageJ. Representative fluorescent images are
shown (X 40). (B) Four independent 20X fluorescent images (120 ± 22 cells in each image) from each
treatment group were analyzed with Squassh plugin of ImageJ. The percentage of cytosolic HuR signal
intensity was calculated, as described in experimental procedures. Asterisks indicate statistical
significance (p<0.05).
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Figure 4.5. PA-induced nucleo-cytoplasmic shuttling of HuR protein (western blotting). Whole cell
lysate, cytosolic and nuclear fractions were isolated from HepG2 cells treated with solvent (Solv.) or 0.3
mM PA for 8 h. The protein lysates were employed for western blotting to detect HuR protein expression
with an anti-HuR primary and an anti-mouse secondary antibody in each fraction. An anti-gapdh or antihistone H3 (H3) antibody was used as cytosol or nucleus marker, respectively.
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Figure 4.6. PA-mediated shuttling of HuR was abolished by staurosporine. (A) Immunofluorescent
staining was performed with HepG2 cells treated with solvent or 0.3 mM PA in the presence of 0.2 µM
staurosporine (STAU) or DMSO as control, as described. Representative fluorescent images are shown
(X 40). (B) Quantification of HuR nuclear localization was performed, as described in experimental
procedures.
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Figure 4.7. PA-mediated HAMP mRNA induction was abolished by PKC inhibitors. HAMP mRNA
expression in HepG2 cells treated with solvent (Solv.) or 0.3 mM PA either in the presence of DMSO (A),
0.2µM staurosporine (STAU) (B), 1 µM Go6976 (C) or 10 µM rottlerin (D) was determined by qPCR.
Gene expression in treated cells was expressed as fold expression of that in control cells incubated with
solvent. Asterisks indicate statistical significance (p<0.05).
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Figure 4.8. PA-induced up-regulation of HAMP expression was inhibited by HuR siRNA. HepG2
cells were transfected with 50 nM of HuR siRNA SMART pool or control siRNA, as described in
experimental procedures. (A) The level of HuR mRNA expression in transfected cells was determined by
qPCR. The inset shows HuR protein expression determined by western blotting. (B) The level of HAMP
mRNA expression in siRNA-transfected cells treated with solvent or 0.3 mM PA for 8 h. was determined
by qPCR. Asterisks indicate statistical significance (p<0.05).
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Figure 4.9. The physical interaction of HuR with HAMP mRNA. RNP-IP assays were performed to
detect the binding of HuR to HAMP mRNA in HepG2 cells treated with solvent or 0.3 mM PA, as
described in experimental procedures. (A) RNA isolated from control IgG or HuR immunoprecipitates
was used to synthesize cDNA to determine HAMP expression by qPCR. HAMP expression in
immunoprecipitates from PA-treated cells was expressed as fold change of that in corresponding solventtreated cells. Asterisks indicate statistical significance (p<0.05). Inset: Detection of HuR protein in HuR
or control IgG immunocomplexes by western blotting. (B) 18s rRNA expression in HuR
immunoprecipitates was determined by qPCR as a negative control.
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Figure 4.10. The regulation of microRNAs by PA and its effect on HAMP mRNA. The expression
levels of miR-122 (A) and miR-214 (B) in PA or solvent-treated HepG2 cells were determined by qPCR.
(C) miR-214 mimic and negative control (Neg.) was transfected into HepG2 cells and the expression
levels of HAMP (C) and MEK3 (D) mRNA were determined by qPCR 24 h. after transfections. Asterisks
indicate statistical significance (p<0.05).
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Chapter V
Ceramide Regulates Human Hepcidin Gene Transcription through JAK/STAT3
Signaling Pathway
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1

ABSTRACT

Hepcidin is both an acute phase and iron-regulatory protein, synthesized in the liver. As an acute
phase protein, its expression is induced by inflammation and infection. Inflammatory processes in
the liver play a major role in the pathogenesis of liver diseases including nonalcoholic fatty liver
disease (NAFLD). Changes in iron metabolism and hepcidin expression in NAFLD patients have
been observed but the causes and significance of these changes are unclear. It might be mediated
by iron or inflammatory signaling in the liver. Transcription of the human hepcidin gene, HAMP
is known to be activated by inflammatory cytokines, IL-1 and IL-6. The lipid intermediates such
as ceramide, which are also generated in livers with lipid accumulation (i.e. NAFLD), have also
been shown to induce inflammatory responses. Despite this knowledge, neither the role of
ceramide and other and lipid intermediates in NAFLD nor their effect on HAMP transcription has
been investigated. In the current study, we examined the regulation of HAMP expression by
ceramide. For these studies, HepG2 human hepatoma cells were treated with two different cellpermeable ceramide analogs. They both significantly activated HAMP mRNA expression in a
concentration-dependent manner. The effect of ceramide on HAMP expression was mediated at
the transcriptional level because it was abolished with the transcription inhibitor, actinomycin D.
Accordingly, ceramide significantly stimulated HAMP promoter activity, which occurred within
the 0.6 kb HAMP promoter region proximal to the transcription start site. The transcription
factors, STAT3, NF-κB and c-Jun/AP-1 play important roles in inflammation. Ceramide
specifically induced the binding of STAT3, but not NF-κB or c-Jun/AP-1, to the HAMP promoter,
as shown by chromatin immunoprecipitation assays. In fact, ceramide exerted a negative effect on
c-Jun/AP-1 binding. Similarly, a chemical inhibitor of c-Jun N-terminal kinase (JNK) did not
abolish the effect of ceramide on HAMP expression. Ceramide stimulated the phosphorylation of
STAT3 on tyrosine 705 residue, NF-κB p65 subunit protein and JNK in HepG2 cells. These
findings further confirm the specificity of ceramide-mediated STAT3 interaction with HAMP
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promoter. To confirm the direct role of this interaction, we mutated the single STAT3 response
element present within 0.6 kb HAMP promoter region. This deletion significantly abolished the
activation of HAMP promoter by ceramide. Furthermore, siRNA-mediated silencing of STAT3
and the inhibition of JAK kinases with a specific chemical inhibitor significantly blunted the
stimulatory effect of ceramide on HAMP mRNA expression. In conclusion, the studies in this
chapter confirmed the direct and significant role of ceramide in the regulation of HAMP
transcription through STAT3. These findings suggest that inflammatory signaling mediated by
lipid intermediates in the liver may modulate iron metabolism and thereby disease severity in
NAFLD patients.

2

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is the accumulation of fat in the liver of patients with
no or little alcohol consumption (1). More than one third of the US adult population is estimated
to have NAFLD and its prevalence is expanding to developing countries and to children (2).
Benign fat accumulation in the liver (steatosis) can progress to nonalcoholic steatohepatitis
(NASH) (3), characterized by inflammation (steatohepatitis) and fibrosis. Alternatively, patients
can present with NASH without previous steatosis (4). If untreated, NASH can eventually lead to
cirrhosis and hepatocellular carcinoma (5). The mechanisms of NAFLD/NASH progression are
unclear. A role for secondary risk factors including iron (6, 7) and inflammation (8) has been
proposed (see Chapter I for detailed overview).
NAFLD patients frequently display elevated levels of serum iron indices and hepatic iron content
(9, 10). The deposition of iron in the liver correlates with disease severity and the development of
fibrosis (11–13). The discovery of hepcidin has helped us to understand the connection between
inflammation and iron homeostasis (14–17). Hepcidin, mainly synthesized in the hepatocytes of
the liver, is both an acute phase protein and pivotal regulator of systemic iron homeostasis (14–
17). As an acute phase protein, hepcidin responds to inflammation and its synthesis in the liver is
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stimulated by inflammatory cytokines, such as IL-1 and IL-6. It has been shown that IL-6 induces
hepcidin expression at the transcriptional level through the activation of JAK/STAT3 pathway
(15, 16, 18). The binding of STAT3 to both human (HAMP) and mouse (Hamp) hepcidin gene
promoters have been demonstrated in different experimental models (15, 16, 18).
Inflammation plays a major role in NAFLD pathogenesis. Several factors including increased gut
permeability, adipose tissue derived cytokines and adipokines, Kupffer cell activation, and lipid
accumulation have all been shown to induce inflammatory reactions in the livers of NAFLD
patients (8, 19). In a study with overly obese patients undergoing bariatric surgery, a relationship
between adipose tissue-derived-IL-6 and elevated hepcidin expression in the adipose tissue has
been shown (20). However, elevated hepcidin expression could also be due to increase in the
number of adipocytes in obese individuals compared to normal weight controls. Further studies
investigating the direct effect of hepatic lipid accumulation and inflammation on hepcidin
expression are therefore required. Although the in vivo relevance needs to be established, we have
shown a direct effect of saturated fatty acids on hepcidin expression in human hepatoma cells (see
Chapter IV). Namely, palmitic acid induced hepcidin expression at the post-transcriptional level
through the activation of protein kinase C signaling and AU-rich element binding protein HuR
(see Chapter IV).
Both inflammation and lipid accumulation are potent stimulators of ceramide synthesis in the
liver through different well-defined pathways (i.e. de novo and sphingomyelinase pathways) (21,
22). Increased ceramide production and its association with hepatic fat content have been reported
in obese and/or insulin resistant patients (23, 24). Similarly, animal studies with high fat diet
feeding have also demonstrated an increase in hepatic ceramide content (25, 26). Despite all these
observations, the involvement of ceramide in the pathogenesis of NAFLD has not been
investigated. Nevertheless, weight loss studies have alluded to the importance of liver ceramide
synthesis in NAFLD (27). Namely, the reversal of NASH pathogenesis correlated with weight
loss-mediated decrease in pro-ceramide gene expression in the liver (27).
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Although initially recognized only as a structural component of biomembranes, ceramide in
recent years has gradually been appreciated as an important signaling molecule (28). Besides
negatively modulating insulin signaling (29), ceramide also activates inflammatory signaling
pathways. The tyrosine phosphorylation of the transcription factor, STAT3 and its DNA binding
activity has been shown to be stimulated by ceramide in a JAK-dependent manner in cultured
fibroblasts (30). Besides STAT3, ceramide has been reported to activate the transcription factor,
NF-κB and its down-steam targets in HepG2 and other cells (31–33). The c-Jun N-terminal
kinase (JNK) is also involved in inflammation. Deletion of JNK has been shown to reverse
steatohepatitis in mice livers induced by methionine-choline deficient diets (34). JNK is activated
by phosphorylation, which in turn phosphorylates c-Jun and transactivation of AP-1 enhancercontaining genes (35). Ceramide has been reported to stimulate JNK activation (36–38). Although
ceramide has been shown to both modulate and be modulated by inflammation, the effect of these
changes on hepatic HAMP expression is unknown. Understanding these mechanisms will further
our knowledge of NAFLD/NASH pathogenesis. In this chapter we present studies, examining
HAMP regulation by ceramide and the underlying mechanisms in human hepatoma cells.

3
3.1

RESULTS
Ceramide analogs-induced transcriptional regulation of HAMP

In order to study the role of ceramide in the regulation of human hepcidin gene, HAMP
expression in human hepatoma cells, we treated HepG2 cells with synthetic cell-permeable
ceramide analogs, C2 and C6 ceramide, which are extensively used for in vitro experiments (21,
37, 39). We chose 30 μM and 60 μM concentrations based on previous reports, which have
shown that cells treated with these concentrations of ceramide analogs for 8 hours exhibit over
90 % cell viability (32, 40). Similar ceramide concentrations have been detected in the plasma of
human NAFLD patients (41) and rats with acute lipid infusion (42). Control cells were treated
with solvent (0.1 % DMSO). The effect of ceramide analogs on hepcidin expression was
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determined by measuring the level of HAMP mRNA by qPCR, as described in the experimental
procedures (see Chapter II). HepG2 cells treated with 30 μM or 60 μM of C2 ceramide displayed
an 1.78 ± 0.35 and 3.43 ± 0.39-fold increase in HAMP expression, respectively, compared to
control cells treated with solvent (Figure 5.1A). Compared to C2, similar concentrations of C6
ceramide analog induced a less potent but still significant elevation of HAMP mRNA expression
(Figure 5.1A). We therefore employed C2 ceramide analog for further experiments.
Studies to this date have concentrated on transcriptional regulation of hepcidin gene expression
(43–46). However, our recent studies also highlighted the importance of post-transcriptional
mechanisms in the regulation of hepatic HAMP expression (see Chapter IV). We therefore
determined whether the induction of HAMP expression by ceramide occurred at the
transcriptional or post-transcriptional level. For these experiments, HepG2 cells were treated with
ceramide or solvent in the presence of either actinomycin D (a transcription inhibitor) or DMSO
control. DMSO by itself did not alter C2 ceramide-mediated induction of HAMP mRNA
expression (Figure 5.1B). On the other hand. actinomycin D by itself significantly decreased the
levels of HAMP mRNA in HepG2 cells (Figure 5.1B). Similarly, simultaneous treatment with
actinomycin D and ceramide completely blocked ceramide-induced HAMP mRNA up-regulation
(Figure 5.1B and 5.1C). To further confirm the role of transcriptional regulation, we performed
luciferase reporter assays using a 0.6 kb region of HAMP promoter, which harbors binding sites
for various transcription factors (46, 47) (Figure 5.1D). HepG2 cells were transfected with either
empty pGL-3 basic vector or vector containing 0.6kb HAMP promoter (HAMP Prom-Luc). pRLSV40 plasmid encoding renila luciferase was co-transfected as a reference for transfection
efficiency, as described in experimental procedures (see Chapter II). Cells transfected with the
vector harboring the HAMP promoter exhibited a significantly higher level of luciferase activity
(Figure 5.1D). Ceramide treatment of HepG2 cells transfected with HAMP Prom-Luc, but not
with empty vector, resulted in a significant increase of luciferase activity. In conjunction with
actinomycin D experiments, our reporter assay studies with HepG2 cells indicated that ceramide
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regulates HAMP expression at the transcriptional level and that this regulation is conveyed
through cis-elements contained within the 0.6 kb HAMP promoter.
3.2

Physical interactions between transcription factors and HAMP promoter.

Various transcription factors such as STAT3, NF-κB and c-Jun/AP-1 are involved in the
regulation of inflammatory processes (48–50). Recognition sequences for these transcription
factors have been identified in the 0.6 kb promoter of HAMP (Figure 5.2A). In order to confirm
the identity of transcription factors physically interacting with HAMP promoter in ceramidetreated HepG2 cells, chromatin immunoprecipitation (ChIP) assays were performed, as described
in experimental procedures (Figures 5.2B and 5.2C). For these experiments, specific antibodies
for transcription factors, STAT3, NF-κB and c-Jun/AP-1, which have been validated for ChIP
experiments, were employed. Normal rabbit/mouse IgG was used as negative control. The
primers used for ChIP analysis (Chapter II Table 2.4) amplified promoter sequences spanning
consensus sites for respective transcription factors (STAT3: -135bp to -143bp, c-Jun/AP-1: 126bp to -134bp, NF-κB P65: -583bp to -592bp proximal to the start codon, ATG). Ceramide
treatment significantly increased the binding of STAT3 to HAMP promoter (Figure 5.2B).
HepG2 cells treated with the cytokine, IL-6 were employed as a positive control (16). The
binding of STAT3 to HAMP promoter was also induced by IL-6 treatment, which validated our
anti-STAT3 antibody and ChIP protocol (Figure 5.2C). Unlike STAT3, the binding of NF-κB
p65 subunit to HAMP promoter was not activated by ceramide treatment (Figure 5.2B). On the
other hand, the binding of c-Jun/AP-1 to HAMP promoter was weakened in ceramide-treated
HepG2 cells compared solvent-treated cells (Figure 5.2C). The findings of our ChIP experiments
were specific because no significant promoter enrichment was observed when similar chromatin
preparations were incubated with the control IgG (representative images are shown in Figures
5.2B and 5.2C). Furthermore, the total amount of chromatin input was equal across all samples in
our ChIP assays (Figure 5.2B and 5.2C).
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3.3

Phosphorylation and activation of STAT3 and NF-κB in ceramide-treated cells

Western blots were performed with specific phospho-antibodies, which recognize the
phosphorylated (i.e. activated) forms of STAT3 and NF-κB proteins to determine the effect of
ceramide on their activation status (Figure 5.3A and 5.3B). STAT3 is regulated by
phosphorylation both on serine (Ser 727) and tyrosine (Tyr 705) residues (51). Following
ceramide treatment, HepG2 cells displayed a significant increase in tyrosine (Tyr 705), but not
serine (Ser 727), phosphorylation of STAT3 (Figure 5.3A). As a positive control, HepG2 cells
were also treated with recombinant IL-6. Unlike ceramide, IL-6 treatment stimulated
phosphorylation of STAT3 both at Tyr 705 and Ser 727 compared to that in PBS-treated control
cells (Figure 5.3A). Neither ceramide nor recombinant IL-6 altered the expression level of total
STAT3 protein in HepG2 cells (Figure 5.3A). Similar to STAT3, ceramide also stimulated the
phosphorylation of NF-κB subunit, p65 (Figure 5.3B). Our findings collectively suggested, that
despite ceramide inducing the phosphorylation of both transcription factors, only STAT3 (and not
NF-KB) is capable of binding to and stimulating HAMP promoter activity.
3.4

The relationship between ceramide-induced JNK phosphorylation and HAMP upregulation.

MAP kinases such as c-Jun N-terminal kinase (JNK) and extracellular signal-regulated protein
kinases 1 and 2 (ERK1/2) have been suggested to target serine 727 of STAT3 for phosphorylation
(51). We therefore examined the phosphorylation of JNK and ERK1/2 by western blotting.
Ceramide suppresses extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) in some (52,
53) but not all (32) experimental systems. Under our experimental conditions, C2 ceramide
significantly suppressed the phosphorylation of ERK1/2. IL-6 treatment exerted only a minor
effect (Figure 5.3A). In contrast, C2 ceramide significantly induced the phosphorylation of JNK
compared to DMSO (control) (Figure 5.3B).
To further study the effect of ceramide and JNK on HAMP expression, we employed the chemical
inhibitor, SP600125, which has been documented to specifically inhibit JNK activation (54).
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HepG2 cells were treated in the presence of both ceramide and SP600125. In parallel, coincubation with DMSO was also performed, as control. Western blotting was performed to
examine the effect of SP600125 on ceramide-induced JNK phosphorylation (Figure 5.4A).
DMSO did not have any specific effect on ceramide-induced JNK activation (Figure 5.4A). In
contrast, SP600125 co-incubation significantly blocked ceramide-induced activation of JNK
(Figure 5.4A). We then examined the effect of SP600125 co-incubation on ceramide-induced
HAMP expression by qPCR. The inhibitor by itself did not exert any significant effect on basal
HAMP mRNA expression (Figure 5.4B). Similarly, SP600125 was not capable of blocking the
positive effect of ceramide on HAMP mRNA expression (Figure 5.4B). These results indicated
that although activated by ceramide, JNK is not directly involved in transcriptional regulation of
HAMP by ceramide in hepatoma cells.
3.5

The role of STAT3 activation in ceramide-induced HAMP transcriptional regulation.

To validate the specific role of STAT3 in ceramide-mediated transcriptional regulation of HAMP,
the STAT3 response element in the 0.6kbp HAMP promoter was mutated, as described in the
experimental procedures (see Chapter II). Luciferase reporter assays were then performed with
pGL-3 basic vectors harboring the wild-type or mutated HAMP promoter (Figure 5.5A).
Mutation of the STAT3 response element (ΔSTAT3) significantly diminished the stimulatory
effect of ceramide on HAMP promoter, confirming the direct involvement of the STAT3 binding
site (Figure 5.5A). We validated the mutated promoter construct by IL-6 treatment based on the
rationale that this STAT3 response element is essential for IL-6-responsiveness of HAMP
promoter (16, 45). Accordingly, the mutation of STAT3 response element (ΔSTAT3) abolished
IL-6-induced HAMP promoter activation (Figure 5.5B).
In order to study the involvement of JAK/STAT3 signaling pathway in ceramide-mediated
transcriptional regulation of HAMP expression, we employed STAT3 siRNA and a chemical panJAK kinase inhibitor, JAK inhibitor I (55) (Figure 5.6A and 5.6B). The efficacy of STAT3
siRNA was confirmed by qPCR and western blotting experiments. The level of STAT3 mRNA
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(Figure 5.6A) and protein (Figure 5.6A inset) expression were significantly inhibited by STAT3
siRNA, but not control siRNA, in HepG2 cells. The potency of JAK inhibitor I was also validated
by western blotting. Namely, JAK inhibitor I significantly blocked the ceramide-induced
phosphorylation of STAT3 at residue Tyr 705 (Figure 5.6B). The effect of JAK inhibitor I on the
regulation of HAMP mRNA expression by ceramide was determined by qPCR (Figure 5.7A).
The addition of DMSO, which is the vehicle for JAK inhibitor I, did not affect ceramide-induced
HAMP up-regulation (3.44 ± 0.41 fold). In comparison, ceramide-mediated induction of HAMP
expression was significantly attenuated by JAK inhibitor I (2.28 ± 0.23 fold) (Figure 5.7A). The
inhibition was however incomplete. HepG2 cells were therefore pre-treated with both STAT3
siRNA and JAK inhibitor I. In parallel, control cells were administered control siRNA and
DMSO. Both groups of pre-treated cells were then subjected to either ceramide or DMSO
(control) treatment, and HAMP mRNA expression was determined (Figure 5.7B). Control siRNA
and DMSO pre-treatment did not alter the effect of ceramide on HAMP mRNA expression levels
(3.15 ± 0.05 fold increase) (Figure 5.7B). By contrast, the combined pre-treatment with STAT3
siRNA and JAK inhibitor I decreased the induction of HAMP mRNA expression by ceramide
(1.57 ± 0.09 fold increase) (Figure 5.7B). The effect of JAK inhibitor I and STAT3 siRNA on
ceramide-induced HAMP promoter activation was further examined with luciferase reporter
assays (Figure 5.7C and 5.7D). HepG2 cells, transfected with pGL-3 basic vector harboring 0.6
kbp HAMP promoter, were treated with ceramide or solvent in the presence of either JAK
inhibitor I or DMSO as control. Ceramide treatment induced a 2.16 ± 0.32 fold increase in HAMP
promoter activity, as compared to control cells treated with solvent in the presence of DMSO. In
contrast to DMSO, the addition of JAK inhibitor I significantly diminished ceramide-induced
HAMP promoter activation (1.69 ± 0.21 fold) (Figure 5.7C). The level of inhibition was stronger
with the combined pre-treatment of STAT3 siRNA and JAK inhibitor I (1.39 ± 0.10 fold) (Figure
5.7D). HepG2 cells pre-treated with control siRNA and DMSO displayed 2.22 ± 0.36 fold
increase in HAMP promoter activity following ceramide treatment (Figure 5.7D).
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3.6

The involvement of ER stress in ceramide-induced signaling and HAMP up-regulation.

ER stress has also been reported to induce HAMP transcription (56) and ceramide is a known
inducer of ER stress (57–59). We therefore determined the presence of ER stress in ceramidetreated HepG2 cells by XBP1 assays, as described in the experimental procedures (see Chapter
II). Briefly, ER stress activates the inositol-requiring enzyme 1 (IRE1) which splices X-box
binding protein 1 (XBP1) mRNA (60). Spliced form of XBP1, which was detected, as described
in the experimental procedures, has been employed as ER stress marker. Besides ceramide, cells
were treated with tunicamycin, a well-known experimental ER stress inducer (61), as a positive
control. HepG2 cells treated with ceramide did not exhibit any significant changes in the spliced
and unspliced forms of XBP1, as compared to the solvent-treated control cells (Figure 5.8A). In
contrast, cells treated with tunicamycin exhibited a significant increase in the spliced form, and a
decrease in the unspliced form, of XBP1, which confirmed the validity of our assay (Figure
5.8A). These findings clearly demonstrated that, unlike tunicamycin, ceramide is not capable of
inducing ER stress in HepG2 cells. Accordingly, the treatment of HepG2 cells with a chemical
inhibitor of ER stress, salubrinal (57), did not abolish ceramide-mediated up-regulation of HAMP
expression (Figure 5.8B).

4

DISCUSSION

Iron accumulation accompanies NAFLD pathology and contributes to disease severity (6, 7).
Since hepcidin is the key iron regulatory hormone, a clear understanding of the mechanisms
which regulate its expression in NAFLD is important. This may enable the development of novel
treatment strategies to prevent the harmful effects of iron in NAFLD/NASH progression.
Although we have identified novel molecular mechanisms by which lipids regulate hepcidin
expression at the post-transcriptional level, the role of lipid-mediated inflammatory processes is
still unclear. Of note, hepcidin as an acute phase protein is strongly regulated by inflammation.
Furthermore, excess lipid accumulation in the livers of NAFLD patients elevate the production of
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lipid metabolites, such as ceramide, which take part in inflammatory and insulin signaling
cascades (21, 62, 63). However, the role of these biologically active lipid intermediates either in
NAFLD pathology or in the hepcidin regulation have so far not been addressed.
The studies presented in this chapter have collectively shown that the transcription of human
hepcidin gene, HAMP is significantly activated by ceramide in hepatoma cells. Furthermore, our
findings clearly confirmed the role of ceramide-activated JAK/STAT3 signaling in this process.
Interestingly, we have also established a new and unique function for ceramide (i.e.
sphingolipids), namely the regulation of iron metabolism. This novel role of ceramide was
mediated through a specific region in HAMP promoter, which was 0.6kb proximal to
transcription start site, as confirmed by our reporter assays and mutagenesis studies.
We have further dissected the mechanisms involved in ceramide-mediated activation of STAT3.
Ceramide has previously been shown to activate the tyrosine-phosphorylation of STAT3 in
cultured fibroblast cells (30). However, its effect on JAK/STAT3 signaling in hepatoma cells is
unknown. Under our experimental conditions, ceramide exerted differential effects on STAT3
phosphorylation. Namely, it stimulated the phosphorylation at tyrosine 705, but not serine 727,
residue of STAT3. In contrast, IL-6, a classical activator of JAK/STAT3 pathway (and hepcidin
transcription) (16) induced both serine and tyrosine phosphorylation of STAT3. The published
studies up-to-now have established a prominent role for tyrosine, but not serine, phosphorylation
as the key requirement for activation of STAT3 as a transcription factor (51). We therefore
believe that the induction of tyrosine 705 phosphorylation should be sufficient for STAT3
activation in ceramide-treated hepatoma cells. The precise role of serine 727 phosphorylation is
still unclear (64, 65). It has been predicted to support the trans-activation capability of STAT3, as
a DNA-binding protein (66, 67). Other studies have suggested a role for serine phosphorylation to
limit the duration of tyrosine phosphorylation by recruiting a phosphatase (65). Although we did
not observe strong inhibition of serine 727 phosphorylation, a prominent inhibition of ERK
phosphorylation was detected by ceramide. ERK has been shown to phosphorylate STAT3 on
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serine 727 (51, 67). However, whether ERK inhibition and STAT3 stimulation by ceramide are
connected (and the consequences for HAMP transcription) remains to be investigated in future
studies. The findings of our ChIP assays, which validated ceramide-mediated physical interaction
between STAT3 and the corresponding cis-element in HAMP promoter, are also in agreement
with the tyrosine-phosphorylation status of STAT3. Collectively, our data strongly suggest that
ceramide-mediated binding of STAT3 to HAMP promoter is facilitated by the activation of
STAT3 via tyrosine phosphorylation.
The conclusive evidence for the direct involvement of STAT3 in ceramide-induced HAMP
transcription was provided by the following findings: 1- Mutation of the STAT3 response
element in HAMP promoter significantly blunted ceramide-induced promoter activation. 2Experiments using a commercial siRNA pool for STAT3 and a pan-JAK inhibitor have
demonstrated successful inhibition of STAT3 activation in conjunction with the abrogation of
ceramide-induced HAMP mRNA induction and promoter activation. Taken together, these results
confirmed the dependence of ceramide-induced HAMP transcription on JAK/STAT3 signaling
pathway. The reasons, as to why we could not completely block the effect of ceramide on HAMP
mRNA up-regulation and promoter activation following either siRNA silencing of STAT3 in
combination with JAK inhibition or mutation of STAT3 response element in HAMP promoter, is
unclear. It is however feasible that additional signaling pathways may be involved.
The specificity of JAK/STAT3 signaling was also confirmed by our results with NF-κB and JNK
activation, which are known to be involved in inflammation. Namely, we confirmed the
activation (i.e. phosphorylation) of NF-κB and JNK in ceramide treated HepG2 cells, as has been
previously reported in other cell types (31, 32, 36–38). Despite the activation, NF-κB failed to
physically interact with the putative response element in the HAMP promoter as shown by our
ChIP assays. JNK is involved in activation of c-Jun/AP-1 but ceramide decreased the binding of
c-Jun/AP-1 to HAMP promoter. This might be due to a competition by STAT3 because their
DNA-binding sites are in close proximity on HAMP promoter (see Results section above).
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Furthermore, JNK inhibitor studies also confirmed that JNK activation is not required for HAMP
regulation by ceramide.
Experimental ER stress models indicated a role for it in the activation of hepcidin gene
transcription (56). A direct link between dysregulated lipid metabolism in the liver and ER stress
has been demonstrated in mouse models of obesity (68). Moreover, as shown by in vitro studies
using various cell lines, a role for ceramide in lipid-mediated ER stress has also been suggested
(57, 69, 70). We therefore examined whether ceramide-induced HAMP transcription involved ER
stress. Ceramide did not trigger ER stress in HepG2 cells under experimental conditions.
Furthermore, ER stress inhibition by salubrinal (57, 58) did not abolish the stimulatory effect of
ceramide on hepcidin mRNA expression. Taken together, these results excluded the contribution
of ER stress to the activation of HAMP transcription by ceramide.
In summary, we have demonstrated a novel role for the lipid intermediate, ceramide in the
regulation of HAMP expression. Similarly, our findings also demonstrate a unique regulatory
mechanism for HAMP transcription in liver cells mediated by ceramide. The fact, that ceramide
could directly achieve this through the activation of JAK/STAT3 signaling in hepatoma cells, has
clinical implications. Namely, it suggests that the involvement of other inflammatory cells, such
as Kupffer cells, is not required for this regulation. These findings will therefore help us to
understand the connection between lipid intermediates and inflammatory processes in the
regulation of iron metabolism including its relevance to NAFLD/NASH disease progression.
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Figure 5.1. Ceramide analogs induce HAMP expression at the transcriptional level. (A) HepG2 cells
were treated with 30 μM or 60 μM of C2 or C6 ceramide for 8 hours. cDNA, synthesized from RNA
isolated from these cells, were employed as templates in Taqman qPCR to determine HAMP mRNA
expression, as described in experimental procedures (see Chapter II). HAMP mRNA expression in
ceramide-treated cells was calculated as fold change of that in solvent (solv.)-treated control cells. (B)
HepG2 cells were treated with 60 μM C2 ceramide or solvent (solv.) in the presence of 1µg/ mL
actinomycin D (ACTD) or DMSO, as control. HAMP mRNA expression, determined by qPCR, in
ceramide and/or ACTD-treated cells was calculated as fold change of that in cells treated with solvent and
DMSO. (C) HAMP expression in cells treated with ACTD and ceramide was expressed as fold change of
that in cells treated with ACTD and solvent. (D) HepG2 cells were transfected with pGL-3 basic vector
harboring 0.6kbp HAMP promoter (HAMP-Prom-Luc) or empty pGL-3 basic vector (vector), as described
in the experimental procedures. pRL-SV40 plasmid was co-transfected as reference for transfection
efficiency. The transfected cells were treated with solvent (solv.) or 60 μM C2 ceramide for 8 hours. The
cells were lysed and dual luciferase report assays were performed, as described. Relative luciferase unit
was expressed as fold change of that in the empty vector-transfected and solvent-treated cells.
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Figure 5.2. Ceramide treatment stimulated the binding of STAT3, but not NF-κB subunit p65 or cJun/AP-1, to HAMP promoter. (A) Schematic diagram of 0.6kb HAMP promoter showing recognition
sequence for NF-κB P65 (P65), STAT3, and c-Jun/AP-1 (AP-1). (B) Chromatin, isolated from ceramide
or solvent (solv.)-treated HepG2 cells fixed with 1% formaldehyde, was immunoprecipitated with antiSTAT3, -NF-κB subunit p65 or -c-Jun antibodies or normal IgG , as control, as described in experimental
procedures. Eluted and purified chromatin fractions, and total input chromatin (equal loading controls)
were used as templates in PCR to amplify a 0.6 kbb HAMP promoter region using specific primers. PCR
products were resolved with DNA agarose gel electrophoresis and images captured with Gel Doc XR+
system (Bio-Rad). Representative gel images have been shown. (C) HepG2 cells, treated with
recombinant IL-6 or PBS (control), were employed for ChIP assays using an anti- STAT3 antibody, as
described above. PCR products were visualized with ethidium bromide staining of DNA agarose gels.
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Figure 5.3. The effect of ceramide on STAT3, JNK, NF-κB, and ERK1/2 phosphorylation in HepG2
cells. Whole cell lysates, purified from HepG2 cells treated with solvent (solv.), 60 μM C2 ceramide, 40
ng/mL recombinant IL-6 or PBS for 8 hours, were employed for western blotting. PVDF membranes
were incubated with anti-phospho-STAT3 (P-STAT3 Tyr 705), anti-phospho-STAT3 (P-STAT3 Ser 727),
anti-phospho-ERK1/2 (P-ERK1/2) (A), anti-phospho-P65 (P-P65), -total NF-κB P65 (P-65), and antiphospho-JNK (P-JNK) antibodies (B). Immune reactive bands were detected by chemiluminescence, as
described in experimental procedures. An anti- gapdh antibody was employed as a control for equal
protein loading.
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Figure 5.4. Ceramide-induced HAMP mRNA expression is not dependent on JNK activation.
HepG2 cells were treated with ceramide or solvent (solv.) in the presence of 50 μM SP600125 inhibitor or
DMSO, as control. (A) Whole cell lysates isolated from these cells were used for western blots performed
with an anti-phospho-JNK (P-JNK) antibody, as described in experimental procedures. (B) cDNA,
synthesized from RNA isolated from these cells, were used as templates for Taqman qPCR assays to
determine HAMP mRNA expression. Gene expression in treated cells were expressed as fold change of
that in control cells treated with solvent and DMSO.
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Figure 5.5. The effect of STAT3 response element mutation on HAMP promoter activation by
ceramide. The single STAT3 response element within 0.6kbp HAMP promoter region cloned in pGL3
basic vector was mutated, as described in the experimental procedures. HepG2 cells, transfected with
pGL3-basic vector harboring wild-type (WT) or mutated (ΔSTAT3) 0.6 kb HAMP promoter, or empty
vector (vector) as negative control, and pRL-SV40 plasmid, as control for transfection efficiency, were
treated with (A) 60 μM C2 ceramide (C2) and solvent control (solv.) or (B) 40 ng/mL IL-6 and PBS
control for 8 hours. Dual luciferase reporter assays were performed, as described in the experimental
procedures. HAMP promoter activity, expressed in relative luciferase units, in treated cells was calculated
as fold change of that in control cells transfected with empty vector-and treated with solvent. Asterisks
indicate statistical significance (P<0.05).
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Figure 5.6 STAT3 expression and ceramide-induced activation of STAT3 were inhibited by STAT3
siRNA and JAK inhibitor I, respectively. (A) STAT3 mRNA and protein (inset) levels in HepG2 cells
transfected with STAT3 siRNA or control siRNA were determined by qPCR or western blotting,
respectively. Asterisks indicate statistical significance (P<0.05). (B) Cell lysates prepared from HepG2
cells, treated with 60 μM C2 ceramide or solvent (solv.) in the presence of 5 μM JAK inhibitor I or
DMSO as control, were used for western blotting to detect total or tyrosine-phosphorylated (P-STAT3)
STAT3 protein levels using specific antibodies. An antibody for gapdh was used as control for protein
loading.
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Figure 5.7 Activation of STAT3 signaling was required for the induction of HAMP transcription by
ceramide. (A) HAMP mRNA expression in HepG2 cells, treated with solvent (solv.) or C2 ceramide for
8 hours in the presence of either 5 μM JAK inhibitor I or DMSO (control), was determined by Taqman
qPCR. HAMP expression in treated cells was calculated as fold change of that in respective control cells
treated with solvent. (B) HepG2 cells, pre-transfected with STAT3 or control siRNA, were treated with
C2 ceramide or solvent (solv.) in the presence of 5 μM JAK inhibitor I or DMSO. HAMP mRNA levels,
determined by qPCR, were expressed as fold expression of that in respective controls treated with solvent.
(C) HepG2 cells, transfected with pGL3-basic vector harboring 0.6 kb HAMP promoter, were treated with
C2 ceramide or solvent (solv.) for 8 hours in the presence or absence of 5 μM JAK inhibitor I. Dual
luciferase assays were performed and HAMP promoter activity, calculated as fold change of that in
corresponding control cells treated with solvent, was expressed in relative luciferase units. (D) HepG2
cells, pre-transfected with STAT3 or control siRNA, were subsequently transfected with pGL3-basic
vector harboring 0.6 kb wild-type HAMP promoter. After treatment with solvent (solv.) and C2 ceramide
in the presence of either JAK inhibitor I or DMSO, dual luciferase reporter assays were performed.
HAMP promoter activity, expressed as relative luciferase units, was expressed as fold change of that in
respective control cells treated with solvent. Asterisks indicate statistical significance (P<0.05).
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Figure 5.8. ER stress is not involved in ceramide-induced HAMP expression. (A) HepG2 cells treated
with solvent (solv.), 60 μM C2 ceramide or 10 μg/mL tunicamycin (TUNI) for 8 hours were employed for
XBP-1 splicing assays, as described in experimental procedures. (B) HepG2 cells treated with solvent
(solv.), 60 μM C2 ceramide in the presence of 20 μM salubrinal inhibitor or DMSO (control) were used to
determine HAMP mRNA expression by qPCR, as described in experimental procedures. Gene expression
in treated cells was expressed as fold change of that in cells treated with DMSO and solvent.
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Chapter VI
Molecular Analysis of the Livers from hepcidin Knockout Mice with High-Fat and
High-Sucrose Intake in Relationship to Nonalcoholic Steatohepatitis Pathology
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1

ABSTRACT

The pathogenesis of nonalcoholic fatty liver disease (NAFLD) remains under ongoing investigation.
Although current theories consider simple steatosis as benign, it can progress to nonalcoholic
steatohepatitis (NASH). NASH is an advanced stage of disease characterized by inflammation
(steatohepatitis), hepatocyte ballooning, fibrosis, which can ultimately lead to cirrhosis,
hepatocellular carcinoma and mortality. The mechanisms of NAFLD/NASH progression are
unclear but iron is considered as a risk factor for fibrosis development. The current chapter presents
investigations on the potential role of iron in NASH pathology using hepcidin (Hamp) knockout
(KO) mice with high-fat and high-sucrose (HFS) intake, as an experimental model. Hamp KO mice
displaying primary iron overload were administered a high-fat high-sucrose (HFS) diet for different
time periods (3 and 7 months) to mimic different stages of NAFLD/NASH pathology. Although
HFS feeding induced similar increases in body weight in KO and control (Floxed) mice, the liver
weights were significantly different. HFS intake resulted in pronounced hepatomegaly in control,
but not in KO, mice. This was also confirmed with histological and biochemical analysis. Namely,
control, but not KO, mice livers displayed pronounced steatosis and hepatic triglyceride content.
Furthermore, the activation (i.e phosphorylation) of c-Jun N-terminal Kinase (JNK), which plays a
role in steatosis, was higher in the livers of control than KO mice. In contrast, the livers from KO,
but not control, mice exhibited significant level of fibrosis. As shown by Sirius Red staining, liver
fibrosis in KO mice was detected at 3 months of HFS intake, which exacerbated over time, as
observed with NASH patients. In agreement, the expression of α-smooth muscle actin protein, a
marker for fibrogenesis, was more prominent in HFS-fed KO mice compared to controls. To
understand the reasons behind blunted fat accumulation in the livers of KO mice with HFS intake,
the expression of genes involved in lipid metabolism were examined by qPCR. Our results strongly
suggested that lipogenesis and lipid storage capacity of the liver was diminished in Hamp KO mice
with HFS intake. Namely, the expression levels of sterol regulatory element-binding protein 1c
(SREBP-1c), a transcription factor controlling de novo lipogenesis, and fat-specific protein 27
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(FSP27), which facilitates the development of lipid droplets, were significantly attenuated in KO
mice livers. Furthermore, iron overload per se in Hamp KO mice affected hepatic expression of
genes related to mitochondrial energy metabolism. In summary, Hamp KO mice with HFS intake
exhibit a liver pathology similar to NASH and can therefore serve as a novel experimental model
to study NASH development. Furthermore, our findings highlight a role for hepcidin and iron in
the regulation of hepatic lipid metabolism, which has implications for NAFLD/NASH pathogenesis.

2

INTRODUCTION

NAFLD is a wide spectrum of disease, which ranges from simple steatosis to steatohepatitis and
fibrosis. Although the large majority of NAFLD patients display simple steatosis, which in itself is
benign, a small portion of patients present with aggressive nonalcoholic steatohepatitis (NASH).
NASH pathology is characterized by the presence of lobular inflammation, fibrosis, hepatocellular
ballooning and Mallory-Denk bodies (1, 2). The frequency of NASH with progressive fibrosis (i.e.
stage 2 and higher based on Brunt criteria) is low among NAFLD patients but it is strongly
associated with liver-related morbidity. Advanced fibrosis in NASH patients progresses to cirrhosis
with severe clinical conditions, such as ascites, portal hypertension and hepatic encephalopathy
ultimately causing hepatocellular carcinoma and liver failure (1, 3, 4).
Fibrosis, as observed in the livers of NASH patients, is the excessive accumulation of extracellular
matrix (ECM) proteins in response to chronic liver injury (5, 6). Activated hepatic stellate cells,
portal fibroblasts, and myofibroblasts of bone marrow origin play key roles in hepatic fibrosis (6).
Upon activation by inflammatory cytokines and mitogens, these fibrogenic cells produce ECM
proteins. The accumulation of ECM proteins changes the structure of hepatic parenchyma by
forming fibrous scars, which ultimately lead to cirrhosis and end-stage liver disease (Figure 6.1).
Histological examination and specific staining of ECM proteins are useful tools to determine the
degree of fibrosis in the liver. Collagen (I, III, IV), fibronectin, elastin, laminin and proteoglycans
are among the prominent ECM proteins produced by fibrogenic cells (7). In the injured liver,
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activated hepatic stellate cells (HSC) secrete the major amount of ECM and stimulate ECM
degradation. Following activation, HSC trans-differentiate into myofibroblast-like cells and
migrate from the space of Disse into sites of tissue injury and repair (4, 6). Quiescent and activated
HSC express different sets of cell surface markers. Alpha smooth muscle action (αSMA) is a
myogenic marker expressed by activated stellate cells. The increased expression of αSMA is
frequently selected as a marker for liver fibrosis (8, 9).
The precise mechanisms of NASH development are not well understood. Oxidative stress,
inflammation and changes in mitochondrial function has been proposed as risk factors (10–13). Of
note, due to the elevated triglyceride content, the hepatic β-oxidation capacity is challenged in
NAFLD patients, and they display structural and functional abnormalities in liver mitochondria
(14).
Recently, a role for iron has been proposed in NASH pathogenesis (15). Patients with
NAFLD/NASH frequently display elevated serum iron indices and hepatic iron content (16, 17).
Most importantly these studies have shown a strong correlation between hepatic iron content and
the level of liver fibrosis, which determines disease severity in NAFLD/NASH patients (18–20).
Interestingly, these studies have also suggested that the location of iron deposition in the liver is
also a strong prognostic factor for disease severity in NASH patients. Independent studies have also
shown that phlebotomy (iron letting) alleviates insulin resistance in NAFLD patients, which further
support a role for iron in NAFLD pathogenesis (21).
The mechanisms by which iron contributes to NAFLD/NASH pathogenesis have mainly been
attributed to the redox potential of iron, as a transition metal. Iron takes part in Fenton reaction
promoting the production of highly toxic hydroxyl radicals (see Chapter I for overview) (22).
Reactive oxygen species and oxidative stress are the most intensely studied secondary risk factors
in NAFLD/NASH (23). The redox imbalance subsequently induces the peroxidation of intracellular
lipids and the accumulation of toxic lipid radicals (23). All these changes ultimately cause the
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activation of stellate cells and fibrotic signaling (24). Accordingly, the level of αSMA expression
has been shown to be elevated in the livers of patients with genetic haemochromatosis (GH), a
hereditary iron overload disorder. Following phlebotomy, the livers of GH patients displayed
significantly decreased levels of αSMA expression further indicating the connection of iron with
fibrosis (25). Other studies, using dietary experimental models, have suggested that iron modulates
lipid metabolism. In rats, diet-induced iron overload correlated with a decrease in the level of
hepatic triacylglycerols (26). In another study where hepatic triglyceride accumulation was induced
by methionine-choline-deficient (MCD) diet intake, addition of iron into the diet significantly
inhibited the MCD-induced triglyceride accumulation in rat livers (27). In contrast, a study using a
mouse dietary model of iron and HFS failed to show any effect of iron on hepatic steatosis (28).
Furthermore, it should also be noted, that in the MCD diet study where iron ameliorated steatosis,
it also triggered necroinflammation and fibrosis (27). Taken together, these studies suggest a
reverse connection between iron and steatosis but the consequences of these changes in liver lipid
metabolism are unclear. This chapter uses mouse hepcidin-1 gene (Hamp) knockout mice, with
documented iron overload phenotype, as an animal model to address some of these questions. In
parallel, these studies will also establish whether Hamp knockout mice may serve as experimental
NAFLD/NASH models.
Hepcidin is the central regulator of iron homeostasis. It is primarily synthesized by the hepatocytes
in the liver and secreted into the circulation. Hepcidin controls iron homeostasis by decreasing iron
absorption from the absorptive enterocytes in the duodenum and the release of iron from
macrophages (see Chapter I for overview). The lack of hepcidin expression in hepcidin knockout
mice, and in human iron disorders, will therefore result in iron accumulation both in the liver and
other organs (29–31). Unlike humans, which express only one hepcidin gene, HAMP, mice express
two hepcidin genes, Hamp and Hamp2, which arose from gene duplication (32). Overexpression
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and structure analysis studies strongly suggested that Hamp is the mouse equivalent of HAMP,
which by itself is sufficient to regulate iron metabolism (33).
NAFLD patients have been reported to show changes in hepcidin levels both in the serum and the
liver. However, these studies are inconclusive and whether hepcidin and hepcidin-mediated
changes in iron metabolism contribute to the disease progression in NAFLD is unclear.
As stated above, we used hepcidin knockout mice to further understand the role of hepcidin in
NAFLD/NASH. For these studies, we administered a custom-made high-fat high-sucrose (HFS) to
ubiquitous Hamp knockout mice with global hepcidin deficiency, which were created in our
laboratory. Since severe forms of NAFLD develop over a long period of time in patients, mice were
administered these diets for different time points (3 or 7 months). There are a number of animal
models for NAFLD but the histological changes such as fibrosis, as observed in NASH patients,
are not reproduced in many of these models. Methionine-choline-deficient diet-fed mice develop
fibrosis but not the metabolic changes that lead to NAFLD (34). Recently prolonged exposure of
mice to a western diet has been shown to induce fibrosis (35). Besides investigating the role of iron
as a secondary risk factor, Hamp knockout mice might also serve as a novel animal model for
NASH.

3
3.1

RESULTS
Generation and characterization of Hamp knockout (KO) mice

Hamp Floxed (Flx) mice were generated, as published previously (36). The generation of transgenic
constructs are illustrated in Figure 6.2A. The targeting vector was designed by flanking exons 2
and exon 3 of Hamp gene with standard loxP sites, and by inserting a neomycin selection cassette
(PGK-neo), flanked by FRT recognition sequences, downstream of exon 3. The 5’ and 3’ homology
and loxP arms were generated by PCR from C57BL/6 genomic DNA. The Hamp targeting
construct was electroporated into a C57BL/6 embryonic stem (ES) cell line, and ES cells with
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positive homologous recombination were screened by Southern hybridization to be injected into
Balb/CJ blastocysts. Male chimeric mice were obtained and crossed to C57BL/6J females to
establish heterozygous germline offspring on C57BL/6 background. The germline mice were
crossed to a FLP mouse line to remove the FRT-flanked selectable marker cassette. Heterozygous
targeted mice were bred to generate homozygous Hamp Flx mice. These mice were further crossed
with PGK-Cre transgenic mice, which ubiquitously express Cre recombinase protein (37), to excise
the Flox genes. (Figure 6.2A). The F1 heterozygous pups generated from this breeding were
backcrossed to generate homozygous ubiquitous knockout mice lacking Hamp expression in all the
organs. The genotyping of these mice was performed by PCR (Figure 6.2B), as described in
experimental procedures (see Chapter II). For PCR reactions, specific primers recognizing either
the wild-type (WT) or knockout (KO) Hamp alleles (see Chapter II section 15) were used to
identify homozygous ubiquitous knockout offspring (Figure 6.2B). Mice harboring both WT and
KO alleles, or only KO allele were identified as heterozygous or homozygous knockout (KO) mice,
respectively. The homozygous Hamp knockout mice were used for inbreeding to maintain the strain
for the studies presented in this Chapter.
To further validate our experimental model and to confirm the effect of Hamp deletion on iron
content in the liver, we performed inductively coupled mass spectrometry (ICP-MS) with stable
56Fe and 57Fe isotopes (Figure 6.3A and 6.3B). Our studies clearly indicated significant level of
iron accumulation in the livers of Hamp KO, but not Hamp Flx control, mice (Figure 6.3A and
6.3B), and validated the iron overload phenotype of our Hamp KO mice. Furthermore, Magnetic
Resonance Imaging (MRI) analysis also confirmed the accumulation of iron in the livers of Hamp
KO mice (Figures 6.3C and 6.3D). Namely, a characteristic T2* signal loss was observed in KO
mice livers compared to Flx controls (Figures 6.3C and 6.3D).
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3.2

Analysis of body and liver weights in Hamp KO and Floxed (Flx) control mice fed with
high-fat high-sucrose (HFS) or regular diets

To study the interaction of hepcidin-mediated iron overload and lipid metabolism, 4-6 weeks old
homozygous Hamp Flx (control) and KO mice were administered custom-made pelleted regular
(control) diet (17.2% kcal. from fat, 100 g/ kg sucrose) or high-fat and high-sucrose (HFS) diet [42%
kcal. from fat (54% saturated, 9.7% trans-fat), 0.4% cholesterol, 340 g/kg sucrose]. Similar rodent
diets, which resemble human fast food, have been shown to induce liver pathology similar to NASH
after extended periods of administration (35). To differentiate between the short and long-term
effects of iron and/or HFS intake, mice were fed for 3 or 7 months. Water was given ad libitum,
and contained sucrose (40 g/L) in HFS-fed groups to imitate the western diet with high-fat and soda
consumption. The body weights of mice, which were monitored prior to the start of the diet and
weekly throughout the feeding period, are shown in Figure 6.4A and 6.4B. The increase in body
weights induced by HFS diet intake were similar in Flx (Figure 6.4A) and KO (Figure 6.4B) mice
after either 3 or 7 months periods, as compared to respective controls, which were fed with the
regular control diet. Interestingly, the liver weights of Hamp KO mice fed with regular diet was
slightly but significantly higher than those of Flx mice at 3, but not 7, months (Figure 6.4C and
6.4D). This may suggest an initial effect of Hamp deletion (i.e. iron deposition) on basal metabolic
activity, which is later compensated by the liver. 3 month-long HFS intake resulted in slightly lower
liver weight increase in KO mice as compared to Flx mice but the difference was not statistically
significant (Figure 6.4D). However, at 7 months, the liver weight of Flx mice were significantly
higher (i.e. 3.5 ± 0.46 g) than those of KO mice (i.e. 2.42 ± 0.54 g) (Figure 6.4D). This discrepancy
suggests that the gradual increase in iron deposition in Hamp KO mice may interfere with steatotic
processes in the liver.
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3.3

HFS diet-induced steatosis in Hamp KO and Flx mice.

To understand the reasons behind the differences observed regarding the body and liver weights of
HFS-fed Hamp Flx and KO mice, further macroscopic and microscopic analysis of livers from
mice fed for 3 months (Figure 6.5) and 7 months (Figure 6.6) were performed. The absence of
Hamp gene altered the appearance of the liver in both mice fed on regular diet for 3 and 7 months.
Namely, KO mice livers appeared bigger in size and exhibited a darker color compared to Flx mice
(Figure 6.5A and 6.6A), which is probably mediated by iron deposition in the liver. HFS intake
resulted in enlarged livers with lighter color, which indicates steatosis, and visceral fat depots in
both Flx and KO mice, compared to control counterparts fed with regular diet (Figure 6.5A and
6.6A). However, 3 or 7 month-long HFS-induced hepatomegaly was more pronounced in the livers
of Flx mice compared to KO mice (Figure 6.5A and 6.6A). This discrepancy was also confirmed
with hematoxylin and eosin (H&E)-staining of liver sections (Figure 6.5B and 6.6B). Namely,
both short and long-term HFS intake caused significantly higher levels of steatosis in the livers of
Flx mice than in those of KO mice.
In addition to H&E staining, hepatic triglycerides were also quantified by a biochemical assay, as
described (see experimental procedures in Chapter II). For these studies, lipids were extracted from
the livers of mice fed with HFS or regular diets for 3 months (Figure 6.7A) or 7 months (Figure
6.7B). The quantification of liver triglycerides confirmed our histological analysis that HFS intake
significantly increases hepatic triglyceride content but to different extents in Hamp Flx and KO
mice (Figures 6.7Aand 6.7B). At the end of 3 month-long HFS intake, the level of hepatic
triglyceride accumulation (expressed as μmol/L/100 gram b.w.) was 1876.64 ± 370.84 in Flx and
657.98 ± 186.89 in KO mice (Figures 6.7A). Similar measurements at the end of 7 month-long
feeding period yielded 1837.71 ± 118.12 in Flx and 886.91 ± 89.51 in KO mice livers. (Figure
6.7B). The inhibition of HFS-induced lipid accumulation in KO mice livers was higher at 3 months
than at 7 months (Figures 6.7 A and 6.7B). In summary, the findings of our biochemical analysis
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are in alignment with microscopic and macroscopic observations, as presented above. Taken
together, these findings strongly indicated that the absence of hepcidin expression interferes with
and suppresses liver triglyceride accumulation in response to HFS exposure.
3.4

HFS diet-induced fibrosis in Hamp KO and Flx Mice

Advanced stages of NAFLD pathology involve fibrosis. Animal experiments with MCD-diet
administration and DGAT2 deletion (38, 39) have suggested a link between the inhibition of hepatic
fat accumulation and fibrosis. Based on our observations of attenuated steatosis in Hamp KO mice
(see Figures 6.3-6.6), we examined the presence of fibrosis. The liver sections from Hamp Flx and
knockout mice fed with HFS or regular diets for 3 (Figure 6.8A) and 7 (Figure 6.9A) months were
stained with Sirius Red, as described in experimental procedures (see Chapter II). This staining
technique detects the accumulation of ECM protein, collagen in the liver, as an indication for
fibrogenesis. The level of fibrosis was also quantified by using ImageJ analysis, as described in
experimental procedures (see Chapter II) (Figures 6.8B and 6.9B).
Sirius Red-stained livers from Hamp Flx mice fed with HFS or regular diets for 3 months did not
display any significant changes (Figures 6.8). After 7 months of HFS intake, Flx mice livers
exhibited increased levels of basal fibrosis (Figures 6.9). In contrast to Flx mice, Hamp KO mice
exhibited significant levels of fibrosis both after 3 and 7 month-long HFS intake (Figures 6.8 and
6.9). However, the highest level of fibrosis was observed in the livers of Hamp KO mice with 7
months of HFS exposure (Figures 6.9). Although to a lesser extent, elevated level of basal fibrosis
activity was also observed in Hamp KO mice fed with the regular control diet for 3 and 7 months
(Figures 6.8 and 6.9). In summary, the quantification of our Sirius Red staining indicated that HFS
feeding of Hamp KO mice for 3 months is sufficient to initiate fibrogenesis in the liver, which is
exacerbated at 7 months. Interestingly, elevated hepatic iron content in the livers of Hamp knockout
mice per se can induce fibrotic reactions. Taken together, our findings indicate that the synergistic
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action of iron overload, originating from the absence Hamp gene expression, and HFS intake results
in fibrosis, which gradually increases in severity.
3.5

JNK activation and αSMA expression in Hamp KO and Flx mice fed with HFS diet.

The presence of liver fibrosis was further confirmed by examining the expression levels of α smooth
muscle actin (αSMA), a marker for hepatic stellate cell activation, by western blotting (Figure
6.10A and 6.10B). The livers of Hamp Flx mice fed with HFS diet for 3 months did not display
any significant changes in αSMA expression compared to controls fed with regular diet. In contrast,
Hamp KO mice displayed a significant increase in liver αSMA protein expression following 3
months HFS feeding. Furthermore, the basal αSMA expression level was also elevated Hamp KO
mice compared Hamp Flx mice. With 7 month-long HFS intake, the levels of liver αSMA
expression was elevated in both Hamp Flx and KO mice (Figure 6.10A and 6.10B).
c-Jun N-terminal kinase (JNK) signaling pathway has been reported to mediate steatosis in mice
fed with MCD diets (40). JNK is activated by phosphorylation on serine residues (41). The
expression levels of phosphorylated JNK (P-JNK) protein in the livers of Hamp mice were
therefore determined by western blotting using specific anti-phospho JNK antibodies, as described
in the experimental section (see Chapter II) (Figure 6.10C and 6.10D). The livers of Hamp Flx
mice fed with HFS diet for 3 months displayed an increase in the level of P-JNK protein compared
to controls fed with regular diet. In contrast, the livers of Hamp KO mice fed under similar
conditions did not display any significant changes in JNK phosphorylation (Figure 6.10C and
6.10D). Namely, the level of P-JNK expression was similar in HFS or control diet-fed Hamp KO
mice. It should however be noted, that after 7 months, the effect of HFS feeding on JNK activation
was not as prominent as 3 months in Flx mice (Figure 6.10C and 6.10D). Compared to 3 months
feeding, 7 months of HFS diet feeding slightly elevated P-JNK level in Hamp KO mice (Figure
6.10C and 6.10D). This suggests the involvement of JNK in the initial stages of the processes that
underlie the attenuation of steatosis connected to Hamp deletion.
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3.6

Expression of metabolic genes in HFS or regular diet-administered Hamp KO and Flx
mice.

To further investigate the underlying mechanisms of attenuated fat accumulation in the livers of
Hamp KO mice with HFS intake, mRNA expression levels of genes, which are known to be
involved in lipid metabolism, were examined by real-time PCR (see Chapter I for detailed review
of these genes). The results of these studies are presented below (Figures 6.11 and 6.12)
The transcription factor, sterol regulatory element-binding protein 1c (SREBP-1c) is well known
for its role in mediating the stimulatory effect of insulin on genes connected to de novo lipogenesis
pathway. The expression of SREBP-1c itself is also regulated at the transcriptional level (42, 43).
The liver mRNA expression of SREBP-1c was significantly up-regulated in Hamp Flx mice with
3 month-long HFS intake compared to mice fed on control diet (Figure 6.11A). The deletion of
Hamp alleles did not alter basal hepatic SREBP-1c expression (Figure 6.11A). Although to a
significantly lesser extent than in Flx mice, 3 month-long HFS exposure also elevated liver SREBP1c expression in Hamp KO mice compared KO controls (Figure 6.11A). Upon longer (i.e. 7 months)
HFS exposure, the induction of liver SREBP-1c expression was attenuated but still significant in
Flx mice (Figure 6.11B). In contrast, KO mice did not display any significant increase in SREBP1c expression when fed with HFS diet compared to regular diet-fed controls (Figure 6.11B). Taken
together, these findings with short and long-term HFS exposure suggested that diet-mediated
changes in liver SREBP-1c expression are significantly attenuated in Hamp KO mice, which
becomes more prominent with longer HFS exposure.
Fat-specific protein 27 (FSP27) plays an important role in lipid droplet formation (44). Similar to
SREBP-1c, mRNA expression of FSP27 was significantly up-regulated in Hamp Flx mice exposed
to HFS for 3 months compared to Flx mice fed with the regular diet (Figure 6.11C). In contrast to
Flx mice, HFS-fed Hamp KO mice displayed a blunted increase in hepatic FSP27 mRNA
expression (Figure 6.11C). The increase observed in liver FSP27 mRNA expression levels in
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Hamp Flx mice was not significantly different between 3 and 7 month-long HFS intake. In contrast,
HFS-induced FSP27 up-regulation is blunted in Hamp KO mice after 7 months of feeding as
compared to that in Flx mice (Figure 6.11D). Similar to SREBP1-c data, the absence of Hamp in
KO mice inhibited the induction of FSP27 in the liver.
Microsomal triglyceride transfer protein (MTP) is responsible for the production and secretion of
VLDL particles (45). The liver mRNA expression level of MTP was not significantly altered in
Hamp Flx and KO mice fed on regular or HFS diets for 3months (Figure 6.11E). The deletion of
Hamp gene did not also affect the basal liver expression level of MTP gene (Figure 6.11F).
Following 7 month-long HFS exposure, liver MTP expression was significantly suppressed in both
Hamp Flx and KO mice to the same extent, as compared to Flx controls fed with the regular diet
(Figure 6.11F).
Peroxisome Proliferator-Activated Receptor α (PPARα) activates the transcription of genes
involved in fatty acid β-oxidation regulation (46). After 3 month-long HFS exposure, liver PPARα
mRNA expression levels were stimulated in both Hamp Flx and KO mice compared to Flx controls
fed with a regular diet (Figure 6.12A). In contrast, long term HFS exposure significantly inhibited
PPARα mRNA expression in both Hamp Flx and KO mice compared to corresponding Flx controls
(Figure 6.12B).
Carnitine palmitoyltransferase 1 (CPT1) is the rate-limiting enzyme in mitochondrial β-oxidation
pathway (47). The expression of CPT1 did not significantly change in the livers of either Hamp Flx
or KO mice after 3 months of HFS intake (Figure 6.12C). Interestingly, the livers of Hamp KO
mice fed on the regular diet for 7 months expressed higher CPT1 levels compared to Flx mice fed
under similar conditions (Figure 6.12D). On the other hand, 7 month-long HFS exposure
significantly suppressed CPT1 expression in KO mice. This decrease was more prominent in Hamp
KO mice considering the fact that CPT1 basal expression levels were elevated in KO mice (Figure
6.12D).

189
Phosphoenolpyruvate carboxykinase 1 (PCK1) and glucose-6-phosphatase (G6PC) both play an
important role in the regulation of gluconeogenesis. The livers of Hamp Flx and KO mice with
short or long-term HFS exposure displayed a significant inhibition of PCK1 and G6PC mRNA
expression (Figure 6.12E-H). These findings suggest that HFS feeding exerts a consistent
inhibitory of effect on gluconeogenesis in the liver under our experimental conditions. However,
the basal mRNA expression levels of PCK1 and G6PC were different in the livers of Hamp KO
and Flx mice (Figure 6.12E-H). Namely, KO mice expressed higher PCK1 and lower G6PC
expression.

4

DISCUSSION

Liver, as an endocrine organ, plays an important role in both lipid and carbohydrate metabolism.
By synthesizing hepcidin and serving as a major depot for excess iron, liver is also a key organ for
iron metabolism. It is therefore important to understand the interaction of these pathways in the
liver. NAFLD/NASH patients have been reported to frequently display changes in serum iron
parameters and elevated hepatic iron content. The deposition of iron in the liver correlates with
disease severity in NAFLD/NASH patients (17). The mechanisms by which excess iron contribute
to NAFLD/NASH pathogenesis is unclear. Independent human and animal model studies have
identified iron as an important risk factor for fibrogenesis in the liver (25, 48). A role for iron in
lipid metabolism has also been suggested but the findings in published studies are inconclusive
(26–28), where some reported stimulatory (28) but others indicated inhibitory (26, 27) effects of
iron in this process. Although hepcidin is the key regulator of iron metabolism, the role of hepcidin
in NAFLD/NASH pathogenesis has not been investigated in detail. We therefore examined the
effect of hepcidin (i.e. iron homeostasis) on fatty liver disease by feeding hepcidin (Hamp)
knockout (KO) mice with HFS diets. Hamp KO mice, generated in our laboratory, displayed
significant iron accumulation in the liver, as shown by our MRI an ICP-MS analysis. Short and
long-term exposure of Hamp KO and Flx controls to HFS diets led to differential changes in the
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liver, both at macroscopic and microscopic levels, which is similar to the wide spectrum of
NAFLD/NASH pathology observed in human patients (2).
The blunted effect of HFS in stimulating liver weight increase in KO mice compared to Flx mice
indicated the presence of metabolic variations mediated by the absence of Hamp expression. This
prompted us to conduct further histological and biochemical analysis of livers. Collectively, the
findings of these studies strongly suggested, that hepatic iron deposition in KO mice, might exert
an inhibitory effect on liver lipid accumulation. This is in agreement with previous studies showing
a negative effect of iron on lipid metabolism (25, 26). Interestingly, the apparent amelioration of
steatosis in Hamp KO mice exacerbated liver pathology. This was based on our observations that
Hamp KO mice, compared to control counterparts, displayed an earlier and more pronounced
development of fibrosis in the liver. Histological identification of fibrosis was also confirmed by
western blotting showing elevated expression of αSMA protein as an indication of hepatic stellate
cell activation. Our findings are consistent with previous studies using methionine-cholinedeficient diet (MCD)-induced hepatic steatosis as an experimental model (27, 38). It has been
reported that dietary iron supplementation is associated with decreased hepatic steatosis but
increased necroinflammation and fibrosis (27). However, as stated above (see Introduction),
although MCD diet model induces steatohepatitis, it fails to reproduce the metabolic changes
observed in NAFLD patients, such as peripheral insulin resistance, obesity and dyslipidemia (49,
50). In fact MCD-diet induces weight loss and not weight gain (41). High-fat-diet experimental
models are therefore advantageous because they present pathophysiology that is more
representative of what is observed in NAFLD/NASH patients (50, 51). Furthermore, the dietary
supplementation of iron as an experimental model has the disadvantage of creating secondary
effects by indirectly altering hepcidin synthesis in the liver. It is well-recognized that iron is a potent
stimulator of hepcidin transcription through the activation of bone morphogenic (BMP) and SMAD
signaling pathway (52–54). Elevated hepcidin will then inhibit the expression of iron exporter,

191
ferroportin and thereby block iron release from macrophages (see Chapter I for detailed review). It
is therefore feasible that experimental model of dietary iron overload will cause iron deposition in
Kupffer cells and thereby exert an effect on liver inflammation. Accordingly, the study using rats
administered an iron-rich diet reported significant iron accumulation in Kupffer cells (27). We
therefore used a genetic model of iron overload caused by the deletion of key iron-regulatory gene,
Hamp for the following reasons: 1: Hamp deletion is the direct cause of iron accumulation. 2:
Artifacts associated with iron signaling (BMP/SMAD) and Kupffer cell iron deposition will be
avoided due to the lack of hepcidin expression. Furthermore, the prevalence of HFE mutations,
which are responsible for genetic hemochromatosis and inhibition of hepcidin expression, is high
in some NAFLD/NASH patients (55). Accordingly this group of patients display lower levels of
hepcidin, which is associated with increased disease severity (20). We therefore believe that our
Hamp KO mouse model recapitulates the conditions observed in NAFLD patients with HFE
mutations (i.e. inhibition of hepcidin expression) and serves as a good experimental model to study
iron as a secondary risk factor in NAFLD/NASH pathogenesis.
The lipid accumulation in NAFLD (i.e. simple steatosis) is considered to be a benign condition.
Studies with animal models of NAFLD have shown that inhibition of triglyceride production
alleviates steatosis but exacerbates fibrogenesis and liver injury (38). The synthesis of triglycerides
in the liver therefore serves the purpose of protecting the liver from potential lipotoxicity induced
by the accumulation of free fatty acids. This has also been confirmed by in vitro studies (56). It is
therefore possible that the decreased level of steatosis contributes to fibrosis in our HFS-fed Hamp
KO mice. Nevertheless, the synergistic role of hepatic iron in this process cannot be excluded.
Future studies, which involve feeding Hamp KO mice with HFS diets containing iron chelators,
should address these questions directly.
To further understand the mechanisms leading to attenuated hepatic lipid accumulation in Hamp
KO mice, we investigated JNK activation. In studies using JNK knockout mice fed with MCD or
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high-fat diets, the deletion of JNK1, but not JNK2, has been shown to reverse hepatic steatosis (57,
58). JNK is well-known to be activated following phosphorylation on serine residues (41). Our
western blotting studies examining the phosphorylation status of JNK indicated highest JNK
activation in the livers of HFS-fed Hamp Flx mice, which also exhibited high levels of steatosis. In
contrast, the livers of Hamp KO mice with alleviated steatosis did not display any significant JNK
phosphorylation (i.e. activation). Interestingly, these findings were only observed with mice with
short-term (3 months), but not long-term (7 months), HFS intake. Taken together, these findings
are consistent with a potential role for JNK in inhibition on steatosis observed in Hamp KO mice
livers with iron overload. This effect however is an early phenomenon because it was not observed
in later stages of HFS feeding where more injury was developed. Accordingly, the deletion of JNK
has been shown to reverse steatosis, but not fibrogenesis, in NASH animal models (57, 58). The
direct effect of JNK and its regulation by hepcidin and iron need to be validated in future studies.
Lipid and carbohydrate metabolism in the liver is mediated by an intricate web of genes (see
Chapter I for detailed review). The expression levels of most of these metabolic genes are regulated
at the mRNA level. We therefore determined liver mRNA expression of important candidate genes
in HFS-fed Hamp knockout mice. The analysis of genes involved in lipid metabolism (e.g. SREBP1c) indicated that iron blunts the induction of genes involved in HFS intake-induced de novo
lipogenesis in the liver. Furthermore, the expression of FSP27, the gene responsible for lipid droplet
formation and lipid storage, was less responsive to HFS diet administration in livers with elevated
hepatic iron content. These findings clearly establish a relationship between iron overload and
lipogenic gene expression. Studies with rodent models of dietary iron deficiency have shown an
up-regulation of lipogenic gene expression, which indirectly support our findings with Hamp KO
mice (59–61). Lipid homeostasis in the liver is also regulated by lipid export, which is mediated by
VLDL secretion. However, we did not determine any significant changes in the expression of genes
regulating VLDL secretion (i.e. MTP). This suggests that hepcidin and iron do not have an effect
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on HFS-mediated lipid vesicle secretion. Thus, the alleviated steatosis observed in high-fat-fed
Hamp KO mice livers is probably not due to an elevated level of lipid export from the liver. In fact
MTP expression was attenuated in the livers of both Hamp Flx and KO mice following long-term
HFS exposure. Future studies should establish whether the inhibition of VLDL by prolonged fat
intake directly contributes to fibrosis observed in the livers of these mice. Taken together, our data
suggests that iron decreases steatosis by inhibiting lipid storage but not export.
Mitochondrial β-oxidation is also an important pathway to maintain hepatic lipid homeostasis. The
transcription factor, PPARα induces the transcription of genes involved in β-oxidation (62). PPARα
expression itself is also regulated at the transcriptional level (63). In our studies, we detected a
time-dependent response of PPARα mRNA expression in the liver in response to HFS intake.
Namely, short-term (3 months) intake up-regulated but long-term (7 months) intake suppressed
PPARα expression regardless of Hamp genotype. Increased β-oxidation is essential to alleviate
extra-hepatic fat burden in NAFLD by disposing of excess lipids in the liver (64). As a by-product
of the mitochondrial respiratory chain activity, the levels of reactive oxygen species (ROS) in the
liver are increased due to electron leakage. Of note, ROS is accepted to be a prominent secondary
hit factor in the development of NASH pathology (65). It is therefore feasible, that the initial upregulation of PPARα serves the purpose of disposing excess lipids in the liver via mitochondrial βoxidation. The suppression of PPARα observed in later stages might either be a hepatic defense
mechanism to limit mitochondrial ROS production or an indication of mitochondrial dysfunction
in fibrotic livers. Similarly, the expression of CPT1, which is also involved in β-oxidation, was
significantly suppressed in the livers of Hamp KO mice with long-term HFS intake. It is therefore
possible that iron in conjunction with lipid accumulation exert a burden on mitochondria, which
ultimately leads to profound mitochondrial dysfunction in the liver. Of note, changes in
mitochondrial structure and function are regarded as secondary risk factors in NAFLD/NASH
progression (13).
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Besides lipid metabolism, changes in the expression of genes involved in gluconeogenesis were
also observed in the livers of HFS-fed Hamp KO mice. HFS intake induced suppression of
gluconeogenic gene expression (i.e. PCK1 and G6PC) independent of Hamp genotype and feeding
period. However the deletion of Hamp by itself (i.e. KO mice fed with the regular diet) exhibited
opposite effect on the expression of PCK1 and G6PC. Namely, the absence Hamp up-regulated
PCK1 but suppressed G6PC mRNA levels. Overexpression of the Forkhead Transcription Factor,
FKHR (a.k.a., FOXO1a) has been shown to stimulate the expression of G6PC, but not PCK1, in
hepatocytes (66). ROS is known to suppress FOXO1a activity post-translationally (67). It is
therefore feasible that increased ROS levels in Hamp KO mice may impose differential effects on
PCK1 and G6PC through the inactivation of FOXO1a. Further studies are however required to
determine the precise mechanisms of this differential regulation.
Despite being a useful NAFLD model, there are only limited number of studies with long-term
HFS feeding of rodents, which have reported only mild levels of liver fibrosis (50). With our current
model of Hamp KO, fibrosis developed at an early time point (i.e. 3 months) and increased in
severity at 7 months. Our experimental data strongly suggests that the deletion of Hamp, and
resultant hepatic iron overload, exacerbate liver fibrosis while decreasing steatosis. Therefore,
Hamp KO mice might serve as a distinctive experimental model recapitulating NAFLD/NASH
pathogenesis within a relatively short period of HFS diet administration.
In summary, our studies with Hamp KO mice established a correlation of increased hepatic iron
content with both decreased steatosis and increased fibrosis in the liver. Our findings also suggested
a role for hepcidin in HFS-induced mitochondrial dysfunction. Detailed future studies investigating
metabolic signaling pathways in HFS-treated Hamp KO mice will enable us to understand the role
of iron and hepcidin in the regulation of metabolic processes in the liver. We therefore believe that
Hamp transgenic mice are a good new experimental model to study NAFLD/NASH pathogenesis.
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Figure 6.1. Pathology of hepatic fibrosis. Chronic liver injury induces inflammatory cell
infiltration into the liver parenchyma. Hepatocyte apoptosis stimulates the activation of Kupffer
cells, which releases fibrogenic mediators. Hepatic stellate cells (HSC) proliferate and
differentiate into myofibroblasts for the production of extracellular matrix (ECM). Excessive
ECM deposition further hampers liver function by inhibiting the blood flow in the hepatic
sinusoid and nutrient exchanges. (Image adopted from Bataller, R., and Brenner, D. A. (2005)
Liver fibrosis. J Clin Invest. 115, 209–218 with permission)
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B

Figure 6.1
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Figure 6.2. Hamp Floxed (Flx) and knockout (KO) mice generation and genotyping. (A) The
schematic illustration of Hamp construct design has been adopted from a previous publication by
Lu. S. et al (36). (i) The genomic structure of wild-type Hamp loci with exon1, 2, and 3
represented by gray boxes (E1, E2 and E3, respectively). (ii) Hamp targeting vector flanking E2
and E3 with loxP and neomycin (PGK-NEO) selection cassette with FRT recognition sequence
was generated and electroporated into a C57BL/6 embryonic stem (ES) cell line to induce
homologous recombination. (iii) Null alleles after Cre-mediated recombination excising E2 and
E3 leaving a single lox P site, which encodes primarily signaling sequence of hepcidin-1. (B)
Genotyping of wild-type (wt.), heterozygous (het.) and homozygous (hom.) Hamp KO mice were
performed by PCR, as described in experimental procedures (see Chapter II) using primers
specific for the corresponding alleles. PCR products were analyzed by DNA agarose gel
electrophoresis and visualized by ethidium bromide staining. Representative images of DNA
amplicons corresponding to Hamp wt. or KO alleles are shown. The selected primer pairs also
amplify mouse wild-type Hamp2 allele, which remained intact in Hamp KO mice.
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Figure 6.3. Quantification of hepatic iron content in Hamp Flx and KO mice. Inductively
coupled mass spectrometry (ICP-MS) was performed (A, B) with the liver tissues from Hamp Flx
and KO mice, as described in experimental procedures. The level of 56Fe (A) and 57Fe (B)
isotopes, as detected by ICP-MS, are shown. Magnetic resonance imaging (MRI) was performed
in Bioimaging Core Facility at University of Nebraska Medical Center to examine the iron
content in the liver in situ (C, D). Single slice examples from 3D ultra-short echo time images
through the liver of Flx (C) and homozygous KO (D) mice obtained at echo times of 0.02 ms
(upper panel ) and 3.0 ms (lower panel). The T2* of liver is much shorter in KO mice than in Flx
mice, causing significant signal loss selectively in the liver by 3.0 ms.
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Figure 6.4. The initial and end liver weights of Hamp Flx and KO mice fed high-fat and
high-sucrose (HFS) or regular diets. Average body (A, B) and liver (C, D) weights of Hamp
Floxed (Flx) (A, C) and knockout (KO) (B, D) mice fed with high-fat and high-sucrose (HFS) or
regular control (Reg.) diets for 3 or 7 months are shown as gram weight. The average of initial
(Ini.) body weights of mice in each group at the start of the experiments are also shown.
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Figure 6.5. Macroscopic and microscopic changes in Hamp Flx and KO mice fed high-fat
and high-sucrose (HFS) or regular diets for 3 months. Representative images showing the
abdominal cavity of mice (A) and H&E staining of formalin-fixed and paraffin-embedded liver
sections (B) of Hamp Flx and KO mice fed with high-fat and high-sucrose (HFS) or regular diets
were obtained at the end of 3 month-long feeding period. Microscopic images were obtained with
a Nikon Eclipse E400 light microscope using a CC-12 digital camera and analySIS software (Soft
Imaging System), as described in experimental procedures (see Chapter II). Arrows indicate
steatosis.
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Figure 6.6. Macroscopic and microscopic changes in Hamp Flx and KO mice high-fat and
high-sucrose (HFS) or regular diets for 7 months. Representative images showing the
abdominal cavity of mice (A) and H&E staining of formalin-fixed and paraffin-embedded liver
sections (B) of Hamp Flx and KO mice fed with high-fat and high-sucrose (HFS) or regular diets
were obtained at the end of 7 month-long feeding period. Microscopic images were obtained with
a Nikon Eclipse E400 light microscope using a CC-12 digital camera and analySIS software (Soft
Imaging System), as described in experimental procedures (see Chapter II). Arrows indicate
steatosis.
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Figure 6.7. Liver triglyceride content in Hamp Flx and KO mice fed high-fat and highsucrose (HFS) or regular diets. Hepatic triglyceride content in Hamp Floxed (Flx) and knockout
(KO) mice fed with regular (Reg.) or high-fat and high-sucrose (HFS) diets for 3 (A) or 7 (B)
months was quantified using 50 mg of wet liver tissue, as described in the experimental
procedures (see Chapter II). Liver triglyceride amount was expressed as μmol per liver per 100 g
body weight (µmol/L/ 100 g b.w.).
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Figure 6.8. Fibrosis in Hamp Flx or KO mice fed high-fat and high-sucrose (HFS) or regular
diets for 3 months. (A) Liver fibrosis in Hamp Floxed (Flx) and knockout (KO) mice fed on
regular (Reg.) or high-fat and high-sucrose (HFS) diets for 3 months was detected by staining
liver sections with Sirius Red, as described in experimental procedures. Representative
microscopic images obtained with Nikon Eclipse E400 light microscope using a CC-12 digital
camera and analySIS software (Soft Imaging System) are shown. (B) 10 images taken from each
group were quantified using ImageJ software. The collagen proportional area (CPA) was
determined by calculating the percentage of collagen-occupied pixels against the total pixel
values.
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Figure 6.9. Fibrosis in Hamp Flx or KO mice fed high-fat and high-sucrose (HFS) or regular
diets for 7 months. (A) Liver fibrosis in Hamp Floxed (Flx) and knockout (KO) mice fed on
regular (Reg.) or high-fat and high-sucrose (HFS) diets for 7 months was detected by staining
liver sections with Sirius Red, as described in experimental procedures. Representative
microscopic images obtained with Nikon Eclipse E400 light microscope using a CC-12 digital
camera and analySIS software (Soft Imaging System) are shown. (B) 10 images taken from each
group were quantified using ImageJ software. The collagen proportional area (CPA) was
determined by calculating the percentage of collagen-occupied pixels against the total pixel
values.
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Figure 6.10. Protein expression levels of P-JNK and αSMA in Hamp Flx and KO mice fed
HFS diet or regular diet for 3 or 7 months. The expression levels of alpha smooth muscle
action (αSMA) (A) and phosphorylated of JNK (P-JNK) (C) proteins in the livers of Hamp
Floxed (Flx) and knockout (KO) mice fed with regular (Reg.) or high-fat and high-sucrose (HFS)
diets for 3 or 7 months was determined by western blotting using whole liver cell lysates and
commercial antibodies, as described in experimental procedures. An anti-gapdh antibody was
used as control to determine equal protein loading. The western blots were quantified with
densitometric analysis and normalized to gapdh expression. Normalized αSMA (B) and P-JNK
(D) levels were expressed as fold-change of that in Flx mice fed with regular diet for 3 months.
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Figure 6.11. Expression of genes involved in lipogenesis, lipid storage and secretion. The
mRNA expression levels of sterol regulatory element-binding protein-1c (SREBP-1c) (A,B),
FSP27 (C,D), and microsomal triglyceride transfer protein (MTP) (E,F) in the livers of Hamp
Floxed (Flx) and knockout (KO) mice fed with regular (Reg.) and high-fat and high-sucrose
(HFS) diets, was determined by SYBR green qPCR using cDNA synthesized from total liver
RNA and specific primers. Liver gene expression in HFS-fed Hamp Flx or KO and regular dietfed KO mice for 3 (A, C, E) or 7 months (B, D, F) was expressed as fold change of that in Hamp
Flx mice fed with a regular diet for the same time period.
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Figure 6.12. Expression of genes involved in β-oxidation and gluconeogenesis. The mRNA
expression levels of peroxisome proliferator-activated receptor alpha (PPARα) (A, B), carnitine
palmitoyltransferase 1a (CPT1a) (C, D), phosphoenolpyruvate carboxykinase 1 (Pck1) (E, F) and
glucose-6-phosphatase (G6PC) (G, H), in the livers of Hamp Floxed (Flx) and knockout (KO)
mice fed with regular (Reg.) and high-fat and high-sucrose (HFS) diets, was determined by
SYBR green cDNA synthesized from total liver RNA and qPCR using specific primers. Liver
gene expression in HFS-fed Hamp Flx or KO and regular diet-fed KO mice for 3 (A, C, E, G) or
7 months (B, D, F, H) was expressed as fold change of that in Hamp Flx mice fed with a regular
diet for the same time period.
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Chapter VII
Summary and Future Directions

225
1

SUMMARY AND FUTURE DIRECTIONS

Hepcidin is the central iron regulatory hormone. Hepcidin expression is frequently elevated
in patients with obesity and nonalcoholic fatty liver disease (NAFLD). The underlying
mechanisms are however unknown. Inflammatory cytokines or iron loading in NAFLD
patients have been suggested to contribute to increased levels of hepcidin (1–3).
Furthermore, an association between elevated serum hepcidin and lipid content in NAFLD
patients has also been reported (4). Despite the importance of steatosis in NAFLD
pathogenesis, the effect of hepatic lipid accumulation on hepcidin expression or iron
homeostasis has not been investigated. In this dissertation, I have demonstrated novel and
distinct regulatory mechanisms by which hepatic hepcidin expression is regulated by lipidinduced signaling. Saturated fatty acids, specifically palmitic acid, induced hepcidin
mRNA stabilization via the activation and specific binding of AU-rich element binding
protein, HuR to the 3’UTR of hepcidin mRNA (Figure 7.1). On the other hand, the
sphingolipid, ceramide regulated hepcidin at the transcriptional level by activating STAT3
and its binding to HAMP promoter (Figure 7.1). My novel findings therefore confirmed
the significant role of different lipid species in the regulation of hepcidin expression and
iron metabolism. They have also elucidated the underlying mechanisms of these unique
regulatory pathways. Most importantly, my results have for the first time demonstrated a
direct role for post-transcriptional mechanisms, particularly an AU-rich element-binding
protein and protein kinase C signaling, in hepcidin regulation. Moreover, I have confirmed
the ceramide-specific activation of the JAK/STAT3 signaling pathway in hepatoma cells
in the absence of inflammatory immune cells, which transcriptionally up-regulated
hepcidin expression.
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The elevation of hepcidin expression will subsequently lead to the sequestration of iron in
Kupffer cells and hepatocytes via the inhibition of iron exporter, ferroportin (Figure 7.2).
Iron accumulation in the hepatocytes (5) and reticuloendothelial cells (6) have both been
shown to be associated with severe inflammation, injury and fibrosis in the liver. By using
Hamp knockout mice, a genetic model of iron overload, I have directly examined the effect
of iron, and high-fat and high-sucrose (HFS) intake on NAFLD pathogenesis. Compared
to controls, Hamp knockout mice exhibited significantly attenuated steatosis but more
prominent fibrosis following HFS administration. My Hamp knockout mice studies further
supported the conclusion that iron overload correlates with NAFLD disease progression.
Since hepcidin is the central iron regulator, lipid-mediated changes in hepatic hepcidin
expression may alter systemic iron homeostasis. The long term effect of hepcidin upregulation should not be neglected. Furthermore, my studies with Hamp knockout mice
have also strongly suggested a role for hepcidin and iron in the regulation of metabolic
gene expression in the liver. Future studies are therefore required to determine the longterm in vivo consequences of increased hepcidin expression on iron homeostasis and
metabolic processes with regard to NAFLD pathogenesis.
In summary, experiments in this dissertation have demonstrated novel mechanisms by
which hepatic hepcidin expression is stimulated by lipid signaling. The in vivo relevance
of these findings needs to be validated with other experimental models and human patients
of NAFLD. My findings confirming that HFS-fed Hamp knockout mice develop fibrosis
within 3 months have also underlined the advantages of this novel experimental model in
the study of NAFLD disease progression. Taken together, the studies in this dissertation
will improve our understanding of hepcidin regulation by lipid metabolism in the liver, and
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its significance in NAFLD pathogenesis. Since there are currently no FDA-approved drug
treatments for NAFLD, the elucidation of these pathways may be beneficial for the
development of treatment strategies for patients with NAFLD and metabolic syndrome.
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Figure 7.1. Molecular mechanism of lipid-induced up-regulation of hepcidin. Different
lipid species induce hepcidin up-regulation through distinct mechanisms. Saturated fatty
acids activate HuR through PKC signaling. The subsequent binding of HuR to the 3’UTR
of hepcidin mRNA stabilizes the mRNA of hepcidin and therefore up-regulates steadystate mRNA level through a post-transcriptional mechanism. Ceramide activates the
JAK/STAT3 signaling pathway. The binding of STAT3 to the hepcidin promoter activates
transcription of hepcidin mRNA.
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FIGURE 7.1
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Figure 7.2. Biological consequences of elevated hepcidin in the liver. Elevated hepcidin
level results in the post-translational down-regulation of ferroportin, the iron exporter
expressed on the plasma membrane of Kupffer cells and hepatocytes. Decreased
ferroportin subsequently leads to decreased iron export and iron sequestration in the
hepatocytes and macrophages, which exacerbates NAFLD/NASH pathogenesis.
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